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National regulatory authorities (NRAs) are responsible for the evaluation of medicines 
and for ensuring that only those products which meet the requirements of quality, 
safety and efficacy are registered and made available to patients.  The NRAs are 
required to effect such regulatory mandates efficiently and ensure timely patients’ 
access to medicines.  Many NRAs, especially in resource-limited settings or emerging 
markets face challenges in fulfilling these mandates as resources are stretched to 
capacity.  Adopting a risk-based approach to medicine evaluation can provide relief 
for NRAs striving towards improved regulatory performance.  The NRAs may 
implement facilitated regulatory pathways, appropriate frameworks for benefit-risk 
(BR) assessment and abridged review processes in order to leverage reliance 
mechanisms and good regulatory practices to improve regulatory efficiencies. 
 
The aim of this research was to evaluate the regulatory environment in South Africa 
with a view to improve the review process for medicines and to ensure their timely 
access by patients.  This was achieved through a review of the legislative framework 
and historical context supporting the new regulatory environment in South Africa and 
the transition from the Medicines Control Council (MCC) to South African Health 
Products Regulatory Authority (SAHPRA).  The regulatory performance of the South 
African regulatory authority and how it compared to that of other agencies was 
evaluated and the strategies supporting enhanced BR assessment and reliance 
mechanisms were appraised. 
 
Various methodologies were considered in determining an appropriate study design 
and a mixed method approach, including a combination of self-administered 
questionnaires, focus groups and a case study, was adopted to support achieving the 
study objectives.  A questionnaire was used to evaluate the review process of the 
MCC and the results demonstrated that the MCC was not able to meet target timelines 
for the review of new active substances (NASs).  A comparison was made between 
the MCC and other similar NRAs using the same questionnaire.  The results indicated 
that the MCC had similar requirements to other agencies and all the NRAs conducted 
a full assessment of applications for the registration of NASs. However, the approval 
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times for the MCC were considerably longer.  Further investigation into these lengthy 
timelines resulted in the analysis of the performance metrics of the MCC between 
2015-2017 and of SAHPRA in 2018.  A case study approach and focus group were 
used to evaluate strategies for enhanced communication of BR assessments and a 
questionnaire and two focus groups were conducted to understand the implications of 
the application of an abridged review in the evaluation of NASs.  The results of these 
studies culminated in the development of a proposed improved model for the 
regulatory review process of new active substance (NASs) for SAHPRA. 
 
This programme of research has presented, in a seminal piece of work, key 
recommendations for the improvement of the regulatory review process as it may be 
applied by SAHPRA.  The results from this work provide, for the first time, a baseline 
against which future improvements, implemented by SAHPRA, may be measured.  
The implementation of these recommendations will contribute towards an enhanced 
regulatory performance, underpinned by good regulatory, good review and good 
reliance practices. This will result in a stream-lined review process, improved 
regulatory responsiveness, consistency, transparency and accountability and 
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General Introduction  
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The intersection of legislative frameworks and medicines dates back to antiquity 
(Halwani & Takrouri, 2006) while the systemic failings in the regulation of medicines, 
publicised extensively with the advent of the thalidomide scandal (McBride, 1962), 
were the catalyst for rigorous medicine regulation in many countries (Rago & Santoso, 
2008).  Today governments remain responsible for safeguarding their citizens from 
the use of ineffective, poor quality and harmful medicines and national regulatory 
authorities (NRAs) have been established to ensure that medicines are regulated 
effectively through the implementation of laws, evidence-based scientific evaluation 
and safety monitoring programmes (Rago & Santoso, 2008).  The regulation of 
medicines is realised through several activities that mutually contribute to promoting 
and protecting public health (WHO, 2003).  These principal functions include 
inspection and licensing of manufacturers and distributors of medicines, control of the 
advertising, post-market surveillance and vigilance activities as well as the scientific 
evaluation of medicines and the issuing of market authorisation for approved 
medicines (WHO, 2003). 
 
Global perspective for regulatory requirements 
Emanating from the sixty-seventh World Health Assembly (WHA) in 2014, WHA 
Resolution 67.20, identified the need for effective regulatory systems and emphasised 
the importance of strengthening regulatory processes and the regulatory performance 
of NRAs (WHA, 2014).  This includes developing strong legal foundations with a clear 
focus on transparency in decision-making and recognising the importance of 
collaboration to promote greater access to quality, safe and effective medical products 
(WHA, 2014).  The role of the World Health Organization (WHO) in the regulation of 
medical products has been demonstrated through regulatory capacity-building for 
NRAs in Member States, ensuring the safety, quality and efficacy of medical products 
through the WHO prequalification programme, as well as the support provided for 
monitoring and pharmacovigilance activities and the establishment of norms and 
standards by the WHO Expert Committees (WHO, 2014a). 
 
As regulatory authorities around the world enforced legislative mandates; differences 
and increases in regulatory requirements were observed.  The rising need for 
harmonisation brought together pharmaceutical associations and regulators from 
Europe (EU), the United States of America (USA) and Japan.  The efforts of these 
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three regions resulted in the establishment of the International Conference on 
Harmonization (ICH) in 1990 (ICH, 2019).  The work of the ICH aimed to address the 
scientific and technical issues related to the harmonisation of medicine registration.  
Initially the ICH focused on new active substances (NASs) and biotechnology products 
however, over time, the recommendations of the ICH have been applied to generic 
medicines.  The efforts of the ICH have enabled mutual acceptance of data across 
ICH countries and have also influenced non-ICH countries (ICH, 2019). 
 
One of the key initiatives of the ICH was manifested in the establishment of a common 
technical document (CTD).  The CTD made provision for the assembly and 
presentation of the quality, safety and efficacy data required for the scientific 
assessment of market authorisation applications in a common format.  The CTD is 
organised into five modules.  Module 1 is region specific and Modules 2, 3, 4 and 5 
are intended to be common for all regions.  For industries, the CTD has eliminated the 
need to reformat the information for submission to the different ICH regulatory 
authorities.  For regulators, the CTD has helped to pave the way for the implementation 
of reliance and recognition strategies. 
 
Challenges in the regulatory review process 
Global trends of continuing pressure on NRAs, of all sizes and capacity, have been 
noted, due to the increased volumes of applications received, the complexity of the 
submissions and the increased categories of medical products (WHO, 2014b).  Efforts 
to address these challenges, especially for NRAs in low and middle-income countries, 
have focused on strategies for identifying and performing core regulatory functions 
that have to be undertaken directly by NRAs, to meet country or regional needs (WHO, 
2014b).  The WHO has encouraged NRAs to consider regulatory convergence and to 
collaborate with and recognise the work carried out by other agencies in order to ease 
the regulatory burden (Ward, 2014). 
 
The time taken to review and evaluate applications for NASs is a common measure of 
the performance of a regulator (CIRS, 2019a).  The Centre for Innovation in Regulatory 
Science (CIRS) has studied market approval timelines for medicines for the past three 
decades.  The latest data published by CIRS provided insight into the improvements 
made in the regulatory environment.  Over the last decade, six major NRAs, namely 
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the European Medicines Agency (EMA), the United States Food and Drug 
Administration (USFDA), the Japanese Pharmaceuticals and Medical Devices Agency 
(PMDA), Health Canada, Swissmedic and the Australian Therapeutic Goods 
Administration (TGA) have achieved shortened timelines for the review and approval 
of NASs despite the increase in the number of registrations for NASs (CIRS, 2019a).  
The median approval time for the review of NASs by these six regulatory authorities 
in 2008-2017 is displayed in Figure 1.1 (CIRS, 2019a). 
 
Figure 1.1 New active substance (NAS) median approval times for six 
regulatory authorities in 2009-2018 
 
 





































EMA FDA PMDA Health Canada Swissmedic TGA
5 
 
The median approval times for NASs, achieved by these six agencies for the period 
2014-2018, have been further stratified by review type (standard or expedited) (CIRS, 
2019a) and the results thereof are displayed in Figure 1.2. 
 
Figure 1.2 New active substance (NAS) median approval times by review type 
for six regulatory authorities in 2014-2018 
 
 
Adopted from CIRS, 2019a 
 
Similar data were collected to reflect the median approval times for the review of NASs 
by NRAs in the emerging economies for the period 2014-2018 (CIRS, 2019b).  The 
data presented in Figure 1.3 is based on the median approval times for NASs in each 
country.  Inherent variability in approval times was noted as a result of differences in 
the type of review assessments used by the NRAs.  For example, Argentina makes 
use of a verification review while South Africa and Turkey perform a full review of 
applications for NASs.  At the time of this study, the review times for the approval of 
















































































































Figure 1.3 Regulatory approval times from date of emerging markets 
submission to date of approval for new active substances (NASs) approved 
between 2014-2018
 
Data are shown for NASs that were approved between 01/01/2014 and 31/12/2018. 
(n1) = number of drug applications, (n2) = number of companies providing data. 
Box: 25th and 75th percentiles. Whiskers: 5th and 95th percentiles. 
 
Adopted from CIRS, 2019b 
 
Figure 1.4 provides an analysis and comparison of median interval durations for the 
first regulatory approval for an NAS anywhere in the world followed by submission and 
approval for the same compound to one of the emerging market authorities (CIRS, 
2019b).  The results depicted in Figure 1.4 reflect the extended approval timeline for 
NAS in South Africa.  The results of the study illustrate the South African NRA’s 
historical track record of slow decision making and delays in effecting regulatory 
mandates.  Efforts to address the increasing volume of applications that were received 
by the Medicines Control Council (MCC), the previous South African NRA, were 
unsuccessful, as resources were stretched to capacity, resulting in the development 























Figure 1.4 Median time to roll out to emerging market (EM) countries for new active substance (NASs) 
approved 2014-2018 
 
Denotes the submission to emerging market country was prior to first world approval 
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Similar research in this field has demonstrated that NRAs of varying sizes and capacity 
are able to improve their regulatory performance.  Key elements for consideration 
include the application of risk-stratification approaches and facilitated regulatory 
pathways (FRPs) (Liberti, 2018).  This would be an advantage when considered in line 
with the recommendations of the WHO (Ward, 2014; WHO, 2014b) to embrace 
regulatory harmonisation and/or convergence strategies and engage in reliance and 
recognition activities that allow NRAs, in resource-limited settings, to consider or 
accept the regulatory decisions made by other comparable NRAs.  In addition, this 
would have the potential to reduce the regulatory burden on NRAs and to avoid 
duplication of regulatory effort (Ward, 2014).  Furthermore, this could enable the 
application of an appropriate framework for benefit-risk (BR) assessment to enhance 
consistency in the clinical assessment of medicines (Leong et al., 2015a) as well as 
incorporating the principles of good review practices (GRevP) in routine regulatory 
undertakings (WHO, 2014b).  Thus, the entirety of such an initiative would build quality 
into regulatory decision-making to reinforce transparency (Walker et al., 2014). 
 
Good review practices 
National regulatory authorities (NRAs) are responsible for the review of applications 
for medicine registration and for ensuring that the foundation for regulatory decisions 
is supported by the scientific and evidentiary requirements for safety, efficacy and 
quality (WHO, 2015).  They are also responsible for ensuring timely access to 
medicines (WHO, 2015).  Many NRAs strive towards goals of improved regulatory 
performance and strengthened regulatory systems (WHO, 2015).  The implementation 
of GRevPs provides a mechanism for NRAs to enhance regulatory performance 
(WHO, 2015).  GRevPs provide guidance on the best practices that may be applied 
by NRAs during the regulatory review of a medicine (WHO, 2015).  GRevPs are a 
fundamental part of overall good regulatory practices (GRP) with a focus on the review 
of medicines (WHO, 2015).  The application of GRevPs provides a platform for NRAs 
to effectively manage the regulatory review of medicines and to ensure the 
consistency, transparency and quality of the review process (WHO, 2015).  The WHO 
has provided general guidance for NRAs, through the development of a guideline on 





Figure 1.5 Ten key principles of good review practices (GRevPs) 
 
 
Adopted from WHO, 2015 
 
The consistent application of these principles should be underpinned by a quality 
management system (QMS) supported by standardised procedures.  Intentions to 
establish these systems are shared by NRAs across the world as agencies recognise 
the importance of improved GRevPs as the basis for good decision-making 
(McAuslane et al., 2011).  Commonalities in the functions performed by NRAs and the 
processes applied in the review of medicines provide an opportunity for regulatory 
convergence and for building mutual confidence, among NRAs, in regulatory practices 
(Liu et al., 2013). 
 
A survey was conducted among NRAs of the Asia-Pacific Economic Cooperation 
(APEC) member economies to assess the current use of GRevPs to support quality 
BALANCED A good review is objective and unbiased. 
CONSIDERS CONTEXT A good review considers the data and the conclusions of the applicant in the 
context of the proposed conditions of use and storage, and may include perspectives from patients, 
health-care professionals and other RAs’ analyses and decisions. 
EVIDENCE-BASED A good review is evidence-based and reflects both the scientific and regulatory 
state of the art. It integrates legislative, regulatory and policy frameworks with emerging science. 
IDENTIFIES SIGNALS A good review comprehensively highlights potential areas of concern identified 
by the applicant and the reviewers. 
INVESTIGATES AND SOLVES PROBLEMS A good review provides both the applicant’s and the 
reviewers’ in-depth analyses and findings of key scientific data and uses problem-solving, regulatory 
flexibility, risk-based analyses and synthesis skills to devise and recommend solutions and alternatives 
where needed. 
MAKES LINKAGES A good review provides integrated analysis across all aspects of the application: 
preclinical, nonclinical, clinical, chemistry/biocompatibility, manufacturing and risk management plan. It 
includes timely communication and consultation with applicants, internal stakeholders and, as needed, 
with external stakeholders who have expertise relevant to the various aspects of the application. 
UTILIZES CRITICAL ANALYSES A good review assesses the scientific integrity, relevance and 
completeness of the data and proposed labelling, as well as the interpretation thereof, presented in the 
application. 
THOROUGH A good review reflects adequate follow through of all the issues by the reviewers. 
WELL-DOCUMENTED A good review provides a well-written and thorough report of the evidence-based 
findings and conclusions provided by the applicant in the dossier, and the reviewers’ assessment of the 
conclusions and rationale for reaching a decision. It contains clear, succinct recommendations that can 
stand up to scrutiny by all the parties involved and could be leveraged by others.  
WELL-MANAGED A good review applies project and quality management processes, including clearly 
defined steps with specific activities and targets. 
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decision-making (Liu et al., 2013).  This survey was the first step of the APEC Best 
Regulatory Practice Project that was initiated following the APEC GRevP Workshop 
on Medical Products in 2010.  Fourteen of the NRAs in the APEC member economies 
including Australia, Canada, Chile, Indonesia, Japan, Mexico, Malaysia, New Zealand, 
Peru, the Philippines, Singapore, South Korea, Chinese Taipei and the USA 
participated in the survey.  Participants provided information pertaining to the size of 
the agency, the scope of responsibilities and the types of reviews conducted (Liu et 
al., 2013).  Quality measures undertaken by the agencies were described and insight 
into the progress made and satisfaction with the implementation of GRevPs, QMSs 
and available training mechanisms was provided.  The majority of the APEC regulatory 
agencies responding to this survey recognised the need for employing quality 
measures in the regulatory review of medicines driven by objectives of ensuring 
consistency and improving efficiencies as shown in Figure 1.6 (Liu et al., 2013). 
 
Many NRAs have implemented systems to ensure the consistent application of 
GRevPs and continue to work towards the evaluation and improvement of such 
systems.  It is hoped that mutual confidence will be cultivated among NRAs as they 
progress and share their experiences as well as lessons learned and best practices 
for the effective application of GRevPs. In turn, such practices will contribute to the 
movement towards regulatory convergence and the reliance on, or recognition of, the 
assessment reports and decision-making of reference agencies; ultimately leading to 
improved regulatory performance and timely patient access to medicines. 
 
Harmonisation, reliance and recognition 
The challenges faced by NRAs in meeting demands for improved regulatory 
performance are more acute in low and middle income countries (Ward, 2017).  The 
WHO has supported these NRAs through the development of norms and standards, 
promoting regulatory convergence and harmonisation as well as the optimum use of 
limited resources through collaboration, reliance and recognition (Ward, 2017).  At the 
core of harmonised regulatory activities lies the need to reach convergence in 
regulatory requirements and a prerequisite for NRAs, within participating countries, to 
function at the necessary maturity level. Through harmonisation initiatives, technical 
requirements on safety, quality and efficacy may be standardised and the regulatory 
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burden, faced by many NRAs, may be reduced and the duplication of regulatory efforts 
may be avoided (Ward, 2014). 
 
Figure 1.6 Top reasons given by the Asia-Pacific Economic Cooperation 
(APEC) regulatory agencies for employing quality measures in the regulatory 
review  
 
Adopted from Liu et al., 2013 
 
The use of facilitated review practices (FRPs) may be considered as a mechanism to 
expedite regulatory decision-making in the review of applications for the registration 
of NASs.  Primary FRPs are defined as pathways that are typically used by mature 
NRAs, during the first review of a medicine, to decrease the timeline for the 
development or the regulatory review of a product (Liberti, 2018).  Secondary FRPs 
can be used to expedite regulatory decisions made by NRAs and contribute towards 
decreasing median approval times for medicines resulting in improved patient access 
to medicines.  Secondary FRPs are based on the reliance or recognition of the prior 
review and regulatory decision made by another NRA (Liberti, 2018).  Reliance is 
defined as the act whereby, in making a regulatory decision, an NRA in one jurisdiction 
considers, and in some cases, gives significant weight to the regulatory decision made 
by another NRA (Ward, 2017).  Recognition is defined as the routine acceptance of 
the regulatory decision made by another NRA (Ward, 2017).  Data on the proportion 
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of NASs approved by each NRA in 2017 that benefited from at least one FRP are 
provided in Figure 1.7 (CIRS, 2019a). 
 
Figure 1.7 Proportion of New Active Substances (NASs) approved by each 
agency in 2018 that benefited from at least one  
facilitated regulatory pathway (FRP) 
 
 
Adopted from CIRS, 2019a 
 
Key milestones of the regulatory review process 
A workshop on “The Emerging Markets: Regulatory issues and the impact on patients’ 
access to medicines” was organised in Geneva, Switzerland in March 2006 with the 
aim to discuss the data assessment methods used by NRAs to perform a scientific 
review of applications for NASs (Walker et al., 2006).  The outcomes of the workshop 
informed the identification of three review models that were agreed by the global 
representation of NRAs in attendance at the workshop.  The three scientific review 
models of NAS applications are described below:  
 
Review assessment type I - Verification model 
The verification model is used by NRAs that lack the resources to perform full scientific 
assessments of applications for NASs.  This model allows the NRA to authorise the 
registration of the NAS provided that marketing authorisation for the NAS has been 
obtained, in the form of a Certificate of a Pharmaceutical Product (CPP), from at least 
two recognised NRAs.  The verification model is built on the premise that the NRA has 
verified the data submitted, for compliance with the reference country(s) 
authorisation(s), including the product characteristics (formulation, composition and 
strength) and the proposed labelling information (use, dosage, precautions) for local 
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marketing.  For this model, it is a pre-requisite that the CPP or alternative 
documentation of approval be provided on submission of the application for 
authorisation. 
 
Review assessment type II – Abridged model 
The abridged model makes provision for a truncated review focused on the evaluation 
of clinical data (BR assessment) as well as country specific requirements related to 
quality data.  Requirements pertaining to quality data are generally associated with 
evidence of product stability in the local climatic zone and the suitability of distribution 
networks within the country.  Provided that the scientific data submitted has been 
evaluated and approved by a recognised NRA, local authorities can avoid duplication 
of effort and can forgo the re-assessment of such data.  This model does not require 
the submission of the CPP on application, but may require submission of the CPP or 
alternative documentary evidence of approval, prior to product authorisation. 
 
Review assessment type III - Full review model 
The full review model is intended for use by NRAs that have the necessary resources 
to perform a full independent scientific review of applications for NASs.  This model 
entails a “full” assessment of quality, pre-clinical and clinical data by internal and 
external experts.  The full review model does not require evidence of marketing 
authorisation from any other NRA at the time of submission and thus allows for parallel 
or prior review to first applications worldwide. 
 
Historically, the MCC in South African utilised the full review model in the assessment 
of all applications including NASs and generics for orthodox, biological, 
complementary, and veterinary medicinal products.  A full independent assessment of 
quality, efficacy and safety data was performed for each application received.  The 
MCC had access to reviewers who had the relevant qualification and technical 
experience to perform a full assessment of the data provided.  The majority of the 
reviewers were external consultants.  Reviewers were responsible for preparing a 
detailed assessment report, that was peer-reviewed and then submitted to the relevant 
Scientific Committee for discussion.  The Scientific Committees then made a 





The assessment of the benefits and risks in the context of an application for a NAS is 
a complex process that requires evaluation of a large amount of data (EMA CHMP, 
2008).  Whilst the same data on quality, safety and efficacy could be submitted in 
support of the registration of a new medicine, NRAs may have different views on the 
authorisation of the product.  A report in 2008, by a working group of the EMA 
Committee for Medicinal Products for Human Use (CHMP) stated that there was no 
accepted, universal approach on the methodology to estimate the overall BR balance 
or on how to describe the way the evidence was weighed and balanced (EMA CHMP, 
2008).  However, since 2008, there have been a number of publications supporting 
the BR assessment of medicines (Walker et al., 2014; McAuslane et al., 2017; Leong 
et al., 2015a).  National regulatory authorities (NRAs) have recognised the need for a 
structured, standardised, systematic approach to BR assessment of medicines using 
a framework that should ideally be feasible and practical within the regulatory review 
process.  The NRAs are also under increased pressure to improve transparency, 
consistency and accountability and to establish appropriate documentary governance 
for decision-making processes. 
 
Over the past decade, current global practice frameworks, implemented by both 
pharmaceutical companies and NRAs, have been evaluated (Walker et al., 2014).  
Such models included those recommended by pharmaceutical companies as well as 
the Pharmaceutical Research and Manufacturers of America Benefit-Risk Action 
Team (PhRMA BRAT), the Benefit-Risk Assessment in New and Old Drugs (BRAIN), 
as well as frameworks advanced by NRAs, including the USFDA 5-step framework 
and the EMA Problem, Objectives, Alternatives, Consequences, Trade-Offs, 
Uncertainty, Risk Tolerance, Linked Decisions (PrOACT-URL) (Walker et al., 2014).  
Through this work the need for applicants to submit safety, quality and efficacy data in 
a standardised, well-structured manner was identified and, therefore, the submission 
of intuitive BR assessments, resulting in inconsistent narratives, could be avoided. 
 
In 2008, four regulatory agencies namely the Australian TGA, Health Canada, the 
Health Sciences Authority (HSA) in Singapore and Swissmedic collaborated in the 
development of a universal model for BR assessment.  The development of this model 
was intended to facilitate shared or joint reviews of new medicines submitted 
15 
 
simultaneously to each of the four agencies.  The initiative became known as the 
Consortium on Benefit-Risk Assessment (COBRA) initiative and was subsequently 
renamed Australia, Canada, Switzerland and Singapore (ACSS).  Through the 
facilitation of this collaboration, a BR assessment template was developed based on 
the EMA reflection paper of 2008 (EMA CHMP, 2008).  The template was constructed 
and then evaluated in three phases: a feasibility study, a retrospective pilot study and 
a prospective study (McAuslane et al., 2017; Levitan et al., 2014).  The final template, 
named the Universal Methodology for Benefit-Risk Assessment (UMBRA) was 
developed (Levitan et al., 2014) and incorporated appropriate methodologies for 
evaluating the BR assessment of medicines, as well as tools for supporting 
transparent decision-making.  The UMBRA overarching framework provided the basis 
for a common agreement on the principles for BR assessment of medicines taking into 
account the criteria influencing the quality of the framework, namely the logical 
soundness, comprehensiveness, acceptability of results, practicality, specificity and 
sensitivity, scope and visualisation (Walker et al., 2014).  The EMA CHMP assessment 
report template was used as the basis in the development of UMBRA and the revised 
template included a structured list of benefit and risk criteria. 
 
There was a consensus from regulators who were developing BR frameworks that 
there were eight steps either explicitly or implicitly undertaken in BR methodologies 
for assessing medicines (Leong et al., 2015a).  These steps have been incorporated 
into the UMBRA eight step benefit risk framework (Figure 1.8). 
 
The use of the UMBRA eight step benefit risk framework has potential benefits.  The 
template facilitates consistency in BR assessment in that the template prompts 
evaluators to avoid lengthy narratives.  Through the use of this template, reviewers 
are able to articulate each benefit and risk clearly which is an important mechanism 
for training new reviewers and a means for allowing comparisons with other medicines 
in the same class.  Consequently, its use has the potential to enhance internal 
consistency and the quality of decision-making within the NRA (Walker et al., 2014; 
Bujar et al., 2016; Donelan et al., 2015).  The template contributes towards the 
principles of GRevP in that it allows for transparent, documented decision-making, 
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resulting in a valuable tool that may be beneficial in engaging in joint reviews and 
collaborations with other NRAs. 
 
Figure 1.8 Universal Methodology for Benefit Risk Assessment (UMBRA) eight 
step benefit risk framework 
 
 
Adopted from Leong et al., 2015a 
 
In the event that NRAs engage in such collaborations, it becomes essential that there 
is agreement with respect to the clinical template, with emphasis on the section of the 
template addressing the BR assessment.  Standardisation of the BR assessment will 
facilitate effective exchange between partnered NRAs in communicating the reasons 
for views expressed and the regulatory decisions made.  Further value would be 
gained, should such a universal, standardised model be received internationally, 






Quality decision-making practices 
National regulatory authorities (NRAs) are responsible for making regulatory decisions 
that affect patients’ access to medicines.  Frameworks supporting the science of 
decision-making can be improved with a view to enhance consistency, transparency 
and accountability in decision-making practices. Ten quality decision-making practices 
(QDMPs) have been identified (Donelan et al., 2015) and can be linked to the science 
of decision-making as it unfolds in the review of medicines, particularly in the area of 
BR assessment (Bujar et al., 2016). 
 
Any NRA that aims to improve its decision-making practices should ensure that the 
quality of such decision-making practices is monitored and measured.  An assessment 
of the QDMPs applied by an NRA will provide insight into current strengths and gaps 
in current QDMPs and highlight commonalities and differences that may exist through 
the stratified forums for decision-making inherent within the NRA.   
 
A study conducted by (Donelan et al., 2016) resulted in the development of a tool 
named the Quality of Decision-Making Orientation Scheme (QoDoS) that was 
validated using a standardised approach and qualitative as well as quantitative 
techniques.  Through the application of the QoDoS in a regulatory environment, 
differences in decision-making between individuals and their organisation can be 
identified (Donelan et al., 2016). 
 
Review of the global regulatory environment 
The regulation of medicines is supported by a legislative framework that empowers 
NRAs to effect statutory mandates in ensuring patients’ access to safe, effective, 
quality medicines.  Patient-focused, evidence-based, risk-oriented, transparent, 
effective and flexible practices are the mainstay of medicines regulation (Azatyan, 
2009).  National regulatory authorities (NRAs) of various sizes and maturity levels 
have experienced challenges in the face of resource constraints and have had to 
revise legacy systems and processes in order to adapt to the new regulatory 
environment.  As the demand on NRAs increases, regulators globally have had to re-
engineer regulatory processes in an effort to increase the effectiveness of regulatory 
operations.  International benchmarking, against mature NRAs has driven many NRAs 
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to strive towards the implementation of pragmatic solutions to address regulatory 
inefficiencies. 
 
The WHO has developed a global benchmarking tool (GBT) that has been used to 
perform an evidence-based assessment and comparison of NRAs.  The WHO GBT is 
used by the WHO to assess the regulatory systems of NRAs in Member States, as 
mandated by the WHA Resolution 67.20 on regulatory system strengthening for 
medical products (WHA, 2014; WHO, 2020).  The benchmarking methodology 
embedded within the WHO GBT enables the WHO to identify both strengths and areas 
for improvement within the NRAs’ regulatory system.  The GBT is used to evaluate 
each of the nine component regulatory functions of the regulatory system against a 
series of sub-indicators.  These functions include national regulatory systems, 
registration and marketing authorisation, vigilance, market surveillance and control, 
licensing establishments, regulatory inspection, laboratory testing, clinical trial 
oversight and lot release.  Fact sheets have been developed to describe the scope 
and requirements for each sub-indicator.  During the assessment, NRAs are required 
to provide evidence supporting the implementation of each of the sub-indicators.  A 
number of the sub-indicators highlight the importance of formalising the 
implementation of the QMS and GRevPs.  The sub-indicators require NRAs to 
demonstrate the effective application of QDMPs in regulatory decision-making and 
support the publication of regulatory decisions in the public domain.  The sub-
indicators endorse the measuring and monitoring of regulatory performance, making 
use of effective electronic document management systems (EDMS) and participation 
in regional and/or global networks to promote harmonisation and collaboration.  Each 
sub-indicator is linked to a ‘maturity level’ rating.  The measure of ‘maturity level’ is 
based on the concept adapted from the International Standardization Organization 
(ISO) 9004 standard that provides guidance on quality management and the quality of 
an organisation to achieve sustained success (WHO, 2020).  The GBT facilitates an 
assessment of the maturity level of an NRA on a scale of 1 (existence of some 
elements of regulatory system) to 4 (operating at advanced level of performance and 
continuous improvement).  National regulatory authorities (NRAs) that are operating 
at a maturity level of 3 and above are considered to be competent in effecting 
regulatory mandates and are listed by the WHO as such.  The application of the WHO 
GBT in the assessment of NRAs in WHO Member States provides an opportunity for 
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NRAs that are operating at lower maturity levels or NRAs in resource-limited settings 
to rely on or recognise the regulatory decisions of WHO-listed NRAs. 
 
Technical support under-pinned by efforts promoting regulatory convergence has 
been provided by WHO to Member States.  The WHO has initiated collaborative 
activities between various countries and regions and through these harmonisation 
initiatives participating NRAs have been able to exchange consolidated information 
without challenging the sovereignty of the participants (Azatyan, 2009).  
 
Global trends for convergence and reliance have filtered down into the African region 
as reflected through the informal consultations initiated at the International Conference 
of Drug Regulatory Authorities (ICDRA), held in Bern, Switzerland, in September 2008.  
As a result of these discussions a WHO concept paper was developed to institute the 
African Medicines Registration Harmonization Initiative (AMRHI) to support the 
harmonisation of medicine registration within and across Africa (Azatyan, 2009).  It is 
further anticipated that the African Medicines Agency (AMA) may be established in 
order to further support the regulatory systems of NRAs and build regulatory capacity 
within the region (Ndomondo-Sigonda et al., 2017). 
 
The drive for the establishment of a more effective regulatory framework in South 
Africa has been evident for the past two decades.  In June 2017 the Medicine and 
Related Substances Act, 1965 (Act 101 of 1965), was amended to allow for the 
transition of the MCC to the South African Health Products Regulatory Authority 
(SAHPRA).  This new era, promising regulatory re-form, provided an opportunity to 
study the past practices of the South African NRA, with a view to enhancing regulatory 
operations and the responsiveness of the NRA to the advancing new regulatory 
landscape.  Similarly, to other NRAs, SAHPRA is working towards the development 
and improvement of its regulatory capacity.  At a workshop convened by the CIRS, on 
the Risk-Based Evaluation of Medicines, held in Sao Paulo, Brazil in 2017, many 
NRAs expressed an interest in applying risk-based evaluation approaches focused on 
reliance models that leveraged on the work by other trusted NRAs.  Steps for the 
practical implementation of such models are key to understanding how NRAs may 
apply these mechanisms and is something that SAHPRA is also exploring.  As 
SAHPRA moves forward with its objective for regulatory reform it is important that the 
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agency has the relevant capabilities and decision-making frameworks in place to 
ensure the efficient application of resources, with a view to improve median approval 








The aim of the study is to evaluate the regulatory environment in South Africa with a 
view to improve the review process and patients’ access to medicines. 
 
OBJECTIVES 
 Review the historical context supporting the new regulatory environment in 
South Africa and the transition from the MCC to SAHPRA; 
 Evaluate the regulatory review process for NASs in South Africa through 
consideration of key milestones, timelines and scientific assessment models; 
 Evaluate trends in the review of approved NASs in South Africa during the 
period: 2015-2018; 
 Compare the regulatory review practices of SAHPRA with other similar 
emerging economy NRAs; 
 Determine how the implementation of an appropriate benefit-risk framework 
may support a streamlined review process, coupled with improved timeliness 
and increased consistency and transparency; 
 Provide recommendations for the implementation of an abridged review 
process and a framework for GRelPs; and 























National regulatory authorities (NRAs) are tasked with the evaluation of the safety, 
quality and efficacy of medicines.  Following a successful assessment, a medicine will 
be registered by the NRA and given market authorisation.  Timely patients’ access to 
new medicines is a key pillar in any health care system.  NRAs are responsible for 
their regulatory performance and ensuring assessment of new medicines within target 
timelines.  Many NRAs face challenges in meeting these targets and this undoubtedly 
affects patient’s access to new medicines.  The NRA in South Africa has faced similar 
challenges and a large backlog has developed in the registration of new medicines in 
South Africa.  As such, key elements for consideration in this research include the 
application of strategies, frameworks and systems that may be applied to improve the 
regulatory performance of the South African NRA and ensure timely patients’ access 
to new medicines.  These include: risk-stratification approaches and facilitated 
regulatory pathways which would be an advantage when considered in line with the 
recommendations of the WHO; embracing regulatory harmonisation and convergence 
strategies; engaging in reliance and recognition activities, that allow NRAs in resource-
limited settings to consider or accept regulatory decisions made by other comparable 
NRAs in an effort to reduce regulatory burden and avoid duplication of regulatory 
effort; the application of an appropriate framework for benefit-risk assessment to 
enhance consistency in the clinical assessment of medicines; ingraining the principles 
of GRevPs in routine regulatory undertakings and building quality into regulatory 
decision-making to reinforce transparency.  Similar research in this field has 
demonstrated that NRAs are able to improve their regulatory performance and 
accelerate the timelines for the approval and registration of new medicines. 
 
The first chapter of this programme of research has described the emergence of the 
regulatory system and has provided a review of the global regulatory environment.  
The fundamental elements of the regulatory review process have been explored and 
strategies for regulatory system strengthening have been identified. The regulatory 
environment in South Africa has been reviewed and insight into the historical 
challenges and opportunities experienced by the MCC has been provided.  It has 
provided an account of the evolution of the legislative framework, supporting the 
regulatory system, in South Africa and the developments that led to the establishment 
of SAHPRA.  Previous studies evaluating the regulatory performance of mature NRAs 
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have been conducted and comparisons between NRAs of similar scope and size have 
been performed. 
 
This programme of research will be the first to provide a review of the historical context 
and legislative amendments that have supported the regulatory system in South Africa 
and driven the movement for the establishment of a new NRA in South Africa.  This 
research will also be the first to evaluate the regulatory review process applied by the 
MCC and the juxtaposition thereof against comparable NRAs.  This review will be the 
first to be carried out in determining the current practices of NRAs in performing an 
abridged review of a NAS while considering the practicality of the implementation of 
good reliance practices (GRelPs) and how these principles and practices may be 
applied in the South African context.  An assessment of the approach initiated by 
SAHPRA to document and communicate the BR decision will be coupled with these 
studies. 
 
Following a review of the published literature, an analysis of the progression and 
proactive legislative amendments of the regulatory framework in South Africa and a 
critical analysis of eight years of experience working within the NRA of South Africa, it 
became evident that the focus of this study will be to evaluate the regulatory landscape 
in South Africa with a view to improve patients’ access to medicines. 
 
Based on the information reviewed so far, it is proposed that studies will be carried 
out to:  
 Review the evolving legislative regulatory landscape in South Africa over the 
past two decades and the quintessential statutory drive that lead to the 
establishment of the newly established SAHPRA (Study 1) 
 Assess the organisation of the MCC and the regulatory review process applied 
by the MCC and identify the GRevPs actively codified within the MCC’s 
regulatory system (Study 2) 
 Evaluate the regulatory performance of the South African NRA during the 
period 2015-2017 under the auspices of the MCC and 2018 during the transition 
to SAHPRA (Study 3) 
 Compare the MCC registration process with that of similar NRAs in Australia, 
Canada, Singapore and Switzerland (Study 4) 
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 Evaluate the BR framework and decision-making practices (Study 5) 
 Assess the framework for an abridged review using GRelPs and how the 
application of such a framework may optimise the regulatory review process in 
South Africa (Study 6) 
 Develop recommendations for a proposed improved model for regulatory 
review for SAHPRA 
 
These areas of focus have led to the design of six studies that are to be completed 
through this programme of research.  The results from these studies will be analysed 
and will culminate in the development of a set of recommendations that may be 
adopted by SAHPRA with a view to enhance its regulatory performance and ensure 
timely patients’ access to medicine.  The study rationale and methodological 
framework applied in conceptualising these studies have been documented 
throughout this chapter. 
 
Conceptual framework 
The purpose of research may be either exploratory, descriptive or explanatory 
(Saunders et al., 2009).  Exploratory studies are used in order for the researcher to 
gain a better understanding of a problem (or research question) that has been 
identified.  Exploratory research may be conducted by means of literature reviews, 
focus group discussions or interviews with the relevant experts in order to identify the 
precise nature of the problem (Saunders et al., 2009).  Through the use of exploratory 
studies, the researcher may be able to narrow the initially broad focus of the research 
as it progresses.  The main advantage of exploratory studies is the inherent flexibility 
lent to the enquiry without the loss of direction to the enquiry (Saunders et al., 2009).  
Explanatory studies require the researcher to draw conclusions based on the 
relationships identified between variables, as supported by quantitative or qualitative 
data (Saunders et al., 2009).  Descriptive studies require the researcher to identify the 
data to be described before collecting the data.  Descriptive studies require the 
researcher to draw further conclusions from the descriptive data that has been 
collected (Saunders et al., 2009).  Descriptive studies are often considered to be 
supplementary to exploratory or explanatory studies.  Considering the paucity of the 
research topic identified, this research project will be exploratory in nature in a manner 






The choice of a research method is related to how the researcher uses quantitative 
and qualitative data, or the combination thereof, in the collection and analysis of data.  
Quantitative research relates to the collection of numerical data and the analysis 
thereof using statistical tests in the case of “hypothesis testing” design and descriptive 
statistics and graphs in the case of the “exploratory or hypothesis generating” design 
(Saunders et al., 2009).  Whilst, qualitative research relates to the collection of non-
numerical data and the analysis thereof in order to generate descriptions and opinions 
(Saunders et al., 2009). Such approach could also be exploratory or hypothesis 
generating.  Furthermore, the research method choice relates to the decision to use a 
mono-method (the single use of either quantitative or qualitative methods) or multiple-
method (the mixed use of quantitative or qualitative methods) (Saunders et al., 2009).  
The different choices of research methods are illustrated in Figure 2.1. 
 
Figure 2.1 Research method choices 
 
 
Adopted from Saunders et al., 2009 
 
Selected research method 
A mixed methods approach, incorporating both quantitative and qualitative research 
methods will be applied.  The mixed methods approach was selected in order to 
harness the strengths of both qualitative and quantitative research methods and 
provide a broader perspective on the research question.  This research method 
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provides an opportunity for observational exploration through qualitative research 
which may then be validated or invalidated using analytical tools provided by 
quantitative research methods.  Quantitative research methods will be used in Study 
3 to perform a statistical analysis of the data collected on the overall approval time 
lines achieved by the MCC and SAHPRA, for NASs between 2015-2017 and 2018, 
respectively.  The results from the quantitative research will provide a baseline for 
assessing the changes and improvements within SAHPRA going forward. 
 
Qualitative methods including questionnaires and focus groups will be conducted as 
follows: 
 A systematic and narrative literature review will be considered as part of Study 
1 to identify prior initiatives aimed at establishing an improved regulatory 
framework in South Africa as well as risk stratification approaches adopted by 
other NRAs 
 A questionnaire (McAuslane et al., 2009; CIRS, 2019) will be used in: 
o Study 2 to evaluate the MCC in terms of the requirements and the 
current model used for the regulatory review, the process for managing 
timelines, current review times and the application of GRevPs; and 
o Study 4 in the evaluation of the MCC’s regulatory review process as 
compared with the regulatory agencies in Canada, Australia, 
Switzerland and Singapore 
 A questionnaire (CIRS, 2017; McAuslane, 2019) will be used in Study 6 to 
identify the criteria and current practices that were applied by NRAs for 
implementing an abridged review process 
 Focus group discussions will be conducted as part of Study 5 and Study 6. 
 
Study participants 
While there are six studies within this programme of research, only four of the studies 
required the recruitment of study participants.  An overview of the study participants 




Table 2.1: An overview of the study participants 
 
Study Study Participants 
STUDY 2 
Evaluation of the regulatory review 
process in South Africa 
QUESTIONNAIRE 
 Registrar of Medicines for the MCC 
STUDY 4 
Comparison of regulatory review 
processes of the MCC as compared 
with the regulatory agencies in 
Canada, Australia, Switzerland and 
Singapore 
QUESTIONNAIRE 
 Therapeutic Goods Administration (Australia) 
 Health Canada (Canada) 
 Health Science Authority (Singapore) 
 Swissmedic (Switzerland) 
 MCC (South Africa) 
STUDY 5 
Assessment of a benefit–risk 





 Approximately 12 participants representing 
regulatory authorities, industry, health technology 
assessment groups and patient groups 
STUDY 6 
Evaluation of the implementation of a 
framework for an abridged review 
using good reliance practices 
QUESTIONNAIRE 
 Therapeutic Goods Administration (Australia) 
 Health Canada (Canada) 
 ANVISA (Brazil) 
 Gulf Health Council (Gulf Cooperation Council) 
 Ministry of Health (Israel) 




 Approximately 12 participants representing 
regulatory authorities, industry, health technology 
assessment groups and patient groups 
 







When considering the study design to be employed for this research it is critical to 
ensure that the selected study design will yield suitable evidence upon which 
appropriate logical and scientific conclusions, relating to the research question and 
objectives, may be drawn. 
 
Time horizon 
The time horizon relates to the timescale within which the research will be conducted.  
Cross-sectional research refers to the “study of a particular phenomenon at a 
particular time” (Saunders et al., 2009, p.148).  Longitudinal research refers to the 
collection of data over an extended period of time resulting in a rich, comprehensive 
and representative source of data (Saunders et al., 2009). 
 
Selected time horizon 
The cross-sectional study approach was selected as it allows the researcher to collect 
data at a single point in time and employs a survey technique (Saunders et al., 2009) 
to achieve the aims and objectives of this programme of research.  In addition, a 
retrospective approach will be applied in the data collection and analysis of the 
regulatory performance metrics of the MCC (2015-2017) and SAHPRA (2018).  
 
DATA SOURCE 
In order to achieve the objectives of this research, data will be collected from the public 
domain as well as directly from representatives from NRAs, industry, Health 
Technology Assessment (HTA) groups and patient groups from different jurisdictions.  
The inclusion and exclusion criteria for data sources have been determined as follows: 
 
Inclusion criteria 
A questionnaire technique (see Appendix 1) will be used to collect the data required 
to evaluate the MCC regulatory review process and compare the MCC registration 
process with that of similar NRAs. 
For the evaluation of the regulatory performance of the South African NRA the primary 
inclusion criteria were related to data for NASs, including NCEs, biologicals and MLEs, 
only.  The data will be obtained directly from the NRAs and reflect the timelines 
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between the various milestones of the review process, including dossier validation and 
queue time, scientific assessment as well as the overall approval times for NASs 
registered by the South African NRA during the period 2015-2018.  Another 
questionnaire technique (see Appendix 2) will be used to obtain data directly from a 
number of NRAs in order to assess the framework for an abridged review using 
GRelPs and how the application of such a framework may optimise the regulatory 
review process in South Africa. 
 
Exclusion criteria 
Data related to generic medicines, complementary medicines and veterinary 
medicines will be excluded from this study. 
 
Public domain sources 
Published literature, available in the public domain, will be obtained through various 
search engines such as bibliographic databases (e.g. PubMed), Open Access and 
Google Scholar.  Scientific journal articles and textbooks will be examined and the 
information obtained from the websites of NRAs, guidelines of organisations such as 
the WHO, Pan American Health Organization (PAHO) and ICH as well as 
presentations made during regulatory conference proceedings will be surveyed for the 
purposes of this research. 
 
DATA COLLECTION TECHNIQUES 
Techniques for both quantitative and qualitative data collections have been appraised.  
The most appropriate data collection techniques considered for this research were 
selected based on a review of their strengths, weaknesses and the applicability of 
such techniques to achieve the research objectives for each of the studies that will be 
conducted throughout this programme of research. 
 
Literature review: systematic and narrative 
A literature review will be performed in order to gain an understanding of the global 
and local regulatory environment and the challenges and opportunities identified in the 
regulatory review of medicines.  Conducting a literature review will allow for an 
exploratory search of other studies related to the enhancement of regulatory 
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performance and obtaining validated tools such as surveys or questionnaires, from the 
public domain, that may be used to contribute to the studies within this research. 
 
The advantages and disadvantages of both systematic and narrative literature reviews 
were considered.  The comparison of these two types of literature reviews is outlined 
in Table 2.2. 
 
Table 2.2 Comparison between systematic and narrative literature reviews 
 
 
Abbreviation: PRISMA=Preferred Reporting Items for Systematic reviews and Meta-Analyses 
Adopted from Chi-Un, 2015 
 
 A systematic literature review may be used to summarise a large volume of 
information and provide an explanation of the differences observed amongst 
studies examining the same question (Cook et al., 1997).  Scientific strategies 
are employed during a systematic review in order to ensure an unbiased 
appraisal of the relevant studies that address the research question (Cook et 
al., 1997). 
 A narrative literature review relies on the use of informal methods.  Narrative 
reviews allow the researcher to gain a more comprehensive overview of the 
research topic however subjective selection bias may be evident in the 






Selected data collection using a narrative literature review 
Following a consideration of the advantages, disadvantages and relevance of both 
systematic and narrative literature reviews, it was decided that a narrative literature 
review would be best suited for the purpose of this research.  A narrative literature 
review will be conducted as part of an exploratory search of the global regulatory 
landscape and the challenges faced by NRAs in achieving goals for enhanced 
regulatory performance.  The learnings from the narrative review will be developed 
into Chapter 1: General Introduction.  Bibliographic databases will be searched and 
key search words to be included are: GRPs, regulatory performance, milestones, 
regulatory review process, risk-based review and best practices.  The results from the 
initial narrative review will serve to pre-empt the refined search criteria applied to a 
more complex narrative review.  Diverse search engines, including bibliographic 
databases and Google will be used to conduct a systematic review.  The review will 
be conducted using a protocol-based search method to answer the pre-defined 
research question.  The review will be conducted in order to identify existing tools, 
questionnaires and studies that may be applied to evaluate the regulatory performance 
of an NRA and the review practices of NRAs.  The review will be limited to articles 
available in the English-language. 
 
Structured search terms will be developed and used in the search of databases 
against the following criteria: 
 For inclusion: (1) All articles related to a specific tool, questionnaire or study 
used to evaluate the regulatory review process and regulatory review practices; 
(2) studies that assess the regulatory performance of NRAs; (3) studies that 
draw comparisons between NRAs of similar size and scope. 
 For exclusion: (1) General discussions relating to GRPs; (2) tools, 
questionnaires or studies that are not directly related to the regulation of 
medicines. 
In order to prevent any bias stemming from the author’s subjective intention, an 
independent secondary review will be performed.  The secondary review will inform 





Questionnaire techniques and focus groups 
Data collection tools such as questionnaires, interviews and focus groups will be 




Saunders et al. (2009) describe a questionnaire technique as a research technique 
“that involves the structured collection of data from a sizeable population” (p.640).  A 
questionnaire is a data collection technique in which the sample set is required to 
respond to a series of standardised questions in a pre-determined order, thus enabling 
the researcher to draw comparisons from the results obtained within the sample set 
(Saunders et al., 2009).  For the purpose of this research, self-administered 
questionnaires will be used and will be distributed electronically to study participants 
(Figure 2.2).  The use of self-administered questionnaires is beneficial in terms of the 
limited resources required to facilitate distribution, the large sample size that may be 
reached and minimises bias (Saunders et al., 2009).  The disadvantage of this type of 
questionnaire is the risk of a low response-rate and the limitations experienced by 
participants who might need to seek clarification for certain questions in an attempt to 
provide the most accurate response. 
 
Questionnaire development 
Two different validated questionnaires will be used for the purpose of this research 
(McAuslane et al., 2009; CIRS, 2019).  The questionnaires will be completed by 
representatives from NRAs. 
 
 Study 2 and Study 4: The questionnaire (see Appendix 1) considered for these 
two studies (McAuslane et al., 2009; CIRS, 2019c) was initially developed to 
support the evaluation of the regulatory review process in emerging markets 
and the impact of these processes on patients’ access to medicines 
(McAuslane et al., 2009).  Prior to its use in this programme of research, it was 
reviewed and determined to be applicable in meeting the study objectives.  The 
questionnaire will be distributed electronically to the representatives from the 
participating NRAs.  The questionnaire is aimed to evaluate the structure and 
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organisation of NRAs, identify the milestones within the regulatory review 
process and determine the level of implementation of GRevPs.  The data from 
the completed questionnaires will be analysed using descriptive statistics. 
 
 Study 6: The second questionnaire (see Appendix 2) (CIRS, 2017; McAuslane, 
2019) will be administered to identify the criteria and current practices applied 
by NRAs for implementing an abridged review process.  Prior to use in this 
programme of research, this questionnaire was reviewed and determined to be 
applicable in meeting the study objectives. 
 
Figure 2.2 Types of questionnaires 
 
 
Adopted from Saunders et al., 2009 
 
Focus groups 
Focus groups are exploratory tools that may be used to collect an appropriate amount 
of data within a short time frame (Freitas et al., 1998).  Focus groups may be used to 
generate qualitative data.  The focus group consists of participants with homogenous 
research interests discussing a specific topic that is prescribed by the research 
objectives (Freitas et al., 1998).  The advantages and disadvantages of using focus 





Figure 2.3 The advantages and disadvantages of focus group 
 
 
Adopted from Krueger, 1994 and Morgan, 1988 
 
Focus groups are typically made up of ten to 12 participants that are either experts in 
the discussion topic, or are knowledgeable and have experience with the discussion 
topic (Breen, 2006).  Focus group discussions are led by a moderator that guides the 
participants through a set of pre-determined questions and in doing so facilitates the 
generation of qualitative data. 
 
Self-administered questionnaires will be used during this research in order to obtain 
information from NRAs regarding their regulatory review processes (Study 2 and Study 
4) (CIRS, 2019c) and their current practices in applying an abridged review of 
medicines (Study 6) (CIRS, 2017).  The results obtained from the questionnaires will 
allow for ease of comparison amongst the NRAs participating in the studies.  The 
questionnaires will be sent electronically to representatives from each of the identified 
NRAs.  Given the geographical spread of the participants and the researcher, this 
method of distribution will conserve resources. 
The focus group technique will be applied to explore and identify the use of PARs as 
potential knowledge management tools for stakeholders in understanding a reference 
agency’s decision making (Study 5); and the practical implementation of an abridged 





The case study is defined as “a strategy for doing research which involves an empirical 
investigation of a particular contemporary phenomenon within its real life context using 
multiple sources of evidence” (Robson, 2002, p.178).  Survey or experiment strategies 
are considered to be more scientifically rigorous than case studies, however case 
studies may be a valuable source in generating new research questions (Saunders et 
al., 2009).  Case studies may be categorised into single case or multiple case.  Multiple 
case studies are preferred over single case studies as often they are applied across 
multiple organisations or individuals and generalisations across the multiple cases can 
be made (Saunders et al., 2009). 
 
Selected case study 
A multiple case study approach will be applied in Study 5 when comparing the PARs 
from four reference agencies against the UMBRA BR template (Walker et al., 2014).  
Attempts will be made to identify generalisations across the four PARs and then will 
be compared with the approach initiated by SAHPRA to document and communicate 
the BR decisions. 
 
A summary of the selected data collection techniques 
Table 2.3 provides a summary of the data collection techniques that have been 
selected for the purpose of this research and the relevant research objectives and 




The study plan (Figure 2.4) illustrates the commencement of the research with a 
literature review (Study 1), followed by conceptualisation of the studies, coupled with 
the development of the study question and study design.  A questionnaire (see 
Appendix 1) will be used to evaluate the regulatory review process for NASs in South 
Africa through consideration of key milestones, timelines and scientific assessment 
models (Study 2).  The same questionnaire will also be used in the comparison of the 
















Review of the regulatory environment 





Evaluation of the regulatory review process 
in South Africa 
Chapter 4 
(Study 2) 
Comparison of the Medicine Control Council’s 
Regulatory Review Processes with Australia, 
Canada, Singapore and Switzerland 
Evaluation of MCC’S regulatory review process as 
compared with the regulatory agencies in Canada, 
Australia, Switzerland and Singapore 
Chapter 6 
(Study 4) 
Recommendations for the implementation of a 
model for regulatory reliance in South Africa 
An overview of the principles of good reliance 
practices and recommendations for the 
implementation of a model for good reliance 




Assessment of a benefit–risk framework & 
decision making practices 
An evaluation of the UMBRA framework as applied in 
the South African context and the feasibility of 




Recommendations for the implementation of a 
model for regulatory reliance in South Africa 
An evaluation of the implementation of a framework 




Assessment of a benefit–risk framework & 
decision making practices 
An evaluation of the UMBRA framework as applied in 
the South African context and the feasibility of 





Abbreviations: MCC=Medicines Control Council; SAHPRA=South African Health Products Regulatory 
Authority; UMBRA=Universal Methodology for Benefit-Risk Assessment  
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Data collected directly from the South African NRA, in the form of performance metrics 
for the overall approval timeline for NASs will be used to evaluate trends in the review 
of approved NASs in South Africa during the period 2015-2018.  A second 
questionnaire (see Appendix 2) will be used to identify the criteria and current practices 
that were applied by NRAs for implementing an abridged review process (Study 6).  
Focus group sessions will be held to explore the use of PARs as potential knowledge 
management tools for stakeholders in understanding a reference agency’s decision-
making (Study 5) and determine the practical implementation of an abridged review 
process for new medicines in the light of the WHO’s GRelPs (Study 6).  It is hoped 
that the analysis of the results from these six studies will culminate in a set of key 
recommendations for the proposed improved model for regulatory review for SAHPRA 
and improved patients’ access to medicines.  These recommendations will be further 
explored in Chapter 9, General Discussion. 
 
 
DATA PROCESSING AND ANALYSIS 
Qualitative data will be generated through the application of questionnaires and focus 
groups discussions.  No statistical tests will be used to analyse the qualitative data 
collected in the exploratory studies (Study 1, 5 and 6).  Conclusions drawn from 
hypothesis generating qualitative data may be considered for future research.  The 
quantitative data collected in Study 2, 3 and 4 will be entered into Microsoft Excel for 
data analysis.  The results of these analyses will be presented using descriptive 
statistics such as medians and upper and lower quartiles.  The results may also be 
presented graphically in order to provide visual comparisons and illustrate 
relationships between variables.  Time series analysis will be used to analyse the time 
series data collected in Study 3, which reflects the number of NASs registered by the 
MCC, per quarter, in the period 2015-2017.  The ratio-to-moving-average method will 
be used to calculate seasonally adjusted indices for each quarter in the period 2015-
2017.  This method was selected because it is widely used to measure seasonal 
variation and integrate trends into forecasting.  As the scope of Study 3 is exploratory 
in nature and not designed to support hypothesis testing, no further statistical analysis 









The data generated through the six studies contained within this programme of 
research will be processed and analysed using several methods.  The data analysis 
for each study and the results thereof will be documented across six separate 
chapters.  The key recommendations stemming from these chapters will be 
consolidated into a set of key recommendations for the proposed improved regulatory 




Ethics approval was obtained from the University of Hertfordshire.  This programme 





 This chapter describes the study rationale and provides an outline of the six 
proposed studies that are to be conducted in order to achieve the research aim 
and objectives 
 
 The study purpose was described to be exploratory in nature in a manner that 
supports hypothesis generation as opposed to hypothesis testing 
 
 The data collection techniques used throughout this programme of research 
were described and valued in terms of the study objectives.  As a result, the 
data collection techniques used included literature review, the use of validated 
questionnaires, a focus group approach and a case study 
 
 The methodologies applied in the analysis of the data obtained from the South 
African NRA, comparable NRAs and focus group participants were described 
 
 The data collected during this research was grouped and examined in three 
major areas, namely: 
o the regulatory review process and the associated milestones and 
timelines for review (Study 1-4);  
o the assessment of a benefit-risk framework and decision-making 
practices (Study 5); and  
o recommendations for the implementation of a framework for an abridged 
review using GRelPs (Study 6) 
 
 A detailed study plan was outlined to illustrate the relationship between the six 





















Ensuring effective medicine regulation through the strengthening of regulatory 
systems and improvement of regulatory performance has become a priority for both 
NRAs and governments worldwide.  With the support of government, NRAs are 
responsible for protecting and promoting public health, implementing rigorous 
regulatory standards and maintaining an assured supply of medical products that are 
safe, effective and of good quality (Rägo & Santoso, 2008; WHO, 2018a; Ndomondo-
Sigonda et al., 2017).  Despite the critical role that NRAs play within national 
healthcare systems the importance of medical product regulation often goes under-
recognised and is often under-funded (Rägo & Santoso, 2008).  The WHO has 
indicated that almost a third of NRAs do not have the capacity to perform core 
regulatory functions and would not be able to sustain effective regulatory systems 
without adequate financial support (WHO, 2003). 
 
Global trends toward increased pressure on NRAs of all sizes and capacity due to the 
increased volumes of applications received, the complexity of the submissions and the 
increased number of categories of medical products have been noted (WHO, 2014b).  
These trends and statistics resonate with many NRAs in low- and middle-income 
countries that have historically been faced with resource constraints (WHO, 2014a) 
and that have not participated in global harmonisation initiatives or development 
programs aimed at strengthening regulatory systems (Preston et al., 2012).  Efforts to 
address the challenges faced by NRAs in resource-limited settings have focused on 
identifying and performing core regulatory functions that have to be undertaken directly 
by NRAs to meet country or regional needs (WHO, 2014b; Ward, 2014).  National 
regulatory authorities (NRAs) have also been encouraged by the WHO to consider 
regulatory convergence and to collaborate with and recognise work done by other 
regulators to ease the regulatory burden (WHO, 2014b; Ward, 2014). 
 
Resolution WHA67.20 emanating from the Sixty-seventh World Health Assembly 
(WHA) in 2014 identified the need for effective regulatory systems and highlighted that 
“inefficient regulatory systems create barriers for access to safe, effective and quality 
medical products” (WHA, 2014, p1).  The drive for improved regulatory systems and 
the establishment of a more effective regulatory framework in South Africa has been 
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evident for the past two decades but despite political intentions and legislative 
revisions success has been limited to date. 
 
It is suggested that while multi-factorial elements have resulted in a backlog in 
medicines registration, significant pro-access policies compounded by legislative 
requirements for the expedited review of medicines on the Essential Drugs List (EDL), 
most of which are generics, may be at the root of the problem (Leng et al., 2015).  
Efforts to address the increasing volume of applications that have been received have 
to date failed and resources have been stretched to capacity resulting in the 
development of a significant backlog and extended timelines for product registration. 
The median approval times for fast track applications approved by the MCC in 2015, 
2016 and 2017 were 1218, 921 and 609 calendar days respectively.  There was no 
target time set for the overall review time of new chemical entities (NCEs) and the 
median approval times for NCE marketing authorisation applications approved in 
2015, 2016 and 2017 were 1175, 1641 and 1466 calendar days respectively.  These 
data demonstrate that the MCC was not able to achieve the target timelines of 250 
calendar days set for fast track applications nor meet the targets in 2015, 2016 and 
2017 for the key milestones within the regulatory review process. 
 
Pharmaceutical companies, private clinical research organisations, academic clinical 
research groups and civil society organisations have complained that delays and the 
backlog in medicines registration were harming patients’ access to affordable 
medicines (Leng et al., 2015). It has been reported that prior to 2005 the number of 
applications received and the number of registration certificates issued were in 
equilibrium, however from 2005 the number of applications submitted more than 
doubled whereas the number of certificates issued remained approximately the same 
(Leng et al., 2015). 
 
The South African NRA has a historical average of receiving approximately 4700 
applications per year but has demonstrated that it can only process approximately 
2550 applications per annum (SAHPRA, 2018a).  SAHPRA inherited a backlog of 
approximately 16 000 applications that included all applications submitted up to 31 
January 2018 which are yet to receive final approval (SAHPRA, 2018a).  The SAHPRA 
Board aimed to clear the backlog within the next two years.  Given that more than half 
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of the new registration applications were at least five years old, the industry were 
requested to indicate whether they would like to withdraw those applications submitted 
in 2013 or earlier.  Submissions within the backlog need to be consolidated, updated 
and resubmitted to ensure that those requiring evaluation reflect current data 
(SAHPRA, 2018a).  Applications will be segmented and prioritised according to public 
health priorities (SAHPRA, 2018a).  SAHPRA is committed to operationalise reliance 
models for product review supported by optimal staffing solutions, implementation of 
a digitally powered approach to evaluation, effective change management and 
improved transparency and accountability (SAHPRA, 2018a). 
 
The promulgation of the recently amended Medicines and Related Substance Act, 
1965 (Act 101 of 1965) hereafter referred to as the Medicines Act triggered the 
establishment of SAHPRA as a separate juristic person outside of the National 
Department of Health to replace the former medicine regulatory authority the MCC.  
The amended Medicines Act saw the scope of the Authority’s mandate extended to 
make provision for the regulatory oversight of medical devices and complementary 
medicines in South Africa and to make provision for the Authority to establish and 
strengthen collaborative initiatives with other regulatory authorities or institutions 
(Medicines and Related Substances Act 2017). 
 
The aim of this chapter was to provide the historical context supporting the new 






THE MEDICINES CONTROL COUNCIL 
Prior to the establishment of SAHPRA in February 2018 the MCC was the national 
medicines regulatory authority of South Africa responsible in terms of the Act to 
provide for the monitoring, evaluation, regulation, investigation, inspection, registration 
and control of human and veterinary medicines, scheduled substances, clinical trials 
and related matters in the public interest.  The statutory obligations of the MCC were 
to ensure that medicines that were available in South Africa met the required 
standards of quality, safety, and efficacy (MCC, 2006). 
 
Organisational structure 
The MCC was a statutory body appointed by the Minister of Health consisting of not 
more than 24 members including the chairs of the expert committees.  In addition, the 
council appointed external experts to serve on various expert committees overseeing 
medicine registration, regulation and control functions.  Overall there were 11 active 
expert committees including the Biological Medicines, Clinical, Clinical Trials, 
Complementary Medicines, Good Practice, Legal, Medical Devices, Names & 
Scheduling, Pharmaceutical & Analytical, Pharmacovigilance and Veterinary Clinical 
Committees (MCC, 2017).  The skills of the members of the council and its committees 
were written into law and included expertise in toxicology and medicine safety, basic 
and clinical pharmacology, biotechnology, pharmaceutics, internal medicine, virology, 
pharmaceutical chemistry, neonatology, paediatrics, immunology, veterinary science, 
complementary medicines and law (MCC, 2017). 
 
The Office of the Registrar served as the Executive Secretary to the MCC and provided 
administrative and technical support to the Council and its activities.  The Office of the 
Registrar was a Chief Directorate within the National Department of Health known as 
the Cluster: Food Control, Pharmaceutical Trade & Product Regulation.  There were 
four Directorates within the Cluster namely, Operations & Administration, Inspectorate 
& Law Enforcement, Medicines Evaluation & Research and Clinical Evaluation & 
Trials.  The staff complement of the Cluster included doctors, pharmacists, 
veterinarians, scientists and administrative staff (MCC, 2017).  The MCC 









Regulatory review process 
The registration of medicines in South Africa is governed by the provisions and 
requirements of the Medicines Act including the regulations and the published 
guidelines. Legislative frameworks require that medicines including NCEs, 
multisource/generic medicines, biological medicines, complementary medicines and 
veterinary medicines are evaluated by the NRA prior to marketing of the product.  
Applicants are required to submit technical dossiers to demonstrate the quality, safety, 
and efficacy of such medicines intended for sale in South Africa.  The confidentiality 
of information submitted to the NRA is governed by Section 34 of the Medicines Act 
regarding the preservation of secrecy.  The regulatory review process of the MCC is 
presented in Figure 3.2 and provides a simple representation of the review and 








The NRA made use of both internal and external expertise to evaluate applications for 
the registration of medicines.  A full review of the safety, quality, and efficacy data, 
together with the assessment reports prepared by reviewers were considered by the 
various expert committees to make recommendations on the approval of the 
proprietary name of the product, the allocation of a scheduling status for the active 
pharmaceutical ingredient and the evaluation of the good manufacturing practice 
(GMP) status of the applicant, the manufacturer of the active pharmaceutical 
ingredient, the manufacturer of the finished pharmaceutical product, the packer and 
the quality control laboratory.  The final decision for authorisation or refusal was made 
by the MCC.  
 
History of enabling legislation 
The introduction of the regulation of medicines in South Africa was initiated in the 
1960s when the National Department of Health appointed the Snyman Commission to 
investigate the high cost of medicines and medical services in South Africa (Snyman, 
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1965).  The report of the Commission of Inquiry recommended that at the time the 
medicines should be controlled in terms of their purity, safety and therapeutic efficacy 
(Gouws, 2003, unpublished thesis).  These recommendations resulted in the 
promulgation of the Drugs Control Act, 1965 (Act 101 of 1965) and the establishment 
of the Drugs Control Council responsible for the control of medicines for human use.  
The introduction of a registration procedure in 1968 meant that all medicines intended 
for sale in South Africa were evaluated and approved by the Drugs Control Council 
prior to entering the market.  Medicines available on the market prior to 1968 were 
initially exempt from these requirements and were referred to as “old medicines”.  Over 
the next three decades the legislative framework and regulatory requirements were 
amended several times to reflect the intentions of the regulatory authority as it strived 
towards improved control of medicines in South Africa.  Some of the important 
amendments made to the principal Act, the Medicines and Related Substances Act, 
1965 (Act 101 of 1965) are listed in Table 3.1 and the historic projects and legislative 
changes are noted in Table 3.2 (Gouws, 2003, unpublished thesis). 
 
The Amendment Act, 1997 (Act 90 of 1997) was the first legislative amendment to be 
made to the principal Act following the change of government in South Africa after the 
general elections held in 1994 (Gouws, 2003, unpublished thesis).  With this change 
came the adoption of a programme for health reform and the launch of the National 
Drug Policy.  This Amendment Act, 1997 was promulgated in 1997 and Section 15C 
specifically was the subject of a legal challenge by the Pharmaceutical Manufacturers 
Association (PMA) which prevented the implementation of this Amendment Act, 1997 
until 2003 PMA v. President of the Republic of South Africa (1998).  The then Minister 
of Health, Nkosazana Dlamini-Zuma appointed an advisory panel to review the 
medicine regulatory environment in South Africa (Dukes et al., 1998).  In December 
1998 a report titled “Operational and Financial Review - Discussion Draft” prepared by 
KPMG also endorsed the restructuring of the MCC with the aim of improving 
operational efficiencies.  On the recommendation of the ministerial advisory panel a 
new Amendment Act (South African Medicines and Medical Devices Regulatory 
Authority Act 1998) establishing the (SAMMDRA) to replace the MCC was passed by 
Parliament.  The SAMMDRA Act was promulgated prematurely without the necessary 
Regulations and was subsequently set aside PMA and Another v. In re Ex Parte 
President of the Republic of South Africa and Others (2000). 
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In late 2007, yet another decision was taken to restructure the MCC by establishing a 
new authority as a public entity outside of the National Department of Health.  A report 
on the restructuring of the MCC was presented by a Ministerial Task Team led by 
Professor Green-Thompson who was appointed as a Special Advisor to the Minister 
of Health, Manto Tshabalala-Msimang (SAHPRA, 2016).  The Green-Thompson 
Report recommended the establishment of a new NRA to replace the MCC referred 
to as SAHPRA and emphasised the need for international and regional harmonisation 
to support reliance and recognition frameworks with other regulatory authorities 
(Green-Thompson, 2008).  This report amongst others recommended extending the 
regulatory mandate of the authority to include medical devices and highlighted the 
need to effect BR assessment of medicines and QDMPs to support transparent 
regulatory decision-making.  Regulatory models of other NRAs were benchmarked 
and a key recommendation from this report informed the need for collection of metrics 
to facilitate the measurement and monitoring of regulatory performance and the impact 
of the proposed changes to the regulatory review process (Green-Thompson, 2008).  
The recommendations of the Green-Thompson report resulted in a further amendment 
of the principal Act and the Medicines Amendment Act, 2008 (Act 72 of 2008) was 
signed into law by then President Kgalema Motlanthe in 2009 but not implemented 
(SAHPRA, 2016).  The reason for this was multi-factorial and included the need for 
strengthened governance and certain transitional provisions. 
 
A project team led by Dr Nicholas Crisp was appointed in 2009 by the Minister of 
Health, Barbara Hogan to revive legislative endeavours directed towards regulatory 
reform and the establishment of an improved NRA (SAHPRA, 2016).  The remit of this 
project team was to develop the business case for SAHPRA as well as the transitional 




Table 3.1 Amendments to Drug Control Act 1965 
 
Amendment Number Change 
Amendment Act No 29 of 1968 
 Drugs that were subjected to registration were defined 
 Categories for the classification of these drugs were defined 
Amendment Act No 88 of 1970 
Amendment Act No 95 of 1971 
 Made provision for the control of advertising of drugs 
Amendment Act No 65 of 1974 
 The term “drug” was replaced with “medicine” 
 The Drugs Control Council was changed to the Medicines Control Council 
 The constitution of the Medicines Control Council, remuneration of the Council members and the appointment of 
the Committees of Council and a Medicines Control Appeal Board was defined 
Amendment Act No 17 of 1979 
 The mandate of the Act was extended to include the regulatory oversight of veterinary medicines, including the 
registration, labelling and advertising thereof 
Amendment Act No 94 of 1991 
 The powers, functions and constitution of the Council were defined 
 The establishment of the Medicines Control Appeal Board was repealed 
 Provisions for an alternative appeal procedure against the decision of the Council were defined 
Amendment Act No 90 of 1997 
 The Medicines Control Council was established as a juristic person 
 Members of the Council or the Committees were required to declare commercial interests related to the 
pharmaceutical or health care industry 
 The members of the Executive Committee of the Council, were to be appointed subject to the approval by the 
Minister of Health 




 Provision for expedited registration of essential medicines 
 Re-registration of medicines every 5 years 
 Provisions for compulsory licensing and parallel importation 
 Provisions to enable generic substitution were defined 
 A Pricing Committee for medicines was established 
 The process of appeal against a decision of the Director-General of Health was defined 
 Provision was made for acquiring of additional funds by the Council 
 The powers of the Minister of Health to make regulations pertaining to the Medicines Act were further defined 
Amendment Act 59 of 2002 
 Provision was made for the appointment of Deputy Registrars 
 The term of office of the Pricing Committee members was defined 
  Regulations relating to the marketing of medicines was defined 






Table 3.2 Historic projects and legislative changes 
 
Timeline Initiated by Project Team Objective Recommendation Result 





 Investigate the high 
cost of medicines 
and medical services 
in South Africa 
 Medicines should be controlled in 
terms of their “purity, safety and 
therapeutic efficacy” 
 Promulgation of the Drugs Control 
Act, 1965 (Act 101 of 1965) 
 Establishment of the Drugs Control 
Council 









 Endorsed the restructuring of the 
MCC with the aim of improving 
operational efficiencies 
 The new Amendment Act 
establishing the SAMMDRA to 
replace the MCC was passed by 
Parliament 









 Report on the 
restructuring of the 
MCC 
 The establishment of a new NRA to 
replace the MCC referred to as 
SAHPRA 
 The need for international and 
regional harmonisation 
 The need for collection of metrics 
to facilitate the measurement and 
monitoring of regulatory 
performance 
 Further amendment of the principal 
Act 
 The Medicines Amendment Act, 2008 
was signed into law by then President 
Kgalema Motlanthe in 2009 but not 
implemented 
2009 Minister of Health, 
Barbara Hogan 
Project team 
led by Dr 
Nicholas Crisp 




 Develop the business case for 
SAHPRA 
 Identification of further legislative 
amendments 
 Further amendment to the Medicines 
Amendment Act, 2008 
 The Medicines and Related 
Substances Amendment Bill, 2012 
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 Establishment of an 
improved NRA 
was published for comment in March 
2012 














required for the 
transition to 
SAHPRA 
 Benchmark regulatory procedures 
in identified technical and 
operational areas  
 Explore mechanisms for 
information sharing and systems to 
establish mutual recognition for 
registration requirements and 
product approval 
 Finalisation of the Medicines and 
Related Substances Amendment Bill, 
2012  
 The new Medicines Amendment Act, 
2015 was approved (January 2016) 
 The draft SAHPRA business case 
prepared by Dr Nicolas Crisp was 
amended to reflect current 
developments and the key elements 
required for the transition of the MCC 
to SAHPRA  
 
Abbreviations: HPTTT=Health Products Technical Task Team; MCC=Medicines Control Council; NRA=National Regulatory Authority; SAHPRA=South African 
Health Products Regulatory Authority; SAMMDRA=South African Medicines and Medical Devices Regulatory Authority
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Through the work of the project team further amendments were made to the Medicines 
Amendment Act, 2008 (Act 72 of 2008) and the Medicines and Related Substances 
Amendment Bill, 2012 was published for comment in March 2012 (SAHPRA, 2016).  
In July 2012 the project team presented a draft business case for the establishment of 
SAHPRA (SAHPRA, 2012).  The business case put forward a motion to establish 
SAHPRA as a Schedule 3A Public Entity to reinforce the political will to establish an 
NRA with operational autonomy and accountability.  As a Schedule 3A Public Entity 
SAHPRA would be a separate juristic person outside of the National Department of 
Health accountable for sound corporate governance practices and adherence to 
compliance codes in terms of relevant legislation, financial regulations, directives, 
policies and procedures (National Treasury, 2015).  The business case defined an 
extended mandate for SAHPRA including the regulatory oversight of food, 
complementary medicines, medical devices and radiation control.  The report 
demonstrated historical under-funding of the NRA linked with recommendations for 
levying increased fees and motivated for proactive remuneration strategies to attract 
and retain the expertise required to execute the mandate of SAHPRA.  It also 
expanded on the over-reliance on paper-driven systems and the necessity for an 
EDMS (SAHPRA, 2012). 
 
The Director General of Health, Malebona Precious Matsoso, also appointed a Health 
Products Technical Task Team (HPTTT) in 2012 to consider the project team’s 
recommendations and to advise further on the key legislative, programmatic, 
infrastructural, structural and operational elements required for the transition to 
SAHPRA (HPTTT, 2014; Pharasi & Banoo, 2015).  The HPTTT as part of its mandate 
engaged several NRAs (the EMA, USFDA, Swissmedic, the United Kingdom 
Medicines and Healthcare Products Regulatory Agency (MHRA) and the Australian 
TGA to examine and benchmark regulatory procedures in identified technical and 
operational areas as well as to explore mechanisms for information sharing and 
systems to establish mutual recognition for registration requirements and product 
approval.  These activities were also aimed at maximising regulatory capacity and 
operations under SAHPRA through understanding the structure and functioning of 
these agencies in line with international best practice standards.  One of the outcomes 
of the HPTTT work was the finalisation of the Medicines and Related Substances 
Amendment Bill, 2012 and its introduction to Parliament for consideration.  The new 
56 
 
Medicines Amendment Act, 2015 (Act 14 of 2015) was approved by the Parliament, 
assented to by the President in December 2015 and published in the Government 
Gazette in January 2016 (SAHPRA, 2016).  The draft SAHPRA business case 
prepared by Dr Nicolas Crisp was further amended by the HPTTT to reflect current 
developments and the key elements required for the transition of the MCC to SAHPRA 
(SAHPRA, 2016).  The amended business case defined the preparation and 
operationalisation of the transition, directed the development of a new fee schedule 
published in September 2015 to support the viability of the new NRA, informed the 
development and publication of the regulations for medical devices in December 2016 
and confirmed the withdrawal of food control from the regulatory ambit of SAHPRA 
(SAHPRA, 2016).  With the focus on financial and operational considerations these 
transitional arrangements overlooked the critical need for the review and improvement 
of the regulatory review process of the NRA as recommended in the Green-Thompson 
report.  On the 1st June 2017 the amendments to the principal Act were enacted via 
proclamation of the Medicines and Related Substances Amendment Act, 2008 (Act 72 
of 2008) read together with the Medicines and Related Substances Amendment Act, 
2015 (Act 14 of 2015). 
 
 
THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY 
In February 2017 SAHPRA was legally established as a Schedule 3A Public Entity in 
terms of the Public Finance Management Act (PFMA), 1999 (Act 1 of 1999) to fulfil 
specific responsibilities on behalf of national government (National Treasury, 2015).   
In October 2017 the Minister of Health, Aaron Motsoaledi, announced the appointment 
of 15 SAHPRA Board members.  The Board members were appointed to serve for a 
period of three years under the leadership of Professor Helen Rees, the outgoing 
Chairperson of the MCC and the first Chairperson of the SAHPRA Board.  In contrast 
to the MCC the SAHPRA Board has full operational autonomy and accountability.  
Through the Board the Authority is accountable to the Minister of Health (Medicines 
and Related Substances Act 2017).  The SAHPRA Board after consultation with the 
Minister of Health must appoint a suitably qualified person as the CEO of the Authority 
(Medicines and Related Substances Act 2017).  The CEO is accountable to and 
reports to the SAHPRA Board and is responsible for the general administration of the 
Authority and for the carrying out of any functions assigned to the Authority (Medicines 
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and Related Substances Act 2017). To this effect, Dr Boitumelo Semete-Makokotlela 
was appointed as the first CEO of SAHPRA. The organisational structure of SAHPRA 
is displayed in Figure 3.3. 
 
Figure 3.3 Transitional organisational structure of the South African Health 
Products Regulatory Authority (SAHPRA) 
 
 
Abbreviations: CFO=Chief Financial Officer; SAHPRA=South African Health Products Regulatory 
Authority 
 
The four Directorates depicted will be replaced by five programmes responsible for 
performing the regulatory activities of the Authority.  In order to ensure continuity 
transitional arrangements have been put in place for the expert committees to continue 
providing scientific expertise and support. A Regulatory Advisory/Oversight 
Committee for medicines and medical devices has been appointed by the CEO in 
consultation with the SAHPRA Board to investigate and report to the Authority on any 
matter within its purview in terms of Medicines and Related Substances Act, 1965 (Act 
101 of 1965).  The SAHPRA Board may appoint one or more committees from among 
its members to assist it with the performance of its functions and has appointed a 
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Technical Operations and Regulatory Strategy (TORS) Committee with investigation 
into the backlog in application for registrations as part of its remit. The SAHPRA 
Business Case (SAHPRA, 2016) stated that the legislative mandate of SAHPRA is 
derived from the Constitution of the Republic of South Africa, 1996 which places 
obligations on the state to progressively realise socio-economic rights including 
access to health care as well as the National Health Act, 2003 (Act 61) and the 
Medicines and Related Substances Act, 1965 (Act 101 of 1965) (pp. 23-24). 
 
According to the Medicines and Related Substances Act, 1965 (Act 101 of 1965), 
SAHPRA’s obligations include ensuring public protection, ensuring transparency and 
accountability in its operations and being responsive to the regulatory environment 
(SAHPRA, 2016, p. 26). 
 
The functions of the Authority are defined in Section 2B of the Medicines and Related 
Substances Act, 1965 (Act 101 of 1965). The Authority must, in order to achieve its 
objectives, ensure that the: 
 Evaluation or assessment and registration of medicines and medical devices, 
are efficient, effective and ethical and that registered medical products meet 
the defined standards of quality, safety, efficacy and performance; 
 Process of evaluating or assessing and registering medicines and medical 
devices is transparent, fair, objective and concluded in a timely manner;  
 Medicines and medical devices are re-evaluated or reassessed and monitored 
periodically; 
 Existing and new adverse events, interactions and information with regard to 
post-marketing surveillance and vigilance are monitored, analysed and acted 
upon; 
 Compliance with existing legislation is being promoted and controlled through 
a process of active inspection and investigation; and  
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 Clinical trial protocols are assessed according to prescribed ethical and 
professional criteria and defined standards. 
 
The political will and leadership have seen the efforts for an improved regulatory 
landscape in South Africa come to fruition as the evolving NRA strives towards an 
effective and efficient regulatory authority.  The key operational differences between 
the MCC and SAHPRA are highlighted in Table 3.3.  The mandate of SAHPRA has 
been extended to include medical devices and complementary medicines and the 
legislative framework for reliance and recognition has been finalised.  It is anticipated 
that improvements to the other operational elements listed in Table 3.3 will be realised 
with the establishment of SAHPRA. 
 
Extended mandate 
In the past the MCC was mandated to ensure regulatory oversight of human and 
veterinary medicines.  With the promulgation of the amendments to the principal Act 
the mandate of the Authority has been extended to include medical devices, ionising 
and non-ionising radiation emitting devices, radioactive nuclides and complementary 
medicines. 
 
Challenges and changes 
Historically the MCC faced resource constraints as workloads placed on the regulator 
steadily increased.  As a result, the MCC became dependent on over-committed 
external expertise.  Evaluation structures which relied on external evaluators lacked 
effective performance management contracts and did not provide a sustainable 
mechanism for timely submission of evaluation reports.  The regulatory functions 
mandated to SAHPRA are people-dependent (SAHPRA, 2016).  Adequate, competent 
and motivated human capital plays a vital role in ensuring organisational success 
(SAHPRA, 2016).  “It is the intended goal of SAHPRA to have an adequate number of 
staff with the right skills mix, at the right level, available and employed in appropriate 
positions within the organisation” (SAHPRA, 2016, p. 152).  Efforts to reform 
organisational structures within SAHPRA should be prioritised to build and retain in-




Table 3.3 Key operational differences between the Medicines Control Council (MCC) 
and the South African Health Products Regulatory Authority (SAHPRA) 
 
 
Abbreviations: MCC=Medicines Control Council; SAHPRA=South African Health Products Regulatory 
Authority; QMS=Quality Management System 
 
Harmonisation initiatives 
As an Authority mindful of limited resources and capacity constraints the MCC had 
always recognised the value of harmonisation initiatives and had explored the 
possibility of implementing reliance mechanisms.  In the past the MCC participated in 
regional collaboration initiatives such as the Zazibona collaborative work-sharing 
process which aimed to harmonise regulatory efforts between regional NRAs.  
Harmonisation efforts may now be actively enforced as the inclusion of Section 
2B(2)(a) and 2B(2)(b) in the Medicines Act provides a mandate for the Authority to 
liaise with and enter into agreements with any other regulatory authorities or 
institutions (Medicines and Related Substances Act 2017). 
 
Operational element MCC SAHPRA 
Mandate Human and veterinary medicines 
Medical devices and 







Limited scope for reliance 
mechanisms 
Legal framework for reliance 
mechanisms 
Quality management system Informal implementation of QMS 
Formal implementation of the 




Electronic document management 
systems-driven 
Fee structure 
Collection of fees by National 
Treasury 
Retention of user-fees  
Service delivery History of backlogs Improved timeliness 
Stakeholder relationships Stretched industry relationships Transparency and accountability 
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The advantages of such regulatory relationships are offset by a number of 
prerequisites including the assumption that SAHPRA adopts internationally 
harmonised guidelines and standards (SAHPRA, 2016), relevant memoranda of 
understanding and confidentiality agreements are in place with reliable regulatory 
authorities recognised by SAHPRA (Green-Thompson, 2008), that SAHPRA remains 
accountable for the health and safety of the citizens of South Africa (SAHPRA, 2016), 
that some regulatory decisions may be made based on the regulatory activities and/or 
decisions made by other reliable authorities and recognised by SAHPRA (SAHPRA, 
2016) and that enhancing regulatory convergence and participating in collaboration 
and work-sharing initiatives will contribute towards a decreased regulatory burden and 
a decreased workload on SAHPRA.  SAHPRA will also have the opportunity to make 
better use of the limited resources available to improve post-marketing surveillance 
activities and will contribute towards efforts to minimise duplication of regulatory efforts 
(WHO, 2003). 
 
Quality management system 
The MCC has recognised the importance of formally implementing quality measures 
throughout the agency in order to ensure consistency, increase transparency and 
improve efficiencies.  In the past the MCC did not have a dedicated Quality 
Management Unit however contingencies have been put in place to establish such a 
unit.  This unit will be responsible for formalising the implementation of the QMS for 
the authority and for performing internal quality audits and for implementing strategies 
geared for continuous improvement.  The implementation of a formalised QMS will 
ensure that GRevPs are codified into policies and guidelines, regularly monitored and 
subject to continuous improvement (WHO, 2016).  Through the application of a robust 
QMS underpinned by the drive to cultivate an integral quality culture the regulatory 
performance and responsiveness of SAHPRA will be enhanced.  
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Document management system 
“A regulatory authority must have an effective system of tracking application 
assessment processes and decision-making; these systems require an appropriate 
use of information technology” (Hill & Johnson, 2004, p.27).  The development of an 
integrated information system, improvement of the current information and 
communication technology (ICT) infrastructure and the use of an EDMS will be 
essential for SAHPRA.  Given the large volume of complex applications submitted to 
the Authority and the need for optimal document management it is critical that the 
Authority moves away from the historically paper-driven processes of the MCC.  It is 
the intention of SAHPRA to implement an EDMS that can replace the legacy systems 
currently in use.  SIAMED, a software programme adopted from the WHO, is one such 
system that was used by the MCC and inherited by SAHPRA to track and manage 
applications for the registration of medicines.  This system has become outdated and 
will be phased out as electronic systems capable of facilitating the electronic 




The historical integration of the MCC into the operations of the South African National 
Department of Health has not served the MCC well as it worked towards ambitious 
goals of improved regulatory performance without the financial support required to 
establish a new regulatory authority that would be a viable regulator of medical 
products, trusted and respected by the pharmaceutical industry, civil society and 
patients of the Republic (SAHPRA, 2016).  The Act makes provision for the Authority 
to levy fees for services rendered for example, a fee may be charged for the evaluation 
and registration of medical products.  Fee structures vary significantly between 
different regulatory authorities.  Fees may be set arbitrarily, they may be related to the 
cost of providing a service or they may be scaled, commensurate with the amount of 
data submitted and the time required for evaluation of the data. 
 
The establishment of SAHPRA as a 3A Public Entity allows for change in that the 
finances generated by the Authority will be retained.  This revenue structure is different 
to the past model that existed within the MCC whereby incoming fees were collected 
by the National Treasury and channeled to central government revenue.  Although the 
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Authority will be partially funded from the national government funds a key deliverable 
for SAHPRA will be to raise the required revenue to make the Authority sustainable 
(SAHPRA, 2016).  Suggestions to increase the fees for services levied by the Authority 
may be a solution but this will require significant improvements in regulatory 
efficiencies in order to appease the demands and expectations of stakeholders.  
Furthermore, an opportunity exists to generate more fees as the mandate of the 
Authority is extended to include the regulation of medical devices, complementary 
medicines and radiation control (SAHPRA, 2016). 
 
Service delivery and stakeholder relationships 
“SAHPRA has an obligation to effectively implement a regulatory framework that 
supports regulatory functions, enables the objectives of the National Drug Policy and 
promotes the priority goals of the National Department of Health” (SAHPRA, 2016, 
p.152).  In order to do so it is necessary to improve structures within the Authority and 
advance the functions of the Authority to develop an accessible regulatory service 
footprint (SAHPRA, 2016). 
 
Recognition of SAHPRA as a sustainable-well functioning regulatory system is a key 
feature of the strategic outcome orientated goals for the Authority (SAHPRA, 2016).  
The effectiveness of the regulatory systems developed, implemented and maintained 
by SAHPRA must be periodically measured against GRevP and pre-defined 
performance-based indicators (WHO, 2014b; SAHPRA, 2016).  Global benchmarking 
of the Authority against the indicators of the GBT developed by the WHO to evaluate 
and grade the maturity level of the regulatory systems of NRAs will also provide a 
measurement of the Authority’s performance in assuring independent and competent 
oversight of medical products in South Africa (WHO, 2020).  Delivering on such 
regulatory performance objectives will also provide a platform for building strong and 







THE REGULATORY REVIEW PROCESS IN SOUTH AFRICA: MODALITIES FOR 
CHANGE 
Through the amendment of the Medicines Act and the establishment of SAHPRA a 
new era has dawned bringing about new opportunities for regulatory reform and the 
possibility to re-engineer outdated processes.  Priority should be given to addressing 
the inefficiencies of the current regulatory review process through consideration of 
different types of product review assessments used by NRAs worldwide in the review 
of applications for registration of medicines namely the verification review (type 1), an 
abridged review (type II) and a full review (type III) (McAuslane et al., 2009).  SAHPRA 
may decide to continue with the current approach used historically by the MCC 
whereby a type III full independent assessment of quality, efficacy and safety data is 
performed in the review of all applications for registration however, it may be prudent 
to consider applying a risk-based assessment for those applications already reviewed 
by reference agencies in order to ensure timely access of medicines and medical 
devices. 
 
Risk-based approach to the evaluation of medicines 
The management of limited resources may be improved through the application of a 
risk-based approach to medicinal product regulation.  This approach allows regulators 
to direct the appropriate resources required to those medical products that pose a 
greater risk to patients.  The amount of resources applied by the regulator should be 
commensurate with the level of risk of a medical product and should be applied only 
to the extent necessary to ensure patient safety (TGA, 2018).  Many NRAs including 
resourced and mature regulatory authorities make use of FRPs for the assessment of 
applications for registration of medicines (Liberti, 2018).  Primary FRPs are used to 
decrease review times of medicines that have not been reviewed by another NRA and 
that are not dependent on the review/decision made by another NRA for example 
products for unmet needs and oncology (Liberti, 2018).  Secondary FRPs are used by 
NRAs to decrease review times of medicines that have been reviewed by another 
recognised NRA (Liberti, 2018).  The regulatory decision can be expedited through 
reliance on or recognition of a prior review/decision by another NRA (Liberti, 2018).  
FRPs inform risk-stratification approaches to the assessment of applications for 




If SAHPRA wishes to apply such risk-based approaches the following types of review 
should be considered (Green-Thompson, 2008): The first is a full review of the 
complete quality, pre-clinical and clinical data applicable to medicines that have not 
been reviewed/approved by an NRA recognised by SAHPRA (Green-Thompson, 
2008).  The second is an abridged review applicable to a medicine that has been 
reviewed/approved by one recognised NRA (Liberti, 2018).  Similar to the Mutual 
Recognition Procedure used in the EU the abridged review makes use of the 
evaluation report and the regulatory decision of a recognised NRA to guide the 
evaluation of the medicine by SAHPRA (Green-Thompson, 2008; Liberti, 2018).  The 
third is the verification review that may be used to evaluate a medicine that has been 
approved by at least two recognised NRAs (Liberti, 2018).  Through this review the 
product is validated for conformance to the authorised product specification (Pharasi 
& Banoo, 2015).  The fourth is the evaluation of a dossier for a generic medicine 
(Green-Thompson, 2008).  The generic medicine should be approved by at least one 
recognised NRA and should correspond to the reference product (with the same 
dosage form and strength) registered by SAHPRA (Green-Thompson, 2008). 
Despite the type of review chosen for any given submission SAHPRA may insist that 
a full dossier consisting of complete quality, pre-clinical and clinical data is submitted 
upon application for medicine registration.  Although a full assessment of the complete 
data may not be performed having the full dossier available on file will be 
advantageous for purposes of future reference or for post-market surveillance 
activities.  A letter of intent for submitting an application for registration of medicine 
would be required to allow the regulator to adequately plan and allocate the necessary 
resources required to evaluate upcoming submissions.  Through this process, the 
regulator may also anticipate whether specific expertise would be required in the 
assessment of the application and may be afforded the advantage of recruiting such 
expertise in advance thus circumventing unnecessary delays in the review process.  
This risk-based approach could be successfully applied provided that agreements are 
in place between SAHPRA and recognised NRAs to ensure that information pertaining 
to medicine assessment reports, post-marketing surveillance and post-marketing 
variations and/or amendments is easily shared and disclosed.  As this system 
develops SAHPRA may consider introducing improved processes based on similar 
risk-stratification processes to address the submission of applications for variations 
and amendments to registered dossiers (Green-Thompson, 2008).  In re-designing 
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the regulatory review process it would be prudent to consider the application of an 
appropriate framework for BR assessment to facilitate the evaluation of the BR 
balance of medicines prior to registration (Green-Thompson, 2008; Leong et al., 
2015b).  The implementation of GRP and GRevP (SAHPRA, 2016) and QDMPs are 
also recommended with a view to reinforce transparent decision-making processes.  
Therefore, the application of risk-stratification approaches and FRPs would be an 
advantage when considered in line with the recommendations of the WHO (WHO, 
2014a; Ward, 2014). 
 
Monitoring and measuring 
In the current model there is no target for overall approval time of applications for 
registration and no targets for the key review milestones.  The targets for overall 
approval time and key review milestones need to be identified, codified into policy and 
guidelines, recorded, measured and monitored.  Figure 3.4 provides a generic figure 
of individual milestones that have been used by other regulatory authorities and that 
may be considered for use within SAHPRA. 
 
Appropriate systems and resources need to be put in place to support the accurate 
tracking of the overall approval times and key milestones in the regulatory review 
process.  Administrative and technical screening time, queuing time prior to review 
and clock stops, measuring the time with applicants must be recorded and monitored.  
The metrics collection process must be strengthened in order to allow measurement 
and improvement of SAHPRA regulatory performance. 
 
With accountability and transparency being the focus within the medicine regulatory 
landscape in South Africa, SAHPRA has to be cognisant of the past administrative 
injustices and take ownership of its performance.  SAHPRA targets for regulatory 
review must be communicated to all stakeholders and it must be held responsible for 
meeting its obligations in terms of such targets and demonstrate accountability to 
parliament, to the public, to the industry and to all relevant stakeholders (Green-
Thompson, 2008).  Furthermore, SAHPRA should undertake to employ the basic 
principles of administrative justice within the routine practices and activities of the 
Authority (Green-Thompson, 2008).  Providing written reasons to support regulatory 
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decisions made by the Authority could be one such practice that may support legal 
certainty and contribute to enhanced regulatory efficiencies and transparency (Green-
Thompson, 2008).  Quid pro quo provisions to relieve applicants of consequences of 
regulatory under-performance may also need to be considered (Green-Thompson, 
2008). 
 
Figure 3.4 Benchmarking milestones currently utilised by  




Adopted from CIRS, 2016 
 
 
KEY RECOMMENDATIONS FOR A NEW REGULATORY ENVIRONMENT 
In order to ensure the full potential of the new regulatory environment in South Africa 
the following recommendations are considered to be fundamental in underpinning the 
success of SAHPRA: 
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Quality management system 
Establishment of such a system would help to safeguard accountability, consistency 
and transparency of SAHPRA and streamline the implementation of GRP and GRevP 
including QDMPs and BR assessment. 
 
Measuring and monitoring 
This will ensure the measurement and improvement of regulatory performance, targets 
for overall approval time and key review milestones.  Consequently, this will lead to 
the implementation of appropriate systems for and a culture of accurate metrics 
collection and measurement of key performance indicators and their continuous 
improvement. 
 
Risk-based approach to the evaluation of medical products 
This will help to implement the appropriate allocation of resources, codify the use of 
FRPs in policy and culture, apply a risk-based approach commensurate with the 
product’s risk to patients and apply increased resources for pharmacovigilance 
activities to support the reliance and recognition of reference agencies. 
 
The purpose of this review was to provide insight into the history of the enabling 
legislation and expert reviews and recommendations for regulatory reform that have 
given rise to a new regulatory regime in South Africa.  Many key opportunities and 
modalities for change have been identified and it is evident that re-enforcement of 
strategies to address inadequate financial and human resources, stakeholder 
relationships, paper-driven document management systems, service delivery and 
regulatory review processes, need to be considered in order to strengthen the 
regulatory systems in South Africa.  With time and active leadership from the SAHPRA 
Board together with the SAHPRA CEO and the management team it is hoped that the 
re-engineered strategies and processes, planned for implementation will serve to 





 The drive for improved regulatory systems and the establishment of a more 
effective regulatory framework in South Africa has been evident for the past two 
decades 
 
 A significant backlog has developed and has resulted in extended timelines for 
medicine registration in South Africa 
 
 The promulgation of the recently amended Medicines and Related Substance 
Act of 1965 triggered the establishment of the South African Health Products 
Regulatory Authority (SAHPRA) to replace the former medicine regulatory 
authority the Medicines Control Council (MCC). 
 
 The aim of this review is to provide the historical context supporting the new 
regulatory environment in South Africa and the transition from the MCC to 
SAHPRA. 
 
 Key recommendations to SAHPRA include: 
o The formal development and implementation of a QMS 
o The measurement and monitoring of regulatory performance 
o Setting targets for overall approval time and key review milestones to 
instil a culture of accurate metrics collection and measurement of key 
performance indicators and their continuous improvement 
o Codifying the use of facilitated regulatory pathways in policy and culture 
o The application of a risk-based approach to regulatory review 
commensurate with a medicine’s risk 
o The implementation of reliance frameworks and the recognition of the 
















Evaluation of the Regulatory Review Process 





As part of a multi-country study on effective drug regulation, the WHO described four 
dimensions of medicine regulation, namely, administrative elements, regulatory 
functions, level of regulation, and technical elements (Ratanawijitrasin & 
Wondemagegnehu, 2002).  Further studies by Hill and Johnson (2004) recognised 
that regulators often operated in an environment with insufficient political support 
resulting in inadequate legislative frameworks and financial resources, inconsistent 
application processes and an inappropriate regulatory culture (Hill & Johnson, 2004).  
During the past decade, regulatory authorities have acknowledged the need to 
develop efficient and effective regulatory review processes (Cone & Walker, 2005; 
Cone & McAuslane, 2006).  Regulatory authorities are encouraged to facilitate the 
expedited approval of new medicines within mandated prerequisites of ensuring 
patients’ access to safe, effective and quality medicines.  Regulators face scientific, 
administrative and legislative capacity constraints yielding sometimes inoperable 
regulatory directives, limited solutions for timely evaluations and a drive for maintaining 
sovereignty.  Many regulators have dedicated resources to improve the review 
processes and to develop indicators that go beyond the measurement of time and 
speed (Cone & Walker, 2005; Cone & McAuslane, 2006).  The implementation of 
GRevP plays a pivotal role in ensuring consistency, predictability, clarity and efficiency 
in the product review process (Al-essa et al., 2012; WHO, 2015) and contributes 
toward the evaluation of the performance of the regulatory authority.  This review was 
the first to be carried out to evaluate the current South African regulatory review 
process as it is had been applied by the Medicines Control Council (MCC), prior to the 
establishment of the SAHPRA. 
 
Medicines Control Council of South Africa 
The pharmaceutical market in South Africa was valued at approximately 45 billion 
Rand (US$3.2 billion) in 2015 (Soomaroo, 2017).  The domestic manufacturing 
pharmaceutical industry almost exclusively produces generic products and the South 
African pharmaceutical sector is import dependent (Soomaroo, 2017).  In 2013 generic 
medicines accounted for 63% of the private pharmaceutical market and 80% market 
share in the South African government’s pharmaceutical use (Soomaroo, 2017).  Over 
the last 50 years South Africa has developed a medicines regulatory authority with 
internationally recognised standing (MCC, 2017).  Through the Medicines and Related 
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Substances Act, 1965 (Act 101 of 1965) the MCC was responsible for the monitoring, 
evaluation, regulation, investigation, inspection, registration and control of medicines, 
scheduled substances, clinical trials, medical devices and related matters in the public 
interest (MCC, 2006).  The MCC operated through external experts who were 
members of Council committee structures and a staff component that included 
doctors, pharmacists, veterinarians, other scientists, project managers and 
administrative staff (MCC, 2017).  This study aimed to appraise the regulatory review 
process within the MCC, identify key milestones and evaluate the review times for 
NASs and major line extensions (MLEs) from 2015 to 2017.  The findings of this study 
provided a baseline for assessing the changes and improvements to be made as the 
MCC transitioned into the newly established SAHPRA.  This was the first study to 
evaluate the status quo of the regulatory review process of the MCC since the 
promulgation of the Medicines and Related Substances Act, 1965, as amended on 
June 1, 2017 (Republic of South Africa, 2017). 
 
The aim of this study was to: 
 Assess the current regulatory review process in South Africa; 
 Identify the key milestones, timelines and stages of the review process; 
 Evaluate the effectiveness of the measures used to ensure consistency, 
transparency, timeliness and predictability in the review process; and 
 Review the challenges and opportunities for enhanced regulatory practices in 




Data collection process 
A questionnaire (see Appendix 1) was used to map the key milestones and activities 
associated with the review processes and practices within NRAs (CIRS, 2019c).  
Through the use of the questionnaire, NRAs are able to identify the models of review 
that are being used within the authority, identify target times and the main activities 
between milestones for registration, identify the organisation structure and the 
capacity of the authority.  The questionnaire, on the regulatory review process in South 
Africa, was completed by the Registrar of Medicines for the MCC.  The questionnaire 
was completed with a view of analysing the quality measures that were in place, to 
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identify areas of capacity constraints and to provide a baseline for the MCC review 
process, in the light of the transition to the newly established SAHPRA.  The 
questionnaire (see Appendix 1) consisted of four parts: 
 
Part I - Organisation of the authority 
Part I documented an introduction to the authority; its current structure and size, the 
resources available and the review model(s) currently in place (CIRS, 2019c). 
 
Part II - Key milestones in the registration of medicines within the review 
process 
Part II of the questionnaire was based on a standard process map that was previously 
developed by CIRS, through the study of established and emerging NRAs (McAuslane 
et al., 2009).  This process map provided a detailed description of the pathway of a 
dossier, through administrative and technical screening steps, scientific evaluation 
and Committee and Council processes.  The completed process map enabled the 
collection of information in a standardised format that was used to simplify the 
comparison of the MCC and its review process with the regulatory pathways used by 
other NRAs. 
 
Part III - Good review practice 
Part III of the questionnaire pertaining to building quality into the assessment and 
registration processes provided an account of the activities and practices, 
implemented by the MCC, that contributed towards improved consistency, 
transparency, timeliness and predictability in the regulatory review and to the quality 
of the decision-making process.  This questionnaire had been developed for use in the 
analysis of the regulatory environment in several emerging pharmaceutical markets 
(CIRS, 2019c). 
 
Part IV – Identification of the enablers and barriers 
Part IV of the questionnaire aimed to identify the NRA’s own perception of its unique 
positive qualities (enablers) and the major impediments (barriers) it faced in carrying 






Part I - Organisation of the authority 
The MCC was first established in 1965 and historically operated within the National 
Department of Health.  Since then, the authority had undergone many changes 
including its establishment as a 3A Public Entity (National Treasury, 2015) known as 
SAHPRA.  Provision was made for the restructuring of the authority through the 
amendment of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), 
which was published on the 1 June 2017 (Republic of South Africa, 2017). 
 
The scope of responsibility of the MCC included medicinal products for human and 
veterinary use and medical devices.  The MCC was mandated through the Medicines 
and Related Substances Act, 1965 (Act 101 of 1965) to ensure the efficient, effective 
and ethical evaluation or assessment and registration of medicines and medical 
devices that met the defined standards of quality, safety, efficacy and performance 
(MCC, 2017).  The MCC also performed licensing activities, inspectorate and law 
enforcement functions, laboratory analysis of biological products, post-market 
surveillance and pharmacovigilance activities and controlled the advertising of 
medicines and medical devices. 
 
The MCC had a staff component of approximately 200 full-time personnel including 
management and technical and administrative personnel and approximately 100 
external consultants.  At the time of this study, approximately 100 internal and external 
technical personnel were responsible for the technical evaluation of applications which 
included NASs, generics, biologicals, veterinary and complementary medicines.  The 
majority of the staff responsible for the regulatory review process were qualified as 
pharmacists and many of the assessors had post-graduate qualifications. 
 
Model of assessment in South Africa 
Three types of product review assessments are used by NRAs: the verification review 
(type I), an abridged review (type II) and a full review (type III) (McAuslane et al., 2009).  
The MCC conducted a type III full assessment in the review of all applications including 
NASs and generics for orthodox, biological, complementary and veterinary medicines.  
A full independent assessment of quality, efficacy and safety data was performed.  The 
authority had access to assessors who had the relevant qualification and technical 
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experience to perform a full assessment of the data provided.  The majority of the 
assessors were external consultants who were not bound by contractual performance 
agreements.  Over the last few years the MCC had made major changes in building 
in-house capacity through assistance from the external experts. 
 
Data requirements and assessment 
The Certificate of Pharmaceutical Products (CPP) was not essential for registration 
but a copy of the authorisation letter had to be provided if the product had been 
registered in a reference country (e.g., for fast track/priority products).  Evidence of 
GMP status of the manufacturer and copies of labelling for products authorised in 
reference countries were also required.  Full quality data (Module 3), full non-clinical 
data (Module 4) and full clinical data (Module 5) were required.  A detailed assessment 
of the data was carried out by the MCC and the relevant assessment reports were 
prepared. 
 
The MCC performed BR assessments and the clinical opinion of the authority took 
account of differences in medical culture/practice, ethnic factors, national disease 
patterns and unmet medical needs.  Where relevant, the authority would obtain 
internal assessment reports from other authorities and publicly available reports such 
as European Public Assessment Reports (EPARs).  The MCC referred to 
pharmacovigilance reports and confirmed the GMP status and product compliance 
during the review process.  Although registration elsewhere was not a pre-requisite for 
making an application, information on existing registrations had to be provided, where 
available. 
 
Part II - South African regulatory review process 
The South African regulatory review process is presented in Figure 4.1.  The review 
process map illustrates the main steps in the review process and identifies the key 
milestone dates for monitoring and analysing timelines for review.  The map provides 
a simple representation of the review and authorisation of applications for NASs and 
MLEs that are approved on the first review cycle.  The map does not describe the 
process in the event that the application was refused.  The appeal process that may 





Applications for NASs were received by the Operations and Administration Unit and 
administrative screening of applications was performed within 15 calendar days from 
the time of receipt.  Applications were routed to the relevant unit where they were 
allocated to an assessor to start the review process.  There was no target set for the 
overall review time of an NAS application and there were no targets set for the key 
milestones identified in the review process.  There was a mechanism in place whereby 
priority applications may be fast tracked.  Products that were considered for expedited 
review were medicines on the essential drug list (EDL) and NASs that were considered 
essential for national health but did not appear on the EDL (MCC, 2012).  The scientific 
data requirements did not differ between fast track and other products and the level of 
scientific assessment was the same.  Once submitted however, such products were 
always given priority in the queuing system and an overall target of 250 calendar days 
was set for fast track products.  At the time of this study, there was a substantial 
backlog due to the large number of applications received for the registration of generic 
medicines, however, applications for NASs were not placed in the same queue as 
generic medicine applications and were routed for allocation to assessors upon 
completion of administrative screening. 
 
Scientific assessment 
Scientific data, presented in applications, were assessed in parallel for quality, safety 
and efficacy by the different units within the MCC.  The assessments were performed 
by internal as well as external assessors.  While internal assessors were subject to 
annual performance appraisals, the external assessors were not contractually bound 
by service-level agreements and this limitation had an impact on review times.    
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Figure 4.1 Regulatory review process map for South Africa 
Days reflected are calendar days 
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Detailed assessment reports and recommendations were prepared by the assessors 
and these were peer reviewed and tabled at the relevant Scientific Committee 
meetings for discussion which then made a recommendation to the MCC for 
ratification.  Although there was no set timeline for the scientific assessment of 
applications, a request was sent to assessors to support completion of the assessment 
within 90 calendar days. 
 
Questions to sponsor 
Recommendations pertaining to quality data were sent to sponsors following 
ratification by the MCC and those who had submitted an application for an NAS were 
requested to provide a response to the recommendations within 180 calendar days.  
The response from the sponsor would be reviewed by an assessor and tabled at the 
next Scientific Committee meeting and subsequent Council meeting. 
 
Questions pertaining to safety and efficacy data could be provided to the sponsor at 
any time during the assessment.  Recommendations from the Scientific Committee 
were sent to the sponsor prior to ratification by the Council.  Sponsors were required 
to respond to the recommendations within 180 calendar days.  In the event that major 
deficiencies were identified in the data submitted, the response from the sponsor 
would be subjected to the full procedure of evaluation, discussion at the Scientific 
Committee meeting and ratification at the Council meeting.  The MCC had accepted 
responses that exceed the time limit. 
 
Expert committees 
Applications for an NAS were referred to a number of Scientific Committees for 
discussion prior to the medicine’s consideration for registration by the MCC.  These 
included the Pharmaceutical & Analytical Committee, the Clinical Committee, Good 
Practice (e.g. GMP) Committee and the Names & Scheduling Committee.  There was 
no target time limit for the Committee procedure, however, routine Committee 
meetings were held every 60 calendar days.  Committee processes were conducted 
in parallel to support efficiencies in the review process.  Council meeting dates were 
scheduled to accommodate the work of the Committees and prevent delays between 
the outcome of Committee meetings and Council ratification.  The recommendations 
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made by the Committees were tabled at the Council meeting and the Council was 
responsible for the decision on whether or not to grant authorisation for medicine 
registration.  This decision was based on the scientific assessment of the quality, 
safety and efficacy data submitted by the sponsor.  The Council would also base the 
decision for authorisation or refusal on the approval of the proprietary name of the 
product, the allocation of a scheduling status to the active pharmaceutical ingredient 
(API) and the evaluation of the GMP status of the sponsor, the manufacturer, the 
assembler, the quality control laboratory and the final product release responsibility.  
The decision for authorisation or refusal was neither dependent on sample analysis 
nor on a pricing agreement.  Based on the timing of the Council meetings, the 
authorisation process could take up to 60 calendar days from receiving a positive 
recommendation from the Scientific Committees.  Sponsors were informed of the 
decision of the Council within seven calendar days after the Council meeting and the 
target timelines for the MCC review process can be seen in Table 4.1. 
 




Validation 15 calendar days 
Scientific assessment 90 calendar days 
Sponsor response time (Quality data) 180 calendar days 
Sponsor response time (Safety and efficacy data) 180 calendar days 
Expert Committee(s) 60 calendar days 
Authorisation procedure 60 calendar days 
Notification of decision 7 calendar days 
Overall review time (Fast track) NAS: 250 calendar days 
Overall review time  NAS: No target 
Abbreviation: NAS=New Active Substance 
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The majority of NASs approved over the period 2015-2017 were submitted by 
international companies, while local companies were responsible for 21% of such 
approvals.  The number of approved NASs from international and local companies, 
during the period 2015-2017 is shown in Figure 4.2. 
 
Figure 4.2 Number of approved new active substances (NASs) from local and 




The highest number of approved NASs for international companies was 34 in 2017 
while the highest number of approved NASs for local companies was eight in both 
2015 and 2017.  The highest number of NASs was approved in 2017 (n = 42) with a 
median approval time of 1411 calendar days.  In 2016, 33 NASs were approved with 
a median approval time of 1641 calendar days, which is comparable to the median 
approval time in 2017.  The fastest median approval time of 1218 calendar days was 
achieved in 2015 for 31 NASs (Figure 4.3). 
 
In 2015 and 2016, the approval times for biological products were longer than for 
NASs (Figure 4.4).  However, in 2017 the median approval time for biological 
products (n=5) was less than NASs (n=31).  In 2016 and 2017, fast track products 















































Fast track products also had shorter approval times in 2015-2017 when compared to 
biologicals.  In 2015 and 2017, MLEs had the shortest approval times when compared 
with NASs, biologicals and fast track products.   
 
Figure 4.4 Median approval times for new active substances (NASs) compared 





































































The most commonly approved NASs, by therapeutic class, during the period 2015-
2017 included: cytostatic agents (14 products), analgesics (eight products), 
anticonvulsants, including anti-epileptics (six products) and non-steroidal anti-
inflammatory drugs (six products).  The lowest number of NASs approved, by 
therapeutic class, during the period were: local anaesthetics (one product), 
vasoconstrictors (one product), ophthalmic preparations (one product), medicines 
against protozoa (one product) and macrolides and lincosamides (one product). 
 
Part III - Good review practices: Building quality into the registration and review 
processes 
 
General measures used to achieve quality 
The MCC had developed an internal quality policy that described the overall intentions 
and direction of the authority related to the quality of the review process.  The MCC 
intended to formally implement the quality policy and prescribe the measures that 
would be used to achieve and continuously improve on quality within the next two 
years.  GRevPs are defined as a framework applied to the process and documentation 
related to regulatory review procedures. 
 
GRevP measures aim to standardise and improve overall documentation and to 
ensure timeliness, predictability, consistency and high quality in reviews and 
assessment reports.  The MCC had initiated the development and implementation of 
a GRevP framework however it was acknowledged that the system was still evolving.  
Table 4.2 provides an overview of the status of the implementation of GRevP by the 
MCC and demonstrates that there were a number of elements of the framework that 
needed to be formalised and improved. 
 
The MCC recognised that the currently implemented elements of the GRevP 
framework had been underutilised by staff.  Additional training to learn and understand 
GRevP would be valuable so that the benefits of formally implementing a 





Table 4.2 Status of implementation of good review practices (GRevPs) by the 
Medicines Control Council (MCC) 
 
INDICATOR IMPLEMENTED COMMENTS 
Quality measures 
Internal quality policy   
Planned to formally 
implement 
Good review practice system   
Planned to formally 
implement 
Standard operating procedures 
for guidance of assessors 
  
Planned to formally 
implement 
Assessment templates   
Planned to formalise the use 
of a single, common template 
Dedicated quality department   
Establishment of a dedicated 
quality department is planned 
Scientific committee    
Shared and joint reviews    
Transparency and communication parameters 
Feedback to industry on 
submitted dossiers 
   
Details of technical staff to 
contact 
  
Contact details are made 
available on an ad-hoc basis 
Pre-submission scientific advice 
to industry 
  
Meetings are held with 
industry on an ad-hoc basis 
Official guidelines to assist 
industry 
   
Industry can track progress of 
applications 
  
Implementation of electronic 
document management 
system is planned 
Summary of grounds on which 
approval was granted 
  
Summary is available but is 
currently not published 
Approval times   
Approval times are not made 
available to the public 
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INDICATOR IMPLEMENTED COMMENTS 
Advisory committee meeting 
dates 
   
Approval of products    
Continuous improvement initiatives 
External quality audits   
External quality audits are not 
performed routinely 
Internal quality audits   Planned  
Internal tracking systems   
Implementation of electronic 
document management 
system is planned 
Review of assessors’ feedback    
Reviews of stakeholders’ 
feedback 
  
Planned to be formally and 
routinely reviewed 
Training and education 
International 
workshops/conferences 
   
External courses    
In-house courses   
Training programme to be 
formalised 
On-the-job training   
Training programme to be 
formalised 
External speakers invited to the 
authority 
   
Induction training   
Training programme to be 
formalised 
Sponsorship of post-graduate 
degrees 
   
Placements and secondment in 
other regulatory authorities 
   
 




Furthermore, the MCC intended to formally codify the critical elements of GRevP so 
that they may be written into the internal organisational policy.  The authority also 
aimed to develop a QMS to support the successful application of GRevP.  Standard 
operating procedures (SOPs) were available to describe the routine procedure for the 
regulatory review process and these provided guidance for the scientific assessors 
and the advisory committee who were consulted during the review process.  The SOPs 
needed to be revitalised to provide a detailed description of processes that had been 
enhanced since the inception of the review process and there were plans to update 
these SOPs within the next two years. 
 
Assessment templates that set out the content and format of written reports on 
scientific reviews were available and both external and internal peer reviews were 
carried out when an NAS was assessed.  Elements included in this assessment 
template were a listing of the drug substance, the name of the drug product, comments 
on the product label, non-clinical data, clinical pharmacology, safety and efficacy, good 
clinical practice (GCP) aspects and a list of recommendations to the sponsor. 
 
The Scientific Committees involved in the regulatory review process met 
approximately every 60 calendar days to review NAS applications.  The assessment 
reports discussed at these meetings were prepared by both internal and external 
assessors but these were not published on the MCC website.  The recommendations 
made by the Scientific Committees were tabled at the MCC meeting where the 
decision for acceptance or refusal of the application was made. 
 
Quality management 
The MCC recognised the importance of implementing quality measures throughout in 
order to ensure consistency, increase transparency, improve efficiencies and enhance 
allocation of regulatory resources.  The MCC held regular meetings with external 
stakeholders, in the form of Industry Task Group (ITG) forums, which provided a forum 
for candid discussion between the industry and the regulator.  The MCC maintained 
an open-door policy whereby meetings with the regulator were routinely facilitated.  
Furthermore, the industry and interested parties were invited to participate in 
workshops hosted by the regulator through which opinions, feedback and complaints 
could be received and channeled into corrective and preventative actions. 
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The MCC did not have a dedicated unit for assessing quality in the review process for 
new medicines however, contingencies had been put in place to establish such a unit.  
This unit would be responsible for developing a QMS for the authority, for performing 
internal quality audits and for implementing strategies geared for continuous 
improvement through retrospective evaluation of the assessment and authorisation 
process.  Provision had been made to employ the use of an EDMS.  The tracking 
functionality of the EDMS would allow for internal monitoring of the process, thus 
contributing to efficiency and accuracy in the review process.  The quality unit would 
also be responsible for ensuring that the requirements of the QMS of the authority 
were fulfilled in order to be certified to the quality standards of the International 
Standardization Organization (ISO).  The quality unit would also be responsible for 
ensuring that the requirements, for the relevant sub-indicators of the WHO GBT 
relating to the development, implementation and maintenance of an appropriate QMS, 
are met. 
 
Quality in the review and assessment process 
The MCC has implemented a number of mechanisms in an effort to improve the quality 
of applications received from sponsors and the scientific review of such applications.  
Guidelines for industry have been developed and have been published on the MCC 
website and in official publications.  These guidelines were also available on request 
from the regulator and through industry associations.  There was no policy for 
providing pre-application scientific advice to a sponsor and such advice was not 
routinely monitored.  Pre-application scientific advice could be provided following a 
request from the sponsor who was also given the contact details of technical staff that 
could be contacted to discuss an application during the review.  Formal contact, such 
as scheduled meetings with the regulator, was possible during product development 
and assessment and in this time there was also an extensive amount of informal 
contact between the sponsor and the regulator via telephone or email. 
 
Shared and joint reviews 
The MCC took part in joint reviews through the Zazibona collaborative process which 
aimed to harmonise regulatory efforts across Africa.  The collaborative process started 
as a partnership between the NRAs in Zambia, Zimbabwe, Botswana and Namibia 
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and participation by interested South African Development Community (SADC) 
Member States is encouraged (Regulatory Resources for Africa, 2015).  In order to be 
eligible to participate in the Zazibona collaborative process the sponsor was required 
to submit the application for registration to two of the participating NRAs (MCC, 2012).  
Products that had been registered by recognised regulatory authorities were eligible 
for an abridged review process provided that the assessment report from the 
authorising authority was available.  The collaborative process aimed to complete 
product authorisation or refusal within 11 months.  Products could be considered for 
two review cycles and sponsors were required to respond to the consolidated list of 
regulatory assessment questions within a period of 60 days.  The overall review target 
for the collaborative process was 210 days (Regulatory Resources for Africa, 2015).  
Participating NRAs maintained the right to make a final determination on any 
application and the final regulatory decisions were the responsibility of individual 
participating NRAs (Regulatory Resources for Africa, 2015). 
 
Training 
Training and professional development of internal and external assessors continued 
to contribute to the element of quality within the MCC review process.  Although the 
training programme had not been formalised, assessors were required to take part in 
induction training and on-the-job training.  Mentorship programmes between 
experienced assessors/inspectors and those less experienced were developed to 
support reviews.  The National Department of Health provided financial support to 
assessors enrolled in post-graduate studies and external courses.  Assessors had the 
opportunity to be seconded to other NRAs for further training and regularly attended 
international workshops and conferences to enrich their learning.  Participation in 
training provided by the WHO on topics such as the pre-qualification process and 
QMSs as well as training provided by the European Directorate for the Quality of 
Medicine formed an integral part in the training of assessors. 
 
Transparency of the review process 
The MCC assigned a high priority to being open and transparent in relationships with 
the public, health professionals and industry.  Along with political will, the MCC had 
recognised the need to increase confidence in the regulatory system and to provide 
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assurances on safety safeguards as the main drivers for assigning resources to 
activities that enhanced the transparency of the regulatory system.  Table 4.2 provides 
an overview of the measures that had been put into place by the MCC in an effort to 
promote transparency and improve communication with stakeholders.  The MCC had 
a manual system in place which was used to trace applications that were under review 
and identify the stage at which the application was in the process.  Sponsors were 
able to track the status of their applications via telephone and email contact.  The MCC 
was progressing towards the use of an EDMS that was capable of signaling any target 
review dates that may have been exceeded, recording the terms of the authorisation 
once granted and providing searchable archiving of information on applications.  The 
MCC published the list of licensed manufacturers, wholesalers and quality control 
laboratories, Committee meeting dates and a list of registered products on the MCC 
website.  Where relevant such information was published in the Government Gazette. 
 
Part IV – Identification of the enablers and barriers 
This study identified aspects that the MCC considered to be pivotal enablers in the 
effectiveness and efficiency of the MCC review process and decision-making 
procedures for NAS applications.  These included the eagerness of the NRA in South 
Africa to build confidence in the regulatory system, the minimal staff turnover at the 
MCC that contributed toward the retention of institutional knowledge and the support 
from scientific committees in the regulatory review of applications for market 
authorisation.  The lack of an electronic document management system (EDMS) and 
outdated review processes, coupled with fixed committee structures and decision-
making processes, were deemed to be barriers in effecting the regulatory mandate of 




The NRA in South Africa strived to be an authority of international standing and was 
one of the most developed authorities in the African region.  The authority had taken 
into account international best practices in the development of its legislation, 
guidelines and SOPs.  The MCC was not sufficiently resourced to provide an efficient 
and effective service.  As a result, review times for NASs were in excess of four years 
whereas for mature agencies this was of the order of 10 to 16 months (CIRS, 2019a).  
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This subsequent delay with respect to patients’ access to new medicines was the 
rationale for the establishment of SAHPRA and the re-engineering of the current 
regulatory processes in South Africa.  The success of the new system was imperative 
as the South African authority strived to be considered alongside other comparable 
agencies. 
 
This study evaluated the overall regulatory approval times for NASs, biologicals, MLEs 
and fast track applications in South Africa from 2015-2017.  The number of products 
approved by the MCC had been increasing each year and during 2015-2017, 79% 
were sponsored by international companies.  While local companies did submit 
applications for NASs, these companies often did not have the resources and 
dedicated research facilities to develop such products in-house, but rather enter into 
contractual agreements with international companies to develop the products abroad 
or to sell the product under licence. 
 
The MCC recognised the importance of building confidence into the regulatory system 
and the support from expert review committees as factors that could contribute to the 
effectiveness and efficiency of the review and decision-making processes for NAS 
applications.  While outdated mechanisms for review could be improved through the 
re-engineering of the operational process and decision model, consideration of an 
appropriate benefit-risk model was recommended.  The amendment of the Medicines 
and Related Substances Act, 1965 (Act 101 of 1965) supports reliance and 
harmonisation strategies.  The MCC considered the use of an alternative risk 
stratification model incorporating reliance on reference NRAs.  It was also evident that 
firm target times for the review process needed to be written into the organisational 
policy and had to be tracked through the use of an EDMS in order to realise effective 
regulatory mandates. 
 
This study has evaluated the MCC regulatory review process as it had been applied 
prior to the establishment of SAHPRA.  Key milestones and timelines within the 
regulatory review process have been identified and the measures used for GRevP 
have been considered.  The value added in codifying the guidelines for GRevP and 
formalising the quality policy and QMS were recognised.  The findings from the study 
suggested that the MCC had identified the opportunities for enhanced regulatory 
90 
 
review and could consider an abridged assessment model which encompassed 
elements of risk stratification and reliance.  As the MCC transitioned to the newly 
established SAHPRA it was hoped that the resource constraints could be alleviated 





 Regulatory authorities have acknowledged the need to develop efficient 
and effective regulatory review processes 
 
 The MCC review times for NASs were in excess of four years and a 
significant backlog had developed 
 
 Efforts to address the increasing volume of applications that were received 
had failed as resources were stretched to capacity 
 
 The aims of this study were to assess the regulatory review process in 
South Africa from 2015 to 2017, identify the key milestones and timelines 
and evaluate the effectiveness of measures to ensure consistency, 
transparency, timeliness and predictability in the review process 
 
 A questionnaire (see Appendix 1) was completed by the MCC to describe 
the organisation of the authority, record key milestones and timelines in 
the review process and to identify GRevPs 
 
 The overall regulatory median approval time decreased by 14% in 2017 
(1411 calendar days) compared with that of 2016, despite the 27% 
increase in the number of applications 
 
 The MCC had no target for overall approval time of NAS applications and 
no targets for key review milestones 
 
 The findings from the study suggested that the MCC had identified the 
opportunities for enhanced regulatory review and could consider an 
abridged assessment model 
 
 As the MCC transitioned to the newly established SAHPRA it would be 
crucial for the authority to recognise the opportunities for an enhanced 















Evaluation of Regulatory Review timelines for submissions 




National regulatory authorities (NRAs) are responsible for the registration of NASs and 
patients’ timely access to medicines (Ndomondo-Sigonda et al., 2017; Rago & 
Santoso, 2008; WHO, 2018a). However, the WHO has reported that one-third of the 
world’s population does not have access to such products (Hogerzeil & Mirza, 2011).  
Roth et al. (2018) have suggested that the lack of timely access to new medicines may 
be addressed through the strengthening of registration efficiencies and timelines by 
establishing and refining value-added registration processes, resources and systems.  
An evaluated the South African regulatory review process, as it had been applied by 
the MCC, prior to the establishment of SAHPRA has been carried out (see Chapter 
4).  While this study provided an indication of the overall timelines of NASs approved 
and registered by the MCC during 2015-2017, the study focused on the organisation 
and the regulatory review process of the MCC and the status of good review practices 
that had been implemented. 
 
This study aimed to identify the key milestones of the review process and to evaluate 
review times in South Africa for NASs approved during 2015-2018.  This review was 
the first to be carried out of the specific milestones and timelines embedded within the 
South African regulatory review of NASs, as it had been applied by the MCC between 




The main objectives of this study were to: 
 Identify the key milestones and measure the timelines of the South African 
review process for the period 2015-2018; 
 Evaluate the overall timelines for the different new medicines approved in South 
Africa during this period;  
 Review the challenges and opportunities for expediting the overall review 
timelines to enhance the regulatory performance in South Africa with a view to 





Data collection process 
Data were collected reflecting the timelines between the various milestones including 
dossier validation and queue time, scientific assessment as well as the overall 
approval times for NASs, including NCEs, biologicals and MLEs registered by the 
South African NRA during the period 2015-2018.  The data was sourced directly from 
the directorate within the Authority responsible for recording the timelines required to 
complete the regulatory review process.  The number of NASs registered during this 
period was validated against the notifications of registration of medicines published by 
the Authority in the Government Gazette and available in the public domain.  The 
definitions of the application types included in the study are shown in Table 5.1. 
 
Table 5.1 Definitions of the application types included in the study 
 
APPLICATION TYPE DEFINITION 
New active substances 
(NASs)  
Applications including new chemical entities (NCEs), 
biologicals and major line extensions (MLEs). 
New chemical entity 
(NCEs) 
Applications for medicines that have not previously been 
approved by the MCC or SAHPRA. These included 
chemical and radiopharmaceutical substances that had 
not been previously available in South Africa for the cure, 
alleviation, treatment, prevention or in vivo diagnosis of 




Applications for medicines where the active ingredient 
and/or key excipients had been derived from living 
organisms or tissues, or manufactured using a biological 
process.  Biological medicines can be defined largely by 
reference to their method of manufacture (the biological 
process) and include applications that require additional 
scientific assessment by the Biological Medicines 
Committee of the MCC or SAHPRA (MCC, 2012) 
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Major line extension 
(MLEs) 
Applications for medicines, already registered by the 
MCC or SAHPRA, where a change to the registered 
medicines, was sufficiently great that it could not be 
considered to be a simple variation to the original product, 
but required a new product authorisation. Such changes 
included major new therapeutic indications or new 
disease states, extension to new patient populations 
(e.g., paediatric patients), a new route of administration, 
or a novel drug delivery system. 
Fast track  
 
Applications that were eligible to be assigned to a “fast 
track” status in order to expedite the registration of 
essential medicines.  While the review process was the 
same for “fast track” applications, these applications 
would be prioritised over existing applications, queued for 
allocation to reviewers. 
 
Abbreviations: MCC=Medicines Control Council; MLE=Major Line Extension; NAS=New Active 
Substance; NCE=New Chemical Entity; SAHPRA=South African Health Products Regulatory Authority 
 
Data analysis 
Data collected during the period 2015-2018 were analysed and the characteristics of 
the medicinal products submitted to the Authority for registration were described.  The 
review type (fast-track/standard) applied to each application was identified (Table 5.1) 
as well as the origin (multinational company/local company) of the submission and the 
definition of the milestones within the review process (Table 5.2).  The median 
timelines for each of the milestones within the review process as well as the median 
overall approval times were calculated and analysed.  Median approval times by 





Table 5.2 Definition of the milestones within the review process 
 
MILESTONES DEFINITION 
Overall approval time  The time between the date stamped on receipt of dossier 
when received by the Authority and the date that marketing 
authorisation was granted. 
Dossier validation 
and queue time 
The time between the date stamped on receipt of dossier 
and the “date of allocation” of the dossier to a reviewer. 
Scientific 
assessment time 
Amount of time spent actively reviewing the dossier or 
additional information provided from the “start of scientific 




Time during which the clock was stopped during the review 




Time taken up by the authority during the review for 
administration from the “Completion of Scientific 
Assessment” to the date of “Marketing Authorisation 
Granted”. 
 
*Data pertaining to applicant time was not available 
 
Time series analysis 
Time series analysis was used to identify trends, indicating increases or decreases in 
the number of NASs registered by the MCC between 2015-2017; whether such 
increases or decreases in registrations were observed to be seasonally repetitive and 
related to specific seasons, quarters or months and whether there were any data 
points that did not lie close to the regression line and could be identified as outliers 
(PennState Eberly College of Science, 2019).  As the scope of this study was 
exploratory in nature and not designed to support hypothesis testing, no further 
statistical analysis of the generated data was performed.  The forecasted number of 
NASs registrations for 2018 was compared to the actual number of NASs registered 





The characteristics and number of the NASs approved (NCEs, biologicals and MLEs) 
are shown in Table 5.3.  While the data reflected for the period 2015-2017 represent 
the performance of the MCC, the results described for 2018 reflected the performance 
of SAHPRA during the initial stages of its establishment and transition.  However, the 
results for 2018 do not reflect the re-engineered, streamlined processes developed by 
SAHPRA that were still in the process of being piloted prior to their final 
implementation.  The NRA registered a total number of 121 NASs during 2015-2018.  
The applications for NASs registered during this time were submitted by 22 
multinational companies and six local companies.  The results of this study will be 
valuable in providing a baseline to quantitatively reflect the improvements that are 
envisaged through the implementation of the finalised, enhanced SAHPRA regulatory 
review process. 
 
Table 5.3 Categories of new active substances (NASs) approved (2015-2018) 
 
 Year of Submission (2015 – 2018) 
Submissions 2015 2016 2017 2018 Total 
Number approved (NASs) 31 33 42 15 121 
Number of approved NASs 
submitted by multinational 
companies 
23 27 33 10 93 
Number of approved NASs 
submitted by local 
companies 
8 6 9 5 28 


















































0 0 0 0 0 
 
Abbreviations: MLE=Major Line Extension; NAS=New Active Substance; NCE=New Chemical Entity 
 
*Number of applications submitted by multinational company; Number of applications 
submitted by local company 
 
Milestones and timelines in the regulatory review process 
The milestones in the MCC review process (2015-2017) were similar to those 
identified by other NRAs and are reflected in Figure 5.1 (A – E). 
 
Figure 5.1 Regulatory review process of the Medicines Control Council (MCC) 






Abbreviations: CEO=Chief Executive Officer; GMP=Good Manufacturing Practice; MCC=Medicines 
Control Council; MLE=Major line extension; N&S=Names & Scheduling; NAS=New Active Substance; 
NCE=New Chemical Entity; RAC=Regulatory Advisory Committee; SAHPRA=South African Health 
Products Regulatory Authority 
 
Applications for registration were received and the dossier receipt date (A) recorded.  
Each application underwent administrative and technical screening against the 
evaluation criteria published in the various guidelines prepared by the Authority and 
were made available in the public domain.  Following the validation of the application, 
the acceptance to file date (B) was recorded and the application would be allocated to 
a reviewer for evaluation.  The date of allocation of the application to either an internal 
or external reviewer was recorded and considered to be the start date of the scientific 
assessment (C).  Following the initial assessment of the application the reviewer 
prepares an assessment report which was tabled for discussion at the relevant 
scientific committee meeting and a recommendation was made.  Scientific committee 
meetings were typically planned in 6-8 weeks cycles and there was no limit to the 
number of committee cycles for an application.  The committee either prepared a 
recommendation to the company requesting further information to support the 
registration of the product or a final recommendation supporting its approval or 
rejection.  Companies were required to provide a response to the committee’s request 
for additional information within 180 calendar days.  Once all the relevant scientific 
committees had made a final recommendation the date for the completion of the 
scientific assessment (D) was recorded.  
 
Up until this point, the review process applied previously by the MCC and the 
transitional review process applied by SAHPRA in 2018 were the same.  Under the 
MCC review process (2015-2017) the final recommendation of the various committees 
would be tabled for ratification at a Council meeting.  A Council resolution would then 
be prepared and if this was supported, the registration of the product, a marketing 
authorisation would be granted.  The date of the Council meeting at which the Council 
resolved to register the product was recorded as the date when marketing 




Under the transitional SAHPRA review process (2018), recommendations of the 
various scientific committees were considered by a regulatory advisory committee 
(RAC) that advised the CEO of the Authority on the approval or rejection of an 
application, in line with the amended provisions of the Medicines and Related 
Substances Act, 1965 (Act 101 of 1965) (Medicines and Related Substances Act 
2017).  As such, the SAHPRA CEO was responsible for carrying out the functions of 
the Authority, including regulatory decisions to approve or reject an application for the 
registration of a medicine, as described in Section 3 (4)(e) of Act 101 of 1965 
(Medicines and Related Substances Act 2017).  Section 39 of Act 101 of 1965 allowed 
the CEO to appoint relevant committees to advise on all registration and regulatory 
matters. 
 
Overall approval times 
The NASs approved by the MCC (2015-2017) and SAHPRA (2018) covered 16 
common therapeutic areas of which oncology products (n=25; 14 NCEs – 4 fast track; 
6 biologicals; 1 MLE) were the highest followed by analgesics and anti-infectives 
(Figure 5.2).  The results showed that the largest number of NAS approvals (n=42) 
were recorded in 2017 and that the majority (n=36) approved were NCEs (Table 5.3).  
All the NAS applications (n=121) that were registered during 2015-2018 were 
reviewed by the Authority using the full review process.  Sixteen NCEs were assigned 
priority status and were reviewed through the fast track review process, while no 
applications for biologicals or MLEs were processed through this route. 
 
The overall median approval time for NASs was 1466 calendar days and this included 
NCEs evaluated through the standard and fast track review process as well as 
biologicals and MLEs approved between 2015-2018 (Figure 5.3).  Furthermore, the 
shortest median approval time of 1218 calendar days was achieved in 2015 and the 
longest median approval time of 2124 calendar days was recorded in 2018.  Most 
NASs (n=42) were approved in 2017 and the least number of NASs (n=15) were 
approved in 2018.  
 
Approval times for new chemical entities (NCEs) and biologicals 
During 2015 and 2016 the median overall approval timelines were less for NCEs (1175 
and 1726 calendar days respectively) when compared with biologicals (2010 and 2027 
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calendar days respectively) (Figure 5.4).  In 2017 and 2018, the median overall 
approval timelines for biologicals decreased (725 and 1476 respectively) and was less 
than that observed for NCEs (1466 and 2124 respectively).  The shortest median 
overall approval time achieved during this period was for 6 biologicals approved in 
2017 (725 calendar days).  The longest median overall approval time (2124 calendar 
days) was observed for 12 NCEs approved in 2018. 
 
Figure 5.2 Categories of new active substances (NASs) approved by 
therapeutic area (2015-2018) 
 
 
Abbreviations: NCE=New Chemical Entity  
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· Represents the median 
Figure 5.3 Median overall approval times* for new active substances (NASs) (2015-2018) 
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Figure 5.4 Median overall approval times for new chemical entities (NCEs) 
and biologicals (2015-2018) 
 
 
















































Figure 5.5 Median overall approval time for new actives substances (NASs) by categories (2015-2018) 
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Three biologicals and 16 NCEs were approved in 2015, eight NCEs were approved 
through the fast track review process and the four MLEs approved were also for NCEs 
(Figure 5.5).   There were no MLEs approved in 2016 or 2018.  Only one MLE, which 
was a biological, was approved in 2017. During the SAHPRA transitional period of 
2018, no applications for registration were assigned fast track status.  The fast track 
review process was applied to three NCEs approved in 2016 and five NCEs approved 
in 2017.  Overall this study demonstrated that over the period 2015-2018 the review 
times for NCEs significantly increased from 1175 (2015) to 2124 (2018) while for 
biologicals this decreased from 2010 in 2015 to 1476 in 2018. 
 
Time series analysis 
Time series analysis was used to analyse the data collected during this study, which 
consisted of the number of NASs registered by the MCC, per quarter, in the period 
2015-2017 (Table 5.4). 
 
Table 5.4 Number of new active substances (NASs) registered by the 
Medicines Control Council (MCC) per quarter (2015-2017) 
 
 Quarter 1 Quarter 2 Quarter 3 Quarter 4 TOTAL 
2015 8 5 4 14 31 
2016 7 8 18 0 33 
2017 8 21 13 0 42 
 
The ratio-to-moving-average method was used to calculate seasonally adjusted 
indices for each quarter in the period 2015-2017.  This method was selected because 
it is widely used to measure seasonal variation and integrate trends into forecasting.  
The four-quarter moving average was calculated by dividing the sum of four values for 
“y” by 4 on a rolling basis from quarter 1: 2015 to quarter 4: 2017 (Table 5.5).  The 
centred average was calculated by determining the average of two “four-quarter 
moving averages” on a rolling basis (Table 5.5).  The percentage of average was 




Table 5.5 Calculation of the four-quarter moving average, the centred average 
and the percentage of average for new active substances (NASs) registered by 




Quarter x Code 
y 








2015 Q1 1 8       
2015 Q2 2 5       
        7,75     
2015 Q3 3 4   7,625 52,459 
        7,5     
2015 Q4 4 14   7,875 177,777 
        8,25     
2016 Q1 5 7   10 70 
        11,75     
2016 Q2 6 8   10 80 
        8,25     
2016 Q3 7 18   8,375 214,925 
        8,5     
2016 Q4 8 0   10,125 0 
        11,75     
2017 Q1 9 8   11,125 71,91 
        10,5     
2017 Q2 10 21   10,5 200 
        10,5     
2017 Q3 11 13       
2017 Q4 12 0       
 
Abbreviation: NAS=New Active Substance  
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Table 5.6 Calculation of the mean, adjustment factor and seasonal index for 
new active substances (NASs) registered by the Medicines Control Council 
(MCC) per quarter (2015-2017) 
YEAR Q1 Q2 Q3 Q4 TOTAL 
2015   52,459 177,777  
2016 70 80 214,925 0  
2017 71,91 200    
MEAN 70,955 140 133,692 88,885 433,532 % 
MULTIPLY BY ADJUSTMENT 
FACTOR 
0,922654 0,922654 0,922654 0,922654  
SEASONAL INDEX 65,46691 129,1715 123,3514 82,01009 400 % 
 
The mean for each quarter was determined by calculating the mean of the percentage 
of average for each quarter (Table 5.6).  The adjustment factor was calculated by 
dividing the sum of 100% for each quarter (4 x 100 %) by the sum of the means for 
each quarter (Table 5.6): 




𝐴𝑑𝑗𝑠𝑢𝑡𝑚𝑒𝑛𝑡 𝐹𝑎𝑐𝑡𝑜𝑟 = 0,922654  
 
The seasonal index for each quarter was calculated by multiplying the mean for each 
quarter with the adjustment factor (Table 5.6): 
 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄1 =  70,955 𝑋 0,922654 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄1 =  65,46691 
 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄2 =  140 𝑋 0,922654 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄2 =  129,1715 
 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄3 =  133,692 𝑋 0,922654 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄3 =  123,3514 
 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄4 =  88,885 𝑋 0,922654 
𝑆𝑒𝑎𝑠𝑜𝑛𝑎𝑙 𝐼𝑛𝑑𝑒𝑥 𝑄4 =  82,01009 
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A regression analysis was performed in order to get the line of best fit for the data 
collected. 
Regression line equation: 
𝑦 = 𝑎 + 𝑏𝑥 
𝑦 = 7,42445 + 0,2167 𝑥 
Using this equation, values of y were predicted for quarter 1 to 4 for 2018 and 2019 
and xy and x2 were calculated (Table 5.7). 



























 𝒙 code 𝒚 𝒙𝒚 𝒙𝟐 
 1 8 8 1 
 2 5 10 4 
 3 4 12 9 
 4 14 56 16 
 5 7 35 25 
 6 8 48 36 
 7 18 126 49 
 8 0 0 64 
 9 8 72 81 
 10 21 210 100 
 11 13 143 121 
 12 0 0 144 
∑  78 106 720 650 






  𝑛 = 12 
 
𝑎 =  ?̅? − 𝑏?̅?   
𝑎 =  8,833 − 𝑏 (6,5)  
𝑎 =  8,833 − (0,2167) (6,5)  
𝑎 =  7,42445 
?̅? =  
∑ 𝑥
𝑛
   




?̅? = 6,5 
 
?̅? =  
∑ 𝑦
𝑛
   












∑ 𝑥 ∑ 𝑦
(∑ 𝑥)2








   








Figure 5.6 Scatter plot representing the number of new active substances 
(NASs) registered by the Medicines Control Council (MCC) 
per quarter (2015-2017) 
 
  
Abbreviation: NAS=New Active Substance 
 
𝑎 =  7,42445 indicated the point at which the trend line intercepts the y-axis 
𝑏 = 0,2167 indicated the slope of the trend line which was increasing slightly 
𝑅2 = 0,0141 
 
The standard error (R2 = 0.0141) represented the residual standard deviation and 
indicated the typical deviation between the actual data (actual number of NASs 
registered in 2018) and the predicted value (predicted number of NASs registered in 
2018) which was represented by the trend line.  While the trend line was observed to 
be increasing slightly, the typical fluctuation around the regression line was 6,84 ~ 7 
(Figure 5.6).  The regression statistics were calculated and analysed (Table 5.8) and 
the seasonally adjusted trend estimates used to forecast the number of registrations 
expected for quarter 1 – quarter 4 (2018-2019) were determined (Table 5.9).  The 
results of actual vs. the predicted number of new active substances (NASs) registered 
in 2018 were determined (Table 5.10). 









































Table 5.8 Regression statistics 
Regression Statistics 
Multiple R 0,1188618 
R Square 0,01412813 
Adjusted R Square 0,08445906 
Standard Error 6,84796603 
Observations 12 
 
ANOVA      
  df SS MS F 
Significance 
F 
Regression 1 6,72027972 6,72027972 0,143305928 0,712929123 
Residual 10 468,9463869 46,89463869   
Total 11 475,6666667       
 
  Coefficients 
Standard 









Intercept 7,4244 4,2146 1,7615 0,1086 -1,9665 16,8150 -1,9665 16,8150 
X Code 0,2167 0,5726 0,3785 0,7129 -1,0591 1,4927 -1,0591 1,4927 
 
Abbreviation: ANOVA=Analysis of Variance.
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Table 5.9 Seasonally adjusted trend estimates used to forecast the number of registrations expected for  

















Abbreviation: NAS=New Active Substance 
Values rounded off to the nearest whole number 
Quarter/Year 𝒙 code 𝒚 = 𝒂 + 𝒃𝒙 𝒚 
Multiplied by the seasonal 
index for each quarter 
Expected number of 
NAS to be registered in 
each Quarter * 
QUARTER 1 - 2018 13 𝑦 = 7,42445 + 0,2167(13) 10,24155 𝑦 = 10,24155 𝑥 
65,46691
100
 6,70 = 7 
QUARTER 2 - 2018 14 𝑦 = 7,42445 + 0,2167(14) 10,45825 𝑦 = 10,45825 𝑥 
129,1715
100
 13,51 = 14 
QUARTER 3 - 2018 15 𝑦 = 7,42445 + 0,2167(15) 10,67495 𝑦 = 10,67495 𝑥 
123,3514
100
 13,17 = 13 
QUARTER 4 - 2018 16 𝑦 = 7,42445 + 0,2167(16) 10,89165 𝑦 = 10,89165 𝑥 
82,01009
100
 8,93 = 9 
QUARTER 1 - 2019 17 𝑦 = 7,42445 + 0,2167(17) 11,10835 𝑦 = 11,10835 𝑥 
65,46691
100
 7,27 = 7 
QUARTER 2 - 2019 18 𝑦 = 7,42445 + 0,2167(18) 11,32505 𝑦 = 11,32505 𝑥 
129,1715
100
 14,63 = 15 
QUARTER 3 - 2019 19 𝑦 = 7,42445 + 0,2167(19) 11,54175 𝑦 = 11,54175 𝑥 
123,3514
100
 14,24 = 14 
QUARTER 4 - 2019 20 𝑦 = 7,42445 + 0,2167(20) 11,75845 𝑦 = 11,75845 𝑥 
82,01009
100
 9,64 = 10 
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Table 5.10 Results of actual vs. predicted number of new active substances 
(NASs) registered in 2018 
 
 2018 
 Quarter 1 Quarter 2 Quarter 3 Quarter 4 TOTAL 
Actual number of NAS 
registered per Quarter 
6 5 2 2 15 
Predicted number of NAS 
registered per Quarter 




National regulatory authorities (NRAs) globally measure overall approval timelines for 
the registration of medicines to demonstrate their performance as regulators.  While 
this metric is not the only indicator of regulatory performance, it does contribute 
significantly to achieving the mandate of the NRAs in ensuring timely access of safe, 
quality and effective medicines to patients.  As such, it is critical to any improvement 
to ensure the routine and accurate measurement and monitoring of performance 
metrics of the regulatory review process.  Benchmarking milestones currently used by 
NRAs typically include the times for receipt and validation, scientific assessment, 
applicants’ response, market authorisation to be granted as well as the time taken to 
complete all administrative activities.  The data collected from the MCC and SAHPRA 
for the period 2015-2018 demonstrated that several of these milestones were 
recorded, but not measured and monitored. 
 
The Authority conducted a full assessment for each of the applications registered 
during the period 2015-2018.  This type of review required the scientific assessment 
of the quality, safety and efficacy data submitted by the company to support the 
approval of the medicines on the South African market.  While the dossier receipt date 
and date of allocation of the dossier to a reviewer were recorded it was not possible 
to confirm the time taken to validate the document through administrative and technical 
screening.  Consequently, it could not be determined how long each application spent 
in the queue prior to being allocated to a reviewer.  While there was no set target for 
the completion of the scientific assessment, reviewers were requested to complete 
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assessments within 90 calendar days, however this timeline was not systematically 
monitored and the data collected demonstrated that this timeline was not always met.  
Each application was evaluated in parallel by the various scientific committees and the 
dates of the scientific committee meetings, at which the reviewer’s assessment reports 
were discussed, were available.  There was no limit to the number of times an 
application went through a scientific committee cycle.  The data collected during the 
period 2015-2018 reflected that on average there was a maximum of three cycles for 
an application within any given scientific committee.  While applicants were 
encouraged to respond to the request of the scientific committees for additional 
information within 180 calendar days, this requirement was neither monitored nor 
enforced.  Unfortunately, the data provided did not allow for the accurate calculation 
of the clock stop so it was not possible to determine the amount of time the applications 
spent with the scientific committee nor the time it took for the applicant to respond.  
Based on the data collected and reflecting on the correspondence from companies, 
the consequent assessment report dates and the committee meeting dates, it was 
apparent that the Authority routinely accepted responses from companies that 
considerably exceeded the recommended response timeline of 180 calendar days. 
Nevertheless, if the company response time was to be reduced and implemented, this 
could reduce the time that an application would spend in the system. 
 
The review process of the former MCC as well as that during the transitional period 
for SAHPRA did not set targets for milestones within the review process and no target 
was set for the overall approval time of applications.  It is critical for NRAs to develop, 
maintain and strengthen a culture of performance measurement so that the results 
can be used to optimise regulatory outcomes. 
 
Regulatory review approval timelines 
The overall approval timelines for the regulatory review achieved by the MCC (2015-
2017) and by SAHPRA (2018) were extensive and did not contribute to ensuring timely 
access to medicines for patients in South Africa.  The forecasted number of NASs 
registrations for 2018 was compared to the actual number of NASs registered by 
SAHPRA in 2018.  The actual data for quarter 1 of 2018 was comparable with the 
predicted value for number of NASs registered in quarter 1 2018.  The predictions for 
the number of NASs registered in quarter 2 to quarter 4 of 2018 did not correspond 
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with the actual number of NASs registered for Quarter 2 to 4 in 2018.  The results of 
the time series analysis indicated that there was inconsistency in the data, there was 
no trend, no indication of seasonal fluctuations and no repetition in any particular 
pattern. 
 
As previously described in Chapter 3, both the historical and the operational factors 
contributed to these extended timelines.  There were no comparative studies available 
to reflect the regulatory performance of South Africa relative to other African countries, 
however it was noted that a target overall approval timeline of 330 calendar days had 
been set by the Zazibona collaborative process (Makamure-Sithole, 2019); a 
harmonisation and joint-review initiative in the SADC region, in which South Africa has 
participated since 2016.  This target was almost five times less than the median 
approval timeline for NASs reported in this study.  The scope of Zazibona included 
NASs and was not limited to the assessment of generic medicines although this was 
predominantly the group of products being reviewed.  It also raised the question as to 
whether applicants wishing to register medicines in South Africa preferred to opt for a 
registration through the Zazibona pathway in order to circumvent the longer review 
timelines for NASs demonstrated in this study. 
 
Median approval times for NASs approved during 2014-2018 in developing markets 
have already been studied and demonstrated that the timelines achieved by South 
Africa were the longest when compared to those in other developing markets (CIRS, 
2019b).  The timelines reported for South Africa were nearly double when compared 
to Indonesia and Algeria (for whom the second and third longest timelines were 
reported respectively); and approximately seven times longer when compared to 
Mexico (for whom the shortest timeline was reported) (CIRS, 2019b).  It is, however, 
important to note that while these results demonstrated vast differences in the overall 
approval time achieved by South Africa in comparison to other developing markets, 
many of these countries have implemented FRPs.  The FRPs allow NRAs to reduce 
duplication of regulatory effort, recognise the decisions made by other NRAs and apply 
abridged review or verification processes in their assessment of applications for 
registration of NASs.  All the applications for NASs registration approved by South 
Africa during this period underwent a full review.  All of the NASs registered by 
SAHPRA during 2018 had been previously assessed and approved by at least one or 
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more of the following countries: Australia, Canada, Europe, Japan, Switzerland and 
USA.  Considering that SAHPRA intends to rely on or recognise the regulatory 
decisions of many of these listed countries, FRPs could have been utilised in the 
registration of the NASs approved by SAHPRA in 2018.  The formalised 
implementation of FRPs in the assessment of these NASs could have resulted in a 
considerably reduced time line for registration and accelerated patients’ access to 
these NASs.  To this effect, SAHPRA is considering the use of FRPs in the future. 
 
Challenges and opportunities for improvement 
Historically the MCC did not identify key milestones within the review process and did 
not set or enforce target timelines for these milestones.  The median overall approval 
time for the registration of NASs was neither measured nor monitored and, together 
with a growing number of applications, consequently resulted in a large backlog in 
medicine registration.  At its inception, SAHPRA’s inherited backlog of work comprised 
of approximately 16 000 applications, including 8300 registration applications and 
7200 variation applications (Mahlatji, 2019, unpublished industry update).  Over 90% 
of these applications were for generic medicines and included duplicate applications 
as well as applications for products with multiple strengths.  Of these, approximately 
545 were applications for the registration of NASs. An application survey was 
concluded in January 2019 and an analysis of the information provided through this 
survey resulted in the agreed withdrawal of approximately 3 000 registration 
applications from the backlog.  A validation exercise was completed in consultation 
with the industry stakeholders to facilitate the planning of the backlog work schedule 
and to define the process and timelines for resubmission of updated applications for 
registration.  The work plan was devised to support the prioritisation of applications for 
medicines serving the therapeutic areas that addressed the highest public health need 
within South Africa, as agreed upon in consultation with the South African National 
Department of Health.  A dedicated team was appointed by SAHPRA to address the 
backlog, in an effort to avoid resource constraints or delays in its routine workload.  
The backlog clearance program was planned for implementation in the third quarter of 
2019 and it was the intention of SAHPRA to clear the backlog within two years 
(Mahlatji, 2019, unpublished industry update).  Median overall approval times recorded 
for 2015-2018 demonstrated a noteworthy departure from the approval times achieved 
by other NRAs of a similar size and with a similar regulatory mandate.  All of the NASs 
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approved during this period were evaluated using a full review.  The regulatory effort 
applied in the assessment of applications for registration should be commensurate 
with the level of risk of the product and should not impose an unwarranted regulatory 
burden.  In view of the fact that the NASs, registered during this period, had been 
previously reviewed by one or more reference agency, the review time for these NASs 
could have been considerably reduced if a reliance mechanism had been in place. 
 
Section 2B (2b) of the Medicines and Related Substance Act, 1965 (Act 101 of 1965) 
supported the use of FRPs (Medicines and Related Substances Act 2017).  The 
implementation of FRPs should be considered in order to ensure the effective 
allocation of limited resources (Liberti et al., 2016).  Participation in joint and shared 
review initiatives will continue to support the effort to decrease the overall approval 
time for medicine registration (Azatyan, 2019).  While the former MCC had set a target 
review time of 250 calendar days for products reviewed using the fast track review 
process, this target was not achieved during the period 2015-2017.  SAHPRA should 
define the eligibility criteria for fast track designation and should consider the possibility 
of stratifying the pathways and target timelines within the fast track process (USFDA, 
2018).  SAHPRA should implement systems to accommodate the accelerated 
approval of NASs that address unmet needs, NASs required in response to 
emergency situations and breakthrough NASs that demonstrate substantial 
improvement over available medicines (USFDA, 2018).  This stratified approach may 
also require SAHPRA to consider regulatory trade-offs involving acceptance of 
surrogate end-points supported by strengthened post-marketing commitments such 
as the reallocation of regulatory resources from pre-marketing to post-marketing 
functions (Roth et al., 2018; USFDA, 2018).   
 
As SAHPRA moves forward with the implementation of the newly restructured review 
process it is critical to ensure that the quality management system (QMS) is formalised 
to support the consistent application of GRPs, GRevPs and GRelPs within the review 
process. Furthermore, in an effort to prove itself as an effective, responsive, 
transparent and accountable regulatory authority, SAHPRA should consider the use 
of the UMBRA framework for the BR assessment of NASs and progressive QDMPs 




This study has evaluated the regulatory review process of the former MCC as well as 
that applied by SAHPRA during the initial stages of its establishment and transition.  
The key milestones and timelines of the South African review process for the period 
2015–2018 have been identified and measured and the challenges and opportunities 
for decreasing the overall approval timelines together with an improved review process 
have been considered.  While the extensive delays in NAS approvals could be 
attributed to deficient operational processes, resource constraints and increased 
volume of applications for registration, there is now an opportunity for improvement.  
The SAHPRA have developed a re-engineered, streamlined regulatory review process 
that has been piloted for final implementation. 
 
The following key recommendations may be considered to support the restructuring 
and enhancement of the SAHPRA regulatory review process: 
 
Measuring & Monitoring: Identify, record, monitor and measure milestones in the 
review process, codify and enforce benchmarked targets for each milestone. 
 
Facilitated Regulatory Pathways (FRPs): Define and codify the type of product 
review assessments that will be used by SAHPRA, including a full review, abridged 
review and verification review as well as continuing to enhance regional, continental 
and international collaborations for joint and shared reviews. 
 
Regulatory trade-offs: Consideration of surrogate endpoints to inform expedited 
market authorisation for NASs supported by strengthened post-market surveillance 
commitment. 
 
Robust Information and Communication Technology (ICT) System: The 
development, implementation and maintenance of enhanced ICT solutions, supported 
by dedicated resources, should be considered in order to facilitate the adequate and 
accurate tracking of applications and decision-making as well as improved document 




Quality Management System (QMS): Formalise GRPs, GRevPs and GRelPs within 
the review process, implement the UMBRA framework for BR assessment and ensure 




 The aim of this study was to evaluate the timelines of the milestones of the 
South African review process and the overall approval process for NASs for the 
period 2015-2018 
 
 Data identifying the milestones and overall approval times for NASs, including 
NCEs, biologicals and MLEs registered by the South African Agency during the 
period 2015-2018 were collected and analysed 
 
 The results showed that the largest number of NAS approvals were recorded 
in 2017 (n=42) and that the least (n=15) were in 2018 
 
 The shortest median approval time for NASs, of 1218 calendar days, was 
achieved in 2015 and the longest median approval time of 2124 calendar days, 
was recorded in 2018 
 
 All the applications that were registered during 2015-2018 were reviewed by 
the Authority using the full review process 
 
 Sixteen out of a total of 99 NCEs (16%) were assigned priority status and were 
reviewed and approved through the fast track review process, whereas no 
applications for biologicals and MLEs were processed by this route 
 
 While the extensive delays in NASs approvals may be attributed to inefficient 
operational processes, resource constraints as well as an increased number of 
applications for registration, there is still an opportunity for improvement 
 
 SAHPRA has re-engineered and streamlined its regulatory review process 
















Comparison of the Medicine Control Council’s Regulatory 
Review Processes with Australia, Canada, Singapore  




Efforts toward regulatory harmonisation and convergence have been evident over the 
last 20 years and have been supported through the initiation of both NRAs and the 
pharmaceutical industry.  The impact of these efforts has translated into globally 
standardised technical regulations and requirements for the quality, efficacy, and 
safety of medicines and their improved access by patients (WHO, 2000).  While each 
country has autonomy in the manner in which it effects its regulatory mandate in line 
with national requirements, it is recognised that there is value in benchmarking 
regulatory models and sharing best practices (Mashaki Ceyhan et al., 2018). 
Comparisons between NRAs of similar size, regulatory mandates, structures, 
resource characteristics and regulatory challenges would be more beneficial than 
comparisons between authorities with vastly different characteristics and 
competencies (Mashaki Ceyhan et al., 2018).  National regulatory authorities (NRAs) 
in jurisdictions within the emerging pharmaceutical markets would benefit from 
comparisons with other mature NRAs of similar size such as Health Canada and the 
Australian TGA (Hashan et al., 2016). 
 
The NRA of South Africa was mandated through the Medicines and Related 
Substances Act, 1965 (Act 101 of 1965) to ensure the efficient, effective and ethical 
assessment and registration of medicines and medical devices that met defined 
standards of quality, safety, efficacy and performance (Medicines and Related 
Substances Act 2017).  The South African NRA was also responsible for ensuring that 
the process of assessing and registering medicines and medical devices was 
transparent, fair, objective and concluded within an appropriate time frame (Medicines 
and Related Substances Act 2017).  In June 2017, the Medicine and Related 
Substances Act, 1965 (Act 101 of 1965), was amended to allow for the transition of 
the MCC to SAHPRA.  This transition provided an opportunity to study the regulatory 
processes applied by the MCC with a view to enhancing the regulatory review process 
and the responsiveness of the NRA as it moved toward effecting its improved 
regulatory landscape as SAHPRA.  As SAHPRA moved forward with its objective for 
regulatory reform, it was important that the authority had the relevant capabilities and 
decision-making frameworks in place to ensure the efficient application of resources 
with a view to improving overall approval times and patients’ access to new medicines.  
The former regulatory performance of the MCC served as a baseline from which 
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SAHPRA could monitor progress and achievements whilst benchmarking planned 
reform against that of other NRAs in order to identify the strengths and areas for 
improvement.  A comparative study of the regulatory performance of the MCC 
registration process with that of other NRAs in the developed and emerging markets 
had not been previously performed.  Therefore, there was a need for such a study as 
the South African NRA strived to become a reference NRA in the African region.  
Similar studies have been performed to compare the Turkish Medicines and Medical 
Devices Agency (Mashaki Ceyhan et al., 2018), the Saudi Food and Drug Authority 
(Hashan et al., 2016) and the Jordan Food and Drug Administration (Haqaish et al., 
2017) with the NRAs of Australia, Canada and Singapore.  This study aimed to 
compare the registration process of the MCC in South Africa with the processes of 
Australia, Canada, Singapore and Switzerland.  It allowed for the identification of the 
strengths, challenges and areas of improvement within the regulatory review 
processes applied by the MCC.  This study also aimed to assess the level of 
implementation of quality measures, GRevPs, QDMPs and continuous improvement 





This study provided a comparison of the registration process historically administered 
by the MCC against that of four other NRAs, including TGA, Health Canada, the HSA 
and Swissmedic.  These NRAs were selected as comparators as the size of the 
agencies, the patient population they served, the year established and the nature of 
the review model (full assessment) applied were comparable to those of the MCC.  
The data for the comparator agencies was collected in 2014 and subsequently 
updated in 2017.  It was recognised that it would not be appropriate to compare the 
MCC against an agency such as the USFDA, whose financial resources and number 
of reviewers were not comparable, or an agency such as the EMA, whose review 
process engaged rapporteur and co-rapporteur in the review and constituted a totally 
different review model to that of South Africa.  NRAs in the region, such as Kenya and 
Nigeria were not considered as the population they serve was much larger than that 
of South Africa.  Many NRAs in the emerging economies did not conduct a full review 
of NASs and as such were deemed to be inappropriate as comparator NRAs.  
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Study tool and data collection process 
The questionnaire (McAuslane et al., 2009; CIRS, 2019c) (see Appendix 1) used in 
the study was completed and validated by the then Registrar of the MCC in 2017.  The 
completed questionnaire described the regulatory review system for market 
authorisation of NASs as applied by the MCC and the overall review times of NASs 
from the date of application to the date of approval during the period 2015-2017. The 
questionnaire (McAuslane et al., 2009; CIRS, 2019a) used in this study was initially 
developed to facilitate the collection of data pertaining to regulatory systems in 
emerging market jurisdictions with respect to their implementation of GRevP.  Data 
were collected using a standardised format to allow for appropriate comparison and 
analyses of information collected from multiple NRAs. The questionnaire (see 
Appendix 1) consisted of four parts: part 1 – structure of the NRA, the resources 
available and the review models applied by the authority; part 2 – regulatory review 
process using a standardised process map format to allow for ease of comparison; 
part 3 – indicators and description of the measures that have been implemented to 
build quality into the regulatory review process and decision-making practices and the 
implementation of GRevP to ensure transparent, consistency and timely regulatory 
review outcomes; and part 4 – identification of the enablers and barriers to quality 
decision making.  The completion of the questionnaire and preparation of the report 
by the researcher were validated by the Registrar of the MCC.  Similar questionnaires 
were completed by the Head of the licensing (registration) division of the TGA, Health 
Canada, the HSA and Swissmedic.  The validated country reports that were prepared 
to describe the regulatory systems applied in each of these countries were used to 
inform the results of this study.  The questionnaire (see Appendix 1) used in this study 
was designed to allow for simple comparative analyses of the structure, processes, 
and practices of international NRAs (McAuslane et al., 2009; Mashaki Ceyhan et al., 
2018). 
 
Models of regulatory review 
National regulatory authorities (NRAs) may apply different regulatory pathways 
requiring stratified levels of data assessment depending on the type of medicine under 
review and the regulatory status of the medicine in other reference or benchmark 
jurisdictions.  There are three types of product review assessments used by regulatory 
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authorities: the verification review (type I); abridged (type II); and full review (type III) 




Comparative assessment of regulatory review processes and milestones 
The five NRAs compared in this study had similar mandates for regulating medicines 
for human use.  They were responsible for ensuring that harmonised standards for 
market authorisation of such products were applied whilst ensuring timely access to 
medicines that were safe, effective and of good quality.  National regulatory authorities 
(NRAs) have demonstrated autonomy in the manner in which they executed their 
mandates, however, differences were observed within their regulatory review 
processes, timelines and the application of GRevPs.  The regulatory review processes 
applied by the MCC were shown in the standardised process map (Figure 4.1).  The 
map provided a simple representation of the review and authorisation of applications 
for NASs and MLEs that were approved on the first cycle, but did not include generic 
medicines, biosimilars, complementary medicines, veterinary medicines or medical 
devices.  The map did not describe the process, in the event that the application was 
refused.  The MCC conducted a type III full assessment in the review of all 
applications, including NASs, MLEs and generics for orthodox, biological, 
complementary and veterinary medicines.  A full independent assessment of quality, 
efficacy and safety data was performed and an application for market authorisation for 
NASs and MLEs could be submitted to the MCC prior to approval by any other NRA 
worldwide.  The MCC did not place any reliance on or consider the review performed 
by any other NRAs.  The TGA, Health Canada, the HSA and Swissmedic also 
performed type III full assessments and a CPP was not required at the time of 
submission (Table 6.1). 
 
The type II (abridged) review was employed by the TGA if requested by the sponsor 
and if the medicine had been approved by one or more reference authority.  
Swissmedic used a type II abridged review for selected applications and mainly for 
generic medicine applications and the HSA used the type II abridged review only if the 
medicine had been approved by one or more authority.  The HSA also conducted a 
type I verification review but only if the medicine had been approved by two or more 
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authorities.  While Health Canada were planning to implement this reliance pathway 
(Health Canada, 2018), Swissmedic intended to roll this out by 2019. 
 
Data requirements 
The MCC and the HSA did not have a formal pre-application procedure in place, 
however, Swissmedic offered this in cases of a priority review.  For type III full reviews, 
the HSA required the sponsor to submit a notification of intent to apply for market 
authorisation. The TGA and Health Canada had formalised this process and 
considered it as an opportunity to familiarise reviewers with the medicine, potentially 
uncover any major areas of concern early in the registration process, identify the 
potential for priority review and provide a platform for the sponsor to discuss their 
submission and obtain scientific advice.  The MCC required the full chemistry, 
manufacturing and control (CMC) data, nonclinical data and clinical data to be 
submitted in the CTD format to support the application for market authorisation.  The 
other four comparative NRAs also requested full CMC, nonclinical and clinical datasets 
and also conducted an extensive assessment of these datasets for a type III full 
review.  All five of the NRAs performed a review of quality, safety and efficacy data in 
parallel and pricing negotiations were separate from the technical review of the data 
submitted.  The primary scientific review of the data was performed by internal 
technical staff of the four comparative NRAs, with the possibility of seeking advice from 
contracted external experts on an ad hoc basis.  The quality assessment of NASs and 
MLEs conducted by the MCC was performed by both internal technical staff and 
external reviewers while the assessment of clinical data for NASs and MLEs was 
reviewed by external reviewers only.  Committee structures within the four 
comparative NRAs were similar in that the NRAs engaged with various expert 
committees on an ad hoc basis to support the scientific review process and to provide 




Table 6.1 Models of assessment of the five agencies and extent of the scientific review 
 
TYPE OF REVIEW MODEL South Africa (MCC) Australia Canada Switzerland Singapore 
Verification review (type I)     a 
Abridged review (type II)  b  c d 
Full review (type III)    e  
EXTENT OF SCIENTIFIC REVIEW 
1. Chemistry, manufacturing, and control (CMC) data  
Extensive assessment      
2. Nonclinical data  
Extensive assessment     f 
3. Clinical data  
Extensive assessment      
ADDITIONAL INFORMATION OBTAINED (WHERE APPROPRIATE) 
Other agencies’ internal 
review reports 













Abbreviations: CMC=Chemistry, Manufacturing and Control; MCC=Medicines Control Council 
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a Only if the product had been approved by two or more reference agencies 
b Only if requested by the sponsor and if the product had been approved by two 
or more reference agencies 
c  Used for selected applications, mainly generic applications 
d  Only if the product had been approved by one or more reference agencies 
e  Used mainly for applications for innovative medicines 
f  Only for biological and biosimilar products 
 
The committee structure within the MCC was different in that all assessment reports 
would be channelled to various scientific committees for expert opinion and the final 
regulatory decision would be taken by the Council.  All five NRAs were members of 
the Pharmaceutical Inspection Co-operation Scheme (PIC/S) (PIC/S, 2018) and had 
implemented processes to ensure that evidence of the GMP status of the 
manufacturer was provided during the review process.  Sponsors could submit a copy 
of the GMP certificate issued by a reference agency as evidence of a manufacturers 
GMP status, however, if the GMP status of the manufacturer could not be confirmed 
at the time of application for market authorisation, the regulatory authority could 
conduct a GMP inspection at the manufacturing site in parallel to the review process. 
 
Target and approval times 
The MCC review process consisted of application receipt and validation procedures, 
queue time for allocation of applications to reviewers, a scientific review of CMC, 
nonclinical and clinical data conducted in parallel, company response and final 
authorisation through the regulatory decision taken by the Council.  The milestone 
timelines for the MCC review procedures were displayed in Figure 4.1.  A “fast track” 
status was assigned to eligible applications in order to expedite the registration of 
essential medicines.  While the review process was the same for “fast track” 
applications, these applications would be prioritised over existing applications, queued 
for allocation to reviewers.  The target set for the overall review time of fast track 
applications was 250 calendar days.  The median approval times for fast track NAS 
applications approved in 2015, 2016, and 2017 were 1218, 921, and 609 calendar 
days, respectively.  There was no target time set for the overall review time of NASs, 
but the median approval times for NAS marketing authorisation applications approved 
in 2015, 2016, and 2017 were 1175, 1641, and 1466 calendar days, respectively.  
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These data demonstrated that the MCC was neither able to achieve the target 
timelines set for fast track applications nor meet the targets in 2015, 2016, and 2017 
for the key milestones within the regulatory review process (Figure 4.1).  The data 
represented the overall approval time based on the date of application and the date of 
registration; data that were routinely monitored and measured for the period 2015–
2018.  The median overall approval time did not include or account for sponsor 
response time and the time taken to reach the other milestones identified within the 
regulatory review process. 
 
In comparison the TGA, Health Canada, the HSA and Swissmedic had set overall 
target review times, for standard full approvals, at 305 calendar days, 355 calendar 
days, 270 working days (i.e. 378 calendar days) and 330 calendar days, respectively.  
The overall target review times set by these four NRAs did include sponsor response 
time, unlike those for MCC.  During the period 2013-2017, the TGA, Health Canada 
and Swissmedic achieved median approval times of 364, 350, and 487 days, 
respectively (Bujar et al., 2018).  In 2017, Health Canada, Swissmedic and the TGA 
approved 30, 29, and 24 NASs, respectively.  Despite these numbers varying on an 
annual basis, the number of NAS approvals between 2008 and 2012 increased by 
56% for the TGA, 46% for Health Canada and 41% for Swissmedic when compared 
to the number of NASs approved between 2013 and 2017 (Bujar et al., 2018). 
 
Comparative assessment of good review practices 
This study identified the quality measures that had been established and implemented 
by the five NRAs with a view to comparing the aptitude and culture of the authorities 
in the application of these measures in order to ensure quality, transparency, 
consistency and continuous improvement in the regulatory review process. 
 
Quality measures 
Swissmedic was the only NRA in this comparative study that had a dedicated quality 
department and that had implemented all the listed quality measures (Table 6.2).  The 
MCC and the TGA implemented six of the seven measures and Heath Canada and 
the HSA had implemented five quality measures.  Only Health Canada and 
Swissmedic had formally implemented GRevPs while the other three authorities had 
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informally implemented GRevPs.  All of the five NRAs occasionally participated in 
shared and joint reviews. 
 
Transparency and communication 
Improved transparency and communication were common goals for NRAs worldwide.  
There were nine established transparency and communication parameters that could 
be implemented by NRAs to enhance stakeholder relationships (Table 6.3).  The MCC 
implemented seven out of the nine parameters.  At the time of this study, the industry 
was unable to track the progress of applications.  Although the MCC documented and 
communicated the summary of grounds for regulatory approval with the sponsor, this 
summary was not published or made available in the public domain.  The HSA also 
did not publish the summary basis of approval or provide feedback to the industry on 
submitted dossiers. The TGA implemented all of the nine transparency and 
communication parameters while Swissmedic and Health Canada implemented eight 
and the HSA six of the nine measures (Table 6.3). 
 
Continuous improvement initiatives 
A comparison was made of the continuous improvement initiatives that had been 
implemented by the five NRAs.  Swissmedic implemented all five initiatives, the TGA 
and the HSA implemented four, Health Canada implemented three and the MCC 
implemented two of the five initiatives (Table 6.4).  The MCC did not undergo routine 
external or internal quality audits. Furthermore, reviews of assessors’ feedback were 
performed and the MCC carried out an informal review of feedback from stakeholders. 
 
Training and education 
Various types of training and education such as induction training, on-the-job training, 
attendance at internal and external courses, international workshops and 
secondments in other regulatory authorities can contribute to the development of 






















    

















     
Assessment templates      
Dedicated quality department      
Scientific committee      












Abbreviation: MCC=Medicines Control Council 
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All five of the regulatory authorities in this comparative study implemented all eight of 
the measures for training and education (Table 6.5). 
 
Enablers and barriers to good quality decision-making 
The MCC identified its willingness to improve its regulatory performance as an enabler 
to good quality decision-making and the lack of an EDMS as a major barrier.  The 
other four NRAs in the comparative study listed a variety of enablers that contributed 
to good decision-making, with common themes of regulatory convergence, 
harmonisation and the implementation of GRevPs emerging as top enablers on the 
list.  The barriers identified by these authorities included frustrations with incomplete 
submissions for market authorisation, the need for appropriate electronic systems to 
support the review process and a full integration of electronic tracking systems.  The 
comparison of the key features of the regulatory review process of the MCC, the TGA, 




National regulatory authorities (NRAs) around the world strive to enhance their 
regulatory performance and in doing so ensure timely patients’ access to safe, good 
quality, effective medicines.  A comparison of the regulatory systems and review 
processes implemented by NRAs globally contribute to the understanding of these 
challenges and inform solutions through sharing of best practices and lessons learned.  
The MCC recognised the importance of harmonisation and regulatory convergence 
and was striving to align itself with the systems and processes implemented by mature 
NRAs in an effort to improve regulatory performance and ensure timely patients’ 
access to medicines.  This study aimed to identify the similarities and differences 
between the registration processes applied by similar-sized mature NRAs and those 
applied by the MCC.  The results demonstrated the strengths in the regulatory review 
process of the MCC and the areas that required improvement, evaluated the 
regulatory performance of the MCC review model and reflected on the progress by the 
MCC in applying GRevPs.  The TGA, Health Canada, the HSA and Swissmedic were 
selected for this study as authorities with similar regulatory characteristics and review 
models to allow for an appropriate comparison.  
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Feedback to industry on 
submitted dossiers 
     
Details of technical staff to 
contact 

a     
Pre-submission scientific 
advice to industry 

b     
Official guidelines to assist 
industry 
     
Industry could track progress 
of applications 

c     
Publication of summary of 
grounds on which approval 
was granted 

d     
Approval times e     
Advisory committee meeting 
dates 
     
Approval of products      
 
Abbreviation: MCC=Medicines Control Council 
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a Contact details were made available on an ad hoc basis 
b Meetings were held with industry on an ad hoc basis 
c Implementation of an EDMS was planned 
d Summary was available but was not published 
e Approval times were not made available to the public 
 
In particular, these four agencies have a work-sharing approach, which provided the 
rationale for their comparison. Over the past decade a number of NRAs from the 
emerging economies have been evaluated using this questionnaire.  Therefore, the 
four NRAs selected as comparators for this study were based on the size of the 
agencies, the patient population they serve, the year since established and the nature 
of the review model (full review) applied.   
 
Furthermore, NRAs from the emerging economies, such as Tanzania and Kenya, were 
not considered comparable to MCC because of the size of these NRAs and the size 
of the population they serve.  In addition, the MCC carried out a full review which was 
different to that of the other NRAs in the region.  It was also recognised that the USFDA 
and the EMA were not appropriate NRAs to which benchmark the MCC.  The reasons 
include both the size of the NRA, the population they serve and in particular the 
resources available; both in financial terms and the number of reviewers (which in the 
case of the USFDA included 1200 reviewers of whom 220 are statisticians).  As 
regards EMA, being a consortium of 32 countries, engaging rapporteur and co-
rapporteur in the review process would constitute a totally different review model to 
that of South Africa. 
 
Review type and process 
The MCC conducted a type III full assessment for all NAS applications for market 
authorisation and such applications could be submitted to the MCC prior to approval 
by another NRA.  In line with the other four comparative NRAs, the GMP status of the 
manufacturer was confirmed concurrently with the review process and a CPP was not 
required at the time of submission.  The MCC participated in regional alignment 
initiatives and conducted shared or joint reviews with other NRAs such as Zambia, 
Zimbabwe, Namibia and Botswana (Regulatory Resources for Africa, 2015).    
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External quality audits a     
Internal quality audits b     
Internal tracking systems c     
Reviews of assessors’ 
feedback 
     
Reviews of stakeholders’ 
feedback 

d     
 
Abbreviation: MCC=Medicines Control Council 
 
a External quality audits were not performed routinely 
b Planned to formally implement 
c Implementation of EDMS was planned by SAHPRA 




















     
External courses      
In-house courses      
On-the-job training      
External speakers invited to 
the authority 
     
Induction training      
Sponsorship of post-
graduate degrees 
     
Placements and 
secondments in other 
regulatory authorities 
     
 
Abbreviation: MCC=Medicines Control Council 
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South Africa (MCC) Australia Canada Switzerland Singapore 
Certificate of Pharmaceutical Product was required at 
time of submission 
     
More than 20% of review staff were medically 
qualified 
     
The authority set target time for scientific assessment      
The authority set overall review and approval target 
time 
     
Questions to sponsors were batched at fixed points in 
the review 
 
     
Recording procedures allowed company response 
time to be measured and differentiated in the overall 
processing time 
 
     
The authority recognised medical urgency as a 
criterion for accelerating the review and approval 
process for qualifying products 
 
     
Quality, safety, and efficacy technical data sections 
were reviewed in parallel rather than sequentially 
 
     
Pricing discussions were separate from the technical 
review 
 
     
The focus was on checking quality in the market place 
and requirements for analytical work did not delay 
marketing authorisation 
     
 
Abbreviation: MCC=Medicines Control Council  
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However, no formal measures were put in place to ensure consistent quality during 
shared or joint reviews and participation in this initiative did not influence the way in 
which the MCC conducted reviews in general.  A work-sharing programme was a 
creative way to maximise resources even when NRAs were separated by time and 
distance.  This was the rationale for the collaboration between the NRAs in Australia, 
Canada, Switzerland and Singapore that established efficient work-sharing 
experience (McAuslane et al., 2017). 
 
Considering the resource constraints faced by the MCC and the large volumes of 
applications for market authorisation received; it was beneficial to consider the use of 
FRPs to expedite regulatory decisions and to enhance the re-engineered registration 
process envisaged by SAHPRA.  Applying FRPs that provide a risk-based approach 
for the review of applications for market authorisation may help to conserve limited 
resources and reduce regulatory burden by avoiding duplication of regulatory efforts 
(Alsager et al., 2015).  This would be an advantage when considered in line with the 
recommendations of the WHO (Ward, 2014; WHO, 2014a) by embracing regulatory 
harmonisation/convergence strategies; engaging in reliance and recognition activities 
that allowed NRAs in resource-limited settings to take into account or accept 
regulatory decisions made by other comparable NRAs (McAuslane et al., 2018).  
Furthermore, this would enable the application of an appropriate framework for BR 
assessment to enhance consistency in the clinical assessment of medicines (Leong 
et al., 2015a) as well as incorporating the principles of GRevPs in routine regulatory 
undertakings (WHO, 2014a). 
 
Approval times 
As stated by Leng et al. (2015), “The MCC had been under considerable pressure to 
increase the rate of medicines registration and was accused of delaying patients’ 
access to affordable and essential medicines” (p.1).  The outcomes of an investigation 
into delayed timelines for registration of medicines, initiated in 2006 by the Minister of 
Health, noted a lack of skilled staff, poor infrastructure and inefficient regulatory 
processes as the major barriers affecting patients’ timely access to medicines (Green-
Thompson, 2008).  This demonstrated that the MCC neither achieved the target 
timelines set for the eligible applications of essential medicines, that were assigned 
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“fast track” status, nor met the targets between 2015 and 2017 for the key milestones 
within the regulatory review process (Leng et al., 2015).  Furthermore, the MCC made 
use of a manual system to track applications for market authorisation, but it is hoped 
that the imminent implementation of an EDMS by SAHPRA would promote systematic 
and formal communication regarding timelines and milestones to both internal and 
external stakeholders.  The MCC did not set a target for overall approval time of NAS 
applications.  In order for SAHPRA to measure and improve its regulatory performance 
it was recommended that targets for overall approval time and key review milestones 
needed to be identified, codified into policy and guidelines, recorded, measured and 
monitored.  Appropriate systems and resources, therefore, need to be put in place to 
ensure that regulatory performance metrics were analysed on a continuous basis 
through formal and routine monitoring.   
 
The key milestones in the regulatory review process, including administrative and 
technical screening time, queuing time prior to review and clock stops measuring the 
time with sponsors need to be measured.  There is now the potential to improve 
regulatory review time through ongoing analysis of the performance metrics that may 
inform continuous improvement initiatives, aimed at streamlining and prioritising the 
progression of the review process.  Review times may be improved as a result of the 
more flexible approach to committee structures implemented by SAHPRA.  The 
committee structures within SAHPRA have been revised to allow for more frequent ad 
hoc consultation with scientific committees, limited to applications for market 
authorisation requiring expert review and recommendation, as opposed to routinely 
channelling assessment reports through the committees for recommendation at 6-
weekly intervals.  Nevertheless, operationalisation of the system proposed by 
SAHPRA may not produce satisfactory outcomes and therefore a more fundamental 
review of the entire agency could still be proved to be of value.  
 
Good review practices 
The implementation of GRevPs provides a mechanism for NRAs to enhance 
regulatory performance (WHO, 2015) and previous studies have demonstrated that 
regulatory performance indicators such as overall approval timelines can be enhanced 
by instituting quality management systems and GRevPs into the regulatory review 
process (Cone & McAuslane, 2006).  Good review practices (GRevPs) are a 
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fundamental part of overall GRP with a focus on medical product review (WHO, 2015, 
p193).  These are defined by the WHO as “documented best practices for any aspect 
related to the process, format, content and management of a medical product review” 
(WHO, 2015, p194).  The application of GRevP provides a platform for NRAs to 
“achieve timeliness, predictability, consistency, transparency, clarity, efficiency and 
high quality in both the content and management of reviews”; with a view to achieve 
successful review outcomes (WHO, 2015, p194).  Many NRAs have implemented 
systems to ensure the consistent application of GRevPs and continue to work toward 
the evaluation and improvement of such systems.   
 
The five NRAs in this study implemented the majority of the essential elements of 
GRevPs.  The MCC did not have a dedicated quality department, however, there were 
plans to include dedicated quality personnel within the newly established SAHPRA.  
While key quality measures had been established and were evident in the work 
performed by the MCC, the need to formalise the quality management system, 
including the internal quality policy, GRevP systems, SOPs and harmonised 
assessment templates had to be prioritised in order to enhance SAHPRA operations.  
The establishment of a codified QMS within SAHPRA needs to be supported by 
formally introduced continuous improvement measures such as internal and external 
quality audits that would routinely and formally be implemented underpinned by 
initiation of an EDMS.  The MCC had always recognised the importance of 
transparency and communication with stakeholders.  As SAHPRA moves forward, it 
is hoped that many of the measures that contribute toward transparency and 
communication would be formally and routinely implemented in an effort to enhance 
the consistency, timeliness and predictability of the review process.  The imminent 
application of an EDMS would allow for improved transparency as sponsors would be 
able to track the progress of applications.  In addition, the overall approval times and 
the monitoring and measurement of key milestones in the review process would be 
readily available.  However, whilst it is generally agreed that there are several aspects 
to review practices that are considered important, it is recognised that the summary 
basis of approval has a far greater impact with respect to the regulatory process 




The MCC implemented a guideline in 2007 for the evaluation of BR assessment of 
medicines and prepared a summary basis of approval for each medicine evaluated; 
both of which were key steps in the regulatory review process. The clinical assessment 
of NASs was conducted by external experts who prepared assessment reports that 
were peer reviewed within the clinical committee structure.  Without a standardised 
template for the clinical assessment report, informing regulatory decisions concerning 
the registration of a NAS relied heavily on the experience and expertise of such 
reviewers. SAHPRA should consider improving the benefit-risk assessment 
framework by building quality into the process and standardising the template used for 
BR assessment. SAHPRA should also consider implementing the UMBRA framework 
which has been assessed and applied by several mature NRAs (Walker et al., 2013) 
as well as NRAs in the emerging markets (Mashaki Ceyhan et al., 2018).  This 
structured approach would promote improved consistency and predictability in the BR 
assessment of medicines as the use of the UMBRA framework “assists decision 
makers with clearly defining the decision, agreeing the requisite properties of the 
treatments being considered, assessing the trade-offs among these properties and 
making defensible and transparent decisions regarding the registration of the 
medicine” (Levitan et al., 2014). 
 
The publication of the summary basis of approval is a norm for many mature NRAs 
globally and is a tool that can be used by NRAs to build confidence in the review 
process in order to provide assurance regarding safety provisions (McAuslane et al., 
2009).  It is recommended that SAHPRA consider publishing the summary basis for 
approval that was not previously made available in the public domain by the MCC.  
However, it is recognised that in order to achieve this outcome a change in legislation 
will be required.  The data collected for the purpose of this study has allowed for a 
valuable comparison of NRAs with similar regulatory mandates, size and resources 
characteristics.  A number of recommendations are provided with a view to inform 
areas of improvement that may be prioritised to underpin the success of SAHPRA as 






A comparison of the registration process applied by the MCC with those of similar 
medium-size NRAs such as the TGA, Health Canada, the HSA and Swissmedic has 
highlighted key areas for change and development.  The following recommendations 
should be considered by SAHPRA in order to improve the MCC regulatory review 
process: 
 Defining target timelines for the key milestones in the regulatory review process 
and overall approval time and ensuring the formal and routine monitoring and 
measurement of such metrics; 
 Formally implementing and maintaining GRevPs in order to build quality into 
the review process, resulting in consistent, predictable, transparent and a timely 
regulatory review; 
 Applying the Universal Methodology for Benefit-Risk Assessment (UMBRA) 
framework to enhance consistency in the clinical review of medicines and 
promote defensible and transparent decision-making; 
 Implementing facilitated regulatory pathways (FRPs) and applying a risk-based 
approach to the regulatory review process in order to conserve limited 
resources and avoid duplication of regulatory efforts; 
 Establishing committee structures within the South African NRA should allow 
for ad hoc consultation limited to applications for market authorisation requiring 
expert review and recommendation; and 
 Enhancing transparency and communication through the development of 






 The timely access to new medicines may be addressed through the 
strengthening of registration efficiencies and timelines by establishing and 
refining value-added registration processes, resources, and systems 
 
 The aims of this study were to evaluate the timelines of the milestones of the 
South African review process and the overall approval process for NASs  (2015-
2018) and to provide recommendations for improved patients’ access to new 
medicines through timely registration 
 
 Data identifying the milestones and overall approval times for NASs registered 
by the South African NRA during 2015-2018 were collected and analysed 
 
 The most NASs (42) were approved in 2017 and the least (15) in 2018. The 
shortest median approval time (1218 calendar days) was achieved in 2015 and 
the longest (2124 days), in 2018 
 
 All applications were reviewed using the full review process, and 16/99 (16%) 
were assigned priority status and were reviewed and approved through the fast 
track process 
 
 Extensive delays in NASs approvals in South Africa may be attributed to 
inefficient operational processes, resource constraints and an increased 
number of applications for registration 
 
 SAHPRA has re-engineered and streamlined its regulatory review process 
which has been piloted and will be enhanced prior to final implementation 
 
 Among recommendations for improvement, SAHPRA should consider the 
measurement and monitoring of milestones, facilitated regulatory pathway 


















Evaluation of the Transparency of the Quality Decision 




National regulatory authorities (NRAs) are responsible for making the decision to 
register a medicine based on an assessment of its overall benefits and risks.  Often 
the BR balance, which ideally included an account of the uncertainties and risks and 
relevant stakeholder perspectives (McAuslane et al., 2017), is at the core of the 
regulatory decision to register a medicine (Pignatti et al., 2015).  The NRAs, 
academics and the industry have recognised the need for a common, structured, 
systematic approach to the BR assessment of medicines that may be used during the 
review of an application for the registration of a medicine and for communicating the 
results of the review (Walker et al., 2011).  A number of frameworks for BR assessment 
have been developed over the past few years (Walker et al., 2014).  Many of these 
have incorporated mechanisms to support the systematic processing of data prior to 
making the regulatory decision (Walker et al., 2011) and featured structured, coherent, 
comprehensive approaches to BR assessment (Pignatti et al., 2015). While 
differences amongst these frameworks exist, the principles of “defining the decision, 
agreeing on the requisite properties of the treatments being considered, assessing the 
trade-offs among these properties and making defensible transparent decisions” are 
common (Levitan et al., 2014, 564). 
 
A universal BR assessment framework that incorporates the existing frameworks has 
been developed (Walker et al., 2014) and validated (McAuslane et al., 2017).  The 
Universal Methodology for Benefit Risk Assessment (UMBRA) is an overarching 
acceptable standard BR framework (Figure 1.8) (Leong et al., 2015b) that provides a 
template that may be used during the review and documents the elements considered 
to be essential in the assessment of benefits and risks (Leong et al., 2014).  The BR 
Template is considered useful in collating the conclusions of the BR decisions (Leong 
et al., 2015b) and can be used to effectively communicate the basis for the regulatory 
decision to register a medicine. 
 
In an effort to ensure transparency and accountability, some NRAs publish their 
assessment reports to communicate the regulatory decision in a clear and 
understandable manner for consideration by the public.  Public assessment reports 
(PARs) provide information about how the NRA has assessed the benefits and risks 
of a medicine (Raynor & Bryant, 2013).  The PARs usually include information 
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pertaining to the data submitted to the NRA for evaluation as well as the conclusions 
made by the NRA (Raynor & Bryant, 2013).  The PARs are published in the public 
domain by the NRAs to document the basis of and justification for the regulatory 
decision and to promote transparency (Leong et al., 2014).  The results from a 
previous study (Leong et al., 2014) have demonstrated that making use of a BR 
framework enforces a structured, documented discussion and contributes to the 
improved quality of communication in terms of transparency and consistency (Leong 
et al., 2014). 
 
Ensuring transparency in decision-making and documenting regulatory decisions in a 
structured systematic manner promotes an enhanced understanding of the basis for 
a regulatory decision and the rationale for the inclusion or exclusion of benefits and 
risks and the determinants of the consequent BR balance (Leong et al., 2014).  Many 
NRAs in the emerging economies place reliance on the PARs of reference agencies 
to inform their own regulatory decisions (Ward, 2019).  Users of PARs often criticise 
the redacted nature of the PARs and have experienced challenges in identifying the 
key benefits and risks that underlie the decisions made by reference agencies as well 
as the value judgments and the trade-offs between the benefits and risks (Raynor & 
Bryant, 2013).  This study aims to review the PARs available in the public domain 
against the UMBRA BR Summary Template using a case study approach.  This study 
is the first review carried out to evaluate the approach initiated by SAHPRA to 
document and communicate the BR decision. 
 
Study objectives 
The main objectives of this study were to: 
 Assess the transparency of the SAHPRA’s regulatory review decision making 
process  
 Determine whether the SAHPRA’s review process incorporates an appropriate 
evaluation of benefit and risk of medicines  
 Evaluate the Public Assessment Report of four reference agencies (TGA, 
Health Canada, EMA and USFDA) to determine whether these provide 
sufficient information to identify their decision-making practices 
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 Develop recommendations for SAHPRA for the implementation of an effective 
approach for communicating BR decisions and developing a framework for a 




Case study comparing the PARs from four reference agencies against the 
UMBRA BR Summary Template 
The PARs, for three NASs, including Ertugliflozin l-pyroglutamic acid, Erenumab and 
Durvalumab, recently published by the TGA, EMA, Health Canada and USFDA were 
compared against the validated UMBRA BR Summary Template (Walker et al., 2014).  
The TGA, EMA, Health Canada and USFDA have a long history of established 
regulatory processes and global recognition of regulatory standards.  At the time of 
this study, these NRAs were the only agencies that published a PAR in the public 
domain, namely the TGA: Australian Public Assessment Report (AusPAR), EMA: 
EPAR, Health Canada: Summary Basis of Decision (SBD) and the USFDA: Summary 
Review.  The PARs for Ertugliflozin l-pyroglutamic acid, Erenumab and Durvalumab 
were selected because each of these NASs had been recently approved by the TGA, 
EMA, Health Canada and USFDA and the AusPAR, EPAR, SBD and USFDA 
Summary Review were available for each of these NASs. 
 
Table 7.1 Public assessment reports (PARs) of new active substances (NASs) 
selected for comparison against the Universal Methodology for Benefit-Risk 























A10 Selective inhibitor of the 
sodium-dependent 
glucose cotransporters 
(SGLT) indicated for 
Type II Diabetes 
14/05/2018 21/03/2018 09/05/2018 19/12/2017 
Erenumab N02 Analgesic indicated for 
treatment of migraine 
28/06/2018 26/07/2018 01/08/2018 17/05/2018 
Durvalumab L01 Human immunoglobulin 
G1 kappa (IgG1κ) 
monoclonal antibody 
indicated for locally 
advanced or metastatic 
urothelial carcinoma 
02/10/2018 21/09/2018 03/11/2017 01/05/2017 
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Abbreviations: API=Active Pharmaceutical Ingredient; ATC=Anatomical Therapeutic Classification; 
EMA=European Medicines Agency; TGA=Australian Therapeutic Goods Administration; 
USFDA=United States Food and Drug Administration. 
 
The PARs were retrieved online for each of the NASs.  The comparison of the PARs 
for the three NASs, prepared by the four reference agencies, was conducted by 
comparing the information documented within the PARs against the various section 
headings of the UMBRA BR Summary Template and the findings have been tabulated. 
 
Evaluation of the approach initiated by SAHPRA to communicate the BR 
decisions 
The approach initiated by SAHPRA to document and communicate the BR decisions 
was evaluated.  Since SAHPRA does not currently produce PARs, the following 
guidelines and templates used by SAHPRA to support the review of the quality, safety 
and efficacy of NASs were compared against the section headings of the UMBRA BR 
Summary Template: Guideline 2.09 Clinical Guideline (SAHPRA, 2019a); Guideline 
6.31 Summary of Critical Regulatory Elements (SCoRE) Document (SAHPRA, 2019b) 
and the SCoRE template (SAHPRA, 2018b); the Clinical Full Review Report Template 
(CRT) (SAHPRA, 2019c); and the SAHPRA Guideline for Clinical Reviewers 
(SAHPRA, 2019d).  This study was designed to be exploratory in nature and the 
results of the study provided qualitative interpretations related to the study objectives. 
 
Focus group  
A focus group was conducted with representatives of NRAs, industry, HTA groups and 
patient groups from different jurisdictions.  The focus group consisted of approximately 
12 participants, a moderator responsible for facilitating the discussion and a rapporteur 
who consolidating the results and reported the outcomes.  A brief guide was prepared 
for the focus group and this described the discussion topic, provided background 
information and outlined the objectives for the focus group.  A list of questions and 
issues were developed and made available to the focus group.  The focus group was 
held in Tysons Corner, Virginia, United States in June 2019.  The topic was “PARs – 
Are these good knowledge management tools for stakeholders such as other 
regulatory authorities, HTA agencies, companies and patients in understanding an 




For the purpose of clarity, the results are presented in three parts: 
 Part I – Comparison of the four reference agencies’ PARs against the validated 
UMBRA BR Summary Template 
 Part II – Review of the approach initiated by SAHPRA to document and 
communicate the BR decision 
 Part III – Outcomes of the focus group 
 
Part I – Comparison of the four reference agencies’ PARs against the validated 
UMBRA BR Summary Template 
The TGA, EMA, Health Canada and USFDA produce publically available assessment 
reports to document the agency’s decisions for medicine registration.  The formats of 
these reports have been previously studied (Leong et al., 2014) and found to be 
generally similar and comparable to the format of the UMBRA BR Summary Template 
(Walker et al., 2014).  Three of the four agency’s PARs made provision for a 
documented BR assessment of the medicine.  These included the TGA AusPAR: 
Section VII. Overall conclusion and BR assessment, the EMA EPAR: Section 3. BR 
Balance and the USFDA Summary Review: Section 1. BR Assessment.  The PARs 
produced by each of the four agencies followed a similar format and were comparable 
for each of the three medicines (Durvalumab, Erenumab and Ertugliflozin l-
pyroglutamic acid) selected for the case study.  The results of the three PARs, 
produced by each of the four agencies, was compared against the UMBRA BR 
Summary Template as well as the current approach by SAHPRA in their regulatory 
review (Table 7.2). 
 
TGA AusPAR 
The AusPAR for durvalumab was not available at the time of the study.  The results 
reflected in Table 7.2 were based on the outcomes of the comparison of the AusPARs 
produced for Erenumab and Ertugliflozin l-pyroglutamic acid against the UMBRA BR 
Summary Template.  The assessment of ethnic factors was not well documented 
within the AusPAR.  The list of Phase I, pivotal, supportive and ongoing studies was 
provided but a record of the key benefits or risks identified in the studies was not 
included.  A narrative describing the risks of the medicine was available however, the 
149 
 
summary of risks was not easily identified and a table of the pooled overall incidence 
of events was not provided.  Section V of the AusPAR provided a documented clinical 
rationale for the use of the medicine but did not provide documented justification for 
the decision on the medicine fulfilling or not fulfilling an unmet medical need.  The 
assessment of the benefits and the risks was documented in Section V (clinical 
findings).  The reviewed benefits and risks selected for inclusion in the assessment 
were not explicitly listed or assessed in terms of relative importance and were not 
valued.  The justification for the inclusion or exclusion of the benefits and risks was not 
documented.  The reviewer’s considerations in terms of the BR assessment were 
provided as a narrative discussion in Section VII, however a clear conclusion on the 
BR being positive or not for the proposed indication was not provided. 
 
EMA EPAR 
The regulatory history of the medicine with regard to its assessment by a reference 
agency was not documented.  The list of clinical trials conducted was provided but a 
record of the key benefits or risks identified in the studies was not included.  The EPAR 
documented the favourable and unfavourable effects of the medicine as well as the 
associated uncertainties and limitations of these effects.  However, the EPAR did not 
provide a record of the benefits and risks that were reviewed or the reasons for their 
inclusion or exclusion in the BR assessment of the medicine.  An effects table was 
provided in Section 3.6 of the EPAR and the importance of favourable and 
unfavourable effects was discussed in Section 3.7.1.  The assignment of weighting 
(relative importance) on each of the benefits and risks identified and the valuing of the 
options of the effects was not explicitly recorded.  The EPAR did not provide a record 
of the expected evolution of the BR balance over time. 
 
Health Canada Summary Basis of Decision (SBD) 
The SBD did not make provision for the explicit assessment and documenting of the 
BR balance.  Ethnic considerations were not routinely documented.  The clinical study 
summary and associated benefits and risks identified in each study were not 
documented.  The overall summary of risks, the benefits and risks and the effects table 
were not available.  The relative importance and values of the benefits and risks were 
not documented or the justification for their inclusion or exclusion and no comments 
were made regarding the strengths and uncertainties of the benefits and risks that 
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were included in the review.  No information was available to describe the expected 
evolution of the BR balance over time.  The SBD provided limited information to 
describe the outstanding issues and how these issues were to be addressed.  For 
example, the requirements for additional follow up measures or specific obligations, 
the need for further medicine development as well as studies to improve the BR 
balance were not documented. 
 
US FDA Summary Review 
While the summary review did not document the justification for the decision on the 
medicine fulfilling or not fulfilling an unmet medical need, an analysis of the condition 
was provided and included related evidence and uncertainties as well as brief 
conclusions and reasons justifying the need for the treatment of the condition.  The 
summary review did not specify any local clinical guideline or other issues which 
needed to be considered to contextualise the decision.  The regulatory history of the 
medicine, with regard to any previous assessment by the agency or by another 
reference agency, was not documented.  The consideration of ethnic factors was not 
recorded.  The clinical/statistical efficacy and safety issues were documented in 
Section 7 and Section 8 respectively.  A clinical study summary providing a highlight 
of the study designs, treatments and the conclusions, identifying the key benefits or 
risks, was not included.  In line with the findings noted by Leong et al. (2014) the 
summary review had not been amended to make provision for a record indicating 
which benefits and risks were reviewed by the agency or the rationale as to which 
were subsequently included or excluded.  The summary review did not include a 
record of the relative importance assigned to each benefit and risk and did not make 
provision for valuing the options or commenting on the strengths and uncertainties for 
each benefit and risk identified.  The BR integrated assessment was available but did 
not necessarily describe how the BR balance was expected to evolve over time; for 




Table 7.2 Comparison of TGA, EMA, Health Canada and USFDA Public Assessment Reports (PARs) and South African 
Health Products Regulatory Authority’s (SAHPRA) appraisal of Benefit-Risk (BR) with the Universal Methodology for 
Benefit-Risk Assessment (UMBRA) Summary Template 
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Abbreviations: AusPAR, Australian Public Assessment Report; BR, Benefit-Risk; CRT, Clinical Report 
Template; EMA, European Medicines Agency; EPAR, European Public Assessment Report; SBD, 
Summary Basis of Decision; SAHPRA=South African Health Products Regulatory Authority; TGA, 
Therapeutic Goods Administration of Australia; UMBRA, Universal Methodology for Benefit-Risk 
Assessment; USFDA, United States Food and Drug Administration 
 
Part II – Review of the appraisal initiated by SAHPRA to document and 
communicate BR decisions 
The appraisal initiated by SAHPRA to document and communicate the BR decisions 
to sponsors was evaluated by comparing the SAHPRA guidelines and templates, used 
to support the assessment of NASs, against the section headings of the UMBRA BR 
Summary Template (Table 7.2).  A description of the treatment options evaluated 
(Section 1.1.2 of the BR Template) is included in Section 4.3.1 of the CRT.  The 
description is limited to comments on the stratification between treatment naïve and 
treatment experienced patients.  Information pertaining to the review of the API by a 
reference agency (Section 1.1.6 of the BR Template) is included in Section 3 of the 
CRT, however, the information requested is limited to an indication of the registration 
status of the medicine with regulators with which SAHPRA aligns itself.  An 
assessment of ethnic factors (Section 2.1.4 of the BR Template) is included in Section 
4.3.1 of the CRT, but is limited to comments on patient demographics stratified by 
ethnic groups and how this is related to or affected the intended use described in the 
professional insert.  The CRT: Section 4.4 makes provision for a summary of the BR 
analysis and assessors are required to provide information pertaining to the risk 
management plan or risk minimisation measures and implementation plan.  The 
clinical study summary is required to be presented as a narrative within the CRT and 
is limited in that the key benefits and risks, identified in each clinical study, are not 
documented.  The benefits and risks are not listed, no effects table is available and 
the relative importance, valuing and justification for inclusion/exclusion are not 
documented.  The discussion on the harms, the evolution of the BR balance, 
outstanding issues, the need for further studies, the conclusion on the BR balance and 
the recommended indication are not documented.  An evaluation of the risk 
minimisation plan is only applicable for applications for abridged review and an 




The SAHPRA Clinical Guideline confirmed that the sponsor is required to provide the 
reference agencies’ regulatory history to SAHPRA, however this requirement is limited 
to applications for abridged reviews only (SAHPRA, 2019a).  The internal SAHPRA 
Guideline for Clinical Reviewers provides instruction to SAHPRA clinical reviewers on 
the required format and content of a full clinical review report (SAHPRA, 2019d).  
Clinical reviewers are required to ensure that review reports are sufficiently detailed to 
allow for secondary assessment by other expert clinical reviewers.  During the review 
of clinical data, reviewers are required to comment on: 
 Whether the BR balance at maximum dose was acceptable; 
 The BR balance presented by the applicant; 
 Whether or not the suggested risk management plan and risk mitigation 
measures addressed the safety issues identified within the BR analysis of the 
safety information of the clinical studies; 
 Whether quality of life issues were addressed in the clinical studies; and 
 The safety issues reflected in the periodic safety update report (PSUR) or 
periodic benefit-risk evaluation report (PBRER) or changes in the BR balance, 
risk management plan and risk minimisation measures when a phase IV post-
marketing study was submitted for a medicine that was registered by an NRA 
with to which SAHPRA aligned itself. 
While these requirements are listed in the internal SAHPRA Guideline for Clinical 
Reviewers as elements to be reviewed, provision is not made to document the 
reviewer’s assessment of these elements within the CRT. 
 
PART III – Outcomes of focus group 
The outcome of the focus group that was held in Virginia in June 2019 resulted in 
recommendations for consideration in the use of PARs as potential knowledge 
management tools for stakeholders such as other NRAs, HTA agencies, industry, civil 
society and patients in understanding a reference agency’s decision-making.  The 
participants identified the need for reference agencies, producing PARs, to ensure that 
regulatory decisions were documented in a structured and systematic manner.  The 
participants endorsed and agreed that a harmonised PAR template would support 
improved transparency in regulatory decision-making by aiding the understanding of 
how the regulatory decision was made and by allowing for easy comparison of the 
regulatory decisions made by different reference agencies.  The participants also 
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endorsed initiatives supporting an effective approach to communicate regulatory 
decisions to NRAs that placed reliance on the decisions made by these reference 
agencies.  It was further recommended that reference agencies should consider 
publishing PARs or releasing information related to negative regulatory decisions (i.e. 
the rejection of an application for medicine registration) and regulatory decisions made 
regarding applications for extension of medicine indications.  The focus group 
concluded that the strengths of this work is that it had now compared the PARs 




National regulatory authorities (NRAs) publish PARs in an effort to enhance 
transparency and accountability in the regulatory decision-making process.  In the 
public healthcare sector, the publication of PARs contributes towards building public 
confidence in the regulator and demonstrating the regulator’s ability to ensure that 
medicines available on the market are safe, effective and of good quality.  Patients 
may refer to PARs to better understand the benefits and risks associated with the 
medicines that have been prescribed to them and practitioners may use them to guide 
their decisions in selecting one treatment option over another (Leong et al., 2014).  
The pharmaceutical industry and applicants submitting dossiers to NRAs for medicine 
registration use such reports to better understand the basis of the regulatory decision 
and the regulator’s rationale for supporting the final BR balance (Leong et al., 2014).  
Their availability allows stakeholders to better understand any differences in data 
interpretation and the regulatory opinions that exist amongst NRAs in different 
jurisdictions (Leong et al., 2014).  Other smaller NRAs, particularly in the emerging 
markets, place reliance on reference NRAs or recognise the decisions of reference 
NRAs when making local decisions on BR and the local summary basis of the decision 
to register a medicine in their jurisdiction (McAuslane et al., 2017). 
 
Public assessment reports (PARs) have been recognised by various stakeholders as 
good knowledge management tools in understanding regulatory decision-making.  
National regulatory authorities (NRAs) may have legislative duties to make certain 
information available in the public domain through the publication of PARs or may 
publish these to support the goals of enhanced public transparency (McAuslane et al., 
159 
 
2017).  The preparation and publication of PARs may inherently contribute to the 
effective and timely documenting of regulatory decisions by NRAs to support 
regulatory performance efforts to build quality into regulatory decision-making and 
maintain the consistency of decisions and scientific advice (Skerritt, 2019).  
Documenting the regulatory decision-making process, including both internal and 
external decisions and commitments, is crucial and may serve as a platform whereby 
past decisions may be used to inform future decisions in a consistent manner while 
contributing to evolved regulatory pathways that enlist accelerated review processes. 
 
Regulatory decision-making involves the assessment of the benefits and risks and 
culminates in the final regulatory judgement on the BR balance.  It is recognised that 
several structured approaches to performing the BR assessment exist (Levitan et al., 
2014; Leong et al., 2014) through the identification of the initial set of clinical endpoints 
for the medicine under review and may be illustrated through the use of visualisation 
tools such as the value tree (Levitan et al., 2014).  The importance of incorporating the 
perspectives of different stakeholders, notably that of the patient, has been 
emphasised as a result of the influence of patient reported outcomes on the relevance 
of each endpoint for the decision and the consequent reassessment of the clinical 
endpoints within the value tree (Levitan et al., 2014; Leong et al., 2014; McAuslane et 
al., 2017).  The data for such endpoints should be assessed and the relative 
importance should be assigned to each endpoint.  This should be indicative of the 
relative clinical importance of the endpoint in order to support and contextualise the 
final decision in terms of the BR balance.  Furthermore, the preparation of an effects 
table and the listing of key benefits and risks has been demonstrated to support 
structured discussion through focused gap analysis and supports the identification of 
critical issues (Levitan et al., 2014).  The decision-making process should also 
document the framing of the benefits and risks that should be assessed and the 
justification for their inclusion or exclusion should be recorded (Leong et al., 2014). 
 
In the study conducted by Leong et al. (2014) it was noted that there were 
discrepancies in the information provided through the PARs prepared by reference 
agencies when compared to the UMBRA BR Summary Template.  Since then these 
NRAs have taken steps to enhance their PARs, however, the results of this case study 
indicate that these may be further improved to enhance communication of the BR 
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decision to intereseted stakeholders.  As a result of this study it has been noted that 
the following key elements should be considered for inclusion in the PARs in order to 
effectively communicate the summary basis of the regulatory decisions and the key 
discussion points that lead to the BR decision to accept or reject the application for the 
registration of a medicine: 
 A clinical study summary of the key benefits and risks identified in the clinical 
studies; 
 An effects table, listing each of the benefits and risks identified and a record of 
the justification for the inclusion or exclusion of the benefits and risks assessed; 
 Documented valuing of the options and a record of the strengths and 
uncertainties identified for each benefit and risk; 
 Documented assigned weighting (relative importance) of each of the benefits 
and risks taking into consideration relevant stakeholder perspectives; 
 A record of the expected evolution of the BR balance over time; 
 A record of the regulatory history of the medicine; and 
 A record of the indication of the medicine in comparison with that approved by 
the reference agency. 
 
The results of the study conducted by Leong et al. (2014) and of this case study 
confirm that the PARs prepared by the NRAs were similar in purpose, format and 
context and supports the use of a universal template for documenting and 
communicating BR decisions (Leong et al., 2014).  The UMBRA framework made 
provision for the listing of benefits and risks, assigning relative importance and valuing 
the options.  It also provides a platform for structured discussion and a documented 
appraisal of the BR parameters through the use of a common language and 
presentation.  By using the UMBRA BR Summary Template, the interested 
stakeholder will be able to clearly understand the key messages presented by the NRA 
as the summary basis of the regulatory decision would be prepared in a format that 
was suitable for public consideration (Leong et al., 2014; McAuslane et al., 2017; 
Walker et al., 2014). 
 
The UMBRA BR Summary Template provides a mechanism for NRAs to document 
their BR assessment and build quality into their decision-making practices in a 
structured way as part of their efforts to ensure GRevPs (McAuslane et al., 2017; 
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WHO, 2015).  This approach could be used as an assessment template for NRAs 
wanting to enhance their BR assessment and could potentially serve as a guidance 
on BR assessment and a training tool for both regulatory reviewers and industry 
stakeholders responsible for the assessment of new medicines (McAuslane et al., 
2017).  Making use of the UMBRA BR Summary Template as an outline for a PAR 
would enhance consistency in regulatory decision-making and provide an effective 
tool for the review of past regulatory decisions.  The UMBRA BR Summary Template 
supports the clear articulation of each of the benefits and risks and contributes towards 
the ease of comparison of regulatory outcomes for medicines of the same class and 
the decisions by different NRAs for the same medicine (Leong et al., 2014; McAuslane 
et al., 2017). 
 
The SAHPRA has initiated development of an appraisal document to be used for 
considering BR balance during the review of NASs.  This study has identified a number 
of deficiencies in that appraisal.  The current guidelines and report templates used by 
SAHPRA do not contribute fully to the comprehensive, structured, consistent 
evaluation of each of the benefits and risks and do not provide documented 
justification for the final decision on the BR balance or the decision to accept or reject 
the registration of the medicine. 
 
National regulatory authorities (NRAs) worldwide, irrespective of size and expertise 
have or are considering the implementation of FRPs; entering into work sharing 
arrangements with other NRAs and placing reliance on or recognising the regulatory 
decisions of other NRAs (Azatyan, 2019; Liberti, 2017, unpublished thesis; Liberti et 
al., 2018; Ward, 2019).  A study by McAuslane et al. (2017) demonstrated that making 
use of a common approach to BR assessment and decision-making was pivotal in the 
implementation of work sharing models and in enabling the effective utilisation of 
information and expertise (McAuslane et al., 2017).  Considering the drive by SAHPRA 
to embrace reliance models and the involvement of SAHPRA in work-sharing 
initiatives such as Zazibona, it may be valuable for SAHPRA to consider using a 
universal template and common approach to BR decision-making. 
 
Key recommendations for SAHPRA for the implementation of an effective approach 
for communicating BR decisions include: 
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 Ensuring that the BR assessment is performed in a structured, systematic 
documented manner in alignment with GRevPs in order to build quality into 
decision-making; 
 Preparation and publication of a South African public assessment report 
(ZAPAR) in order to effectively communicate the BR decision to stakeholders 
and to ensure consistency, transparency and accountability in regulatory 
decision making; and 
 A consideration of the UMBRA BR Summary Template as guidance for BR 
assessment and as an outline for the ZAPAR which may further contribute 
towards: 
o Ease of comparison of regulatory decisions made by SAHPRA and other 
NRAs for the same medicine or for decisions made by SAHPRA for 
medicines in the same class; 
o The review of past regulatory decisions to ensure consistency and 
objectivity in post-market assessments and medicine life cycle 
management; and 
o The use of documented BR assessments as a reference to facilitate 
expedited review times; as a result of better understanding of past 
decisions that may support faster decision-making in line with the goals 
of accelerated review times for NASs. 
 
The implementation of an effective approach for communicating BR decisions by 
SAHPRA, based on these recommendations, should have a major impact on ensuring 
consistency in the BR assessment of NASs through the use of a structured template 
that supports transparent quality decision-making. Communicating the regulatory 
decisions of SAHPRA in the public domain will also enhance their goals of being a 
trusted, responsive, accountable regulator in which all stakeholders such as the 





 National regulatory authorities (NRAs) make a decision to register a medicine 
based on an assessment of the overall benefits and risks of a medicine 
 
 Reference agencies publish PARs in order to communicate the basis for the 
regulatory decision 
 
 Many NRAs in emerging economies place reliance on the PARs of reference 
agencies to inform their own regulatory decisions 
 
 The PARs from the TGA, EMA, Health Canada and US FDA were compared to 
the validated UMBRA BR Summary Template to determine whether the BR 
decision had been documented in a systematic and structured manner 
 
 A focus group was conducted to discuss the use of PARs as potential 
knowledge management tools for stakeholders 
 
 The approach initiated by SAHPRA to document and communicate the BR 
decisions was evaluated 
 
 The results of this case study indicated that the following key elements should 
be considered for inclusion in the PARs: a record of the regulatory history of the 
product, an effects table, the valuing of the options and a record of the strengths 
and uncertainties identified for each benefit and risk 
 
 The participants in the focus group agreed that a harmonised PAR template 
would support improved transparency in regulatory decision-making 
 
 The approach initiated by SAHPRA to communicate BR decisions could be 
improved and communicating the regulatory decisions of SAHPRA in the public 

















A Roadmap for the Implementation of a Proposed Model 





Disparities in the regulatory capacity of NRAs between low and high-income countries 
and the lack of collaboration and work sharing in medicines regulation between NRAs 
have been previously identified (Azatyan, 2019).  Approximately 30 % of NRAs do not 
have the necessary capacity in terms of expertise, QMS and human and financial 
resources to fulfil core regulatory functions (Azatyan, 2019).  The WHO has initiated 
the development of guidelines on GRPs to support NRAs’ efforts of increased 
efficiency of regulatory systems, higher quality regulation, improved decision-making 
and better public health outcomes (Azatyan, 2019; WHO, 2016). 
 
The review of quality, efficacy and safety of medicines is considered to be one of the 
key functions of NRAs (Liberti et al., 2018) and the timely review of applications for 
registration of NASs can significantly improve patients’ access to medicines and 
consequently impact public health (WHO, 2015).  The implementation of GRevPs 
supports improved regulatory performance and contributes to the advancement of 
convergence of regulatory requirements of NRAs (WHO, 2015).  This coupled with the 
alignment of the ICH technical guidelines would create opportunities for reliance based 
on the regulatory decisions of other NRAs and supports possibilities for work-sharing 
and joint regulatory initiatives (EFPIA, 2017). 
 
The WHO has defined reliance as “an act whereby a regulatory authority in one 
jurisdiction may take into account/give significant weight to work performed by another 
regulator or other trusted institution in reaching its own decision” (Ward, 2019). The 
NRAs in resource-limited settings may apply facilitated regulatory pathways (FRPs) to 
meet patients’ expectations of timely access to medicines and accelerate the 
regulatory review process by condensing the elements considered in the review of 
new medicines.  Such NRAs remain responsible for the regulatory decisions made 
through FRPs and in this way are able to maintain sovereignty in making regulatory 
decisions (Ward, 2019).  The application of FRPs should be developed on appropriate 
legal frameworks and within the bounds of commensurate resources. 
 
The WHO has developed draft guidance for good reliance practices (GRelPs).  These 
GRelPs are derived from GRevPs and fit within the remit of best practices for the 
regulation of medical products as prescribed by the WHO (Azatyan, 2019).  The 
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GRelPs may be implemented across all regulatory processes and applied to all 
medicines throughout the whole product life cycle, while contributing to an improved 
healthcare environment through the promotion of fully functional national regulatory 
systems (Azatyan, 2019).  Furthermore, NRAs may apply GRelPs in order to advance 
good governance, transparency and regulatory convergence that in turn supports 
good quality decisions by NRAs and presents opportunities for leveraging the 
regulatory effort of other NRAs, while promoting the conservation of limited regulatory 
resources (Azatyan, 2019). 
 
This study aimed to provide recommendations for the implementation of an abridged 
review process and a framework for GRelPs in South Africa.  This review is the first to 
be carried out in determining the current practices of NRAs in performing an abridged 
review of a NAS while considering the practicality of the implementation of GRelPs. 
 
Study objectives 
The main objectives of this study were to: 
 Identify the criteria and current practices within a number of NRAs for 
implementing an abridged review process; 
 Conduct focus groups on the practical implementation of an abridged review 
process for new medicines in the light of the WHO’s GRelPs; and 
 Develop recommendations in the light of the WHO roadmap for the 







Criteria and current practices for implementing an abridged review process 
A questionnaire (see Appendix 2), the abridged review process profile (ARPP), was 
developed by the CIRS (CIRS, 2017; McAuslane, 2019) to identify the criteria and 
current practices that were applied by NRAs for implementing an abridged review 
process.  A number of NRAs have already implemented processes to facilitate an 
abridged review.  The countries recruited into the study were Australia, Brazil, Canada, 
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the Gulf Health Council, Indonesia, Israel, Thailand, Saudi Arabia and Singapore and 
the ARPP was distributed to each for completion. 
 
The ARPP consists of five parts: 
Part I: NRA information 
This part of the questionnaire describes the mandate and scope of the NRA as well 
as its size and type, including information on the number of reviewers within the NRA 
and their areas of expertise. 
 
Part II: Criteria for product inclusion and reliance on reference agency 
The specific criteria applied to determine which products were eligible for inclusion in 
the abridged review process were recorded.  The criteria for the selection as well as 
how many reference agencies on which to rely were also described. 
 
Part III: Data requirements 
This part of the ARPP lists the data requirements for the abridged review.  The type of 
assessment report from the reference agency that would be used to facilitate the 
abridged review and the level of detail of information that would be required were 
described. 
 
Part IV: Clinical Factors 
The clinical factors considered in the BR evaluation were recorded. 
 
Part V: Enablers and Barriers 




Practical implementation of an abridged review process for new medicines and 
GRelPs 
Two focus group sessions were conducted with representatives from NRAs, industry, 
academia and patient groups from different jurisdictions.  The focus group sessions 
held in South Africa and Singapore consisted of 16 and 13 participants respectively, a 
moderator for facilitating the discussion and a rapporteur who was responsible for 
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consolidating the results and reporting on the outcomes of the discussion.  A brief 
guideline was prepared for the participants of each focus group.  The guideline 
described the discussion topic, provided background information and outlined the 
objectives of the focus group discussion.  A list of questions and issues for 
consideration were developed and made available to each of the focus groups to 
further stimulate the discussion. 
 
The first focus group was held at a workshop convened by the CIRS in South Africa in 
March 2018.  The topic of discussion was “The practical implementation of an abridged 
review process for new medicines: where should an agency focus and what are the 
practical steps needed to change process and mind-sets?”  The second focus group 
was held at a workshop convened by the CIRS in Singapore in March 2019.  The topic 
of discussion was “The draft Good Reliance Practice Guideline – how practical is it?  
A stakeholder’s review and discussion.” 
 
The SAHPRA initiated an abridged review process in July 2019 in an effort to reduce 
the evaluation time that was currently around six years.  In addition, it introduced a 
new clinical guideline together with a SCoRE document that was required to be 
submitted with all new applications for registration to SAHPRA.  These documents 
were examined, in the light of the abridged study described, in order to make 
recommendations regarding an appropriate framework for such reviews in South 




For the purpose of clarity, the results were presented in three parts: 
 Part – I:  Criteria and current practices for implementing an abridged review 
process 
 Part – II: Outcomes of focus groups  





Part - I: Criteria and current practices for implementing an abridged review 
process 
Six out of the nine NRAs recruited into the study completed the ARPP including: 
Australia; Brazil; Canada; the Gulf Health Council; Israel; and Thailand.  In addition, 
information from the public domain, such as documents published by SAHPRA for 
public comment and the CIRS workshops held in Singapore and South Africa, were 
included. 
 
National regulatory authority information 
This part of the questionnaire provided insight into the scope, regulatory mandate and 
size of the participating NRAs (Table 8.1). 
 
Criteria for product inclusion and reliance on reference agency 
The participating NRAs concurred that one of the key criterion for product inclusion 
was the submission of an application for an NAS that was identical to that approved 
by, or submitted to, the reference agency.  The application submitted had to be 
identical in terms of dosage form, strength, formulation and manufacture.  Three of the 
participating NRAs reported that the proposed indication for the medicine would need 
to be based on broadly similar population demographics, disease profiles and 
expectations regarding public health outcomes between the NRA and the reference 
agency.  Most of the participating NRAs confirmed that NASs were eligible for inclusion 
but one NRA stated that the abridged review would only be applicable to biological 
products, while biosimilars would be excluded.  One NRA specified that the NAS in 
question had to be approved as well as being available on the market in the reference 
agency country. 
 
The participating NRAs documented inclusion criteria relating to the time frame 
between the submission of the NAS application to the reference agency and the 
submission to the NRA.  Two of the NRAs did not impose restrictions in terms of this 
time frame while two NRAs indicated that applications that had been submitted to the 
reference agency, more than two years before, would not be considered.  One NRA 
indicated that a new guideline had been drafted that echoed this requirement.  One 
NRA stated that a timeframe of not more than one year would be applied for the 
quicker evaluation route.   
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Table 8.1. Scope, size and regulatory mandate of participating national regulatory authorities (NRAs) 
 
Type of agency 
Autonomous agency, independent from 
the Health Ministry administration 
2 
Operates within the administrative structure 
of the Health Ministry 
4 
Size of agency 
Total staff in the agency for medicinal products for 
human use 
731 1958 186 565 40 38 
Number of reviewers for applications for marketing 
authorisations/ product licences 
115 134 186 247 29 17 











and in vitro 
diagnostics 
4 
Blood and Blood 
Products 
1 

























4 Other 1 
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The participating NRAs indicated the following as key considerations in selecting a 
reference agency: utility and compliance to global standards and technical guidelines; 
the availability of reference agency assessment report, integrity in decision-making 
and transparent communication.   
 
Six of the participating NRAs selected the USFDA and the EMA as reference agencies 
on which reliance would be placed for the purposes of implementing an abridged 
review.  Four of the NRAs indicated that reliance was also placed on the MHRA of the 
United Kingdom and the Swiss agency for therapeutic products (Swissmedic) while 
other reference countries considered for reliance included Australia (3), Canada (3), 
Japan (3), New Zealand (1), Norway (1), Singapore (1), Iceland (1) and the WHO 
prequalification of medicines programme.  Six of the participating NRAs stated that 
reliance would be placed on only one reference agency in the application of the 
abridged review process and one NRA stated two reference agencies, namely the 
USFDA and the EMA.  In the event that reliance was placed on more than one 
reference agency and a difference in the regulatory decisions of the two reference 
agencies was noted, the NRA would apply the reference regulatory decision most 
appropriate to the requirements of the jurisdiction. 
 
Data requirements 
Assessment report - Five of the participating NRAs stated that un-redacted 
assessment reports would be required in order to facilitate the abridged review 
process.  Three of the six NRAs indicated that redacted reports could be used, 
provided that these reports were only lightly redacted and that all the necessary 
information was available.  Also required was a list of questions to sponsors and their 
responses as well as post-marketing commitments.  Three of the NRAs made use of 
PARs that were available in the public domain.  Five of the six NRAs indicated that 
while only parts of the technical document would be reviewed during an abridged 
review, it was a requirement that a full ICH/Association of Southeast Asian Nations 
(ASEAN) CTD had to be submitted for the abridged review.  All of the six participating 




Table 8.2. Depth of review of the common technical document (CTD) by the 
national regulatory authorities (NRA) in the abridged review 
 
Area of the CTD 
reviewed 
Only reviewed if 










Quality / (CMC) 
0 0 3 3* 
Human 
Pharmacology 3** 1 0 2** 
Clinical 
1 1 0 4*** 
Non-Clinical 
3** 1 0 2** 
 
Abbreviations: CTD=Common Technical Document; CMC=Chemistry, Manufacturing and Controls 
 
* Reflected the current situation, however in the new draft guidelines the NRA 
would only review the reference agency assessment report, but could review 
data in CTD if necessary. 
** One NRA indicated that currently the level of review was dependent on the 
product and availability of the reference agency assessment report.  The new 
draft guidelines stated that the NRA would only perform a review of the data in 
the CTD if an issue was identified by the reference agency. 
*** One NRA stated that the new draft guidelines described that only the pivotal 
studies would be reviewed  
 
Application - In support of the requirement for an abridged review, participating NRAs 
verified that applications submitted should be identical to that approved by the 
reference agency.  All of the participating NRAs required the dosage form and strength 
of the NAS to be identical with that of the NAS submitted to the reference agency.  All 
of the six participating NRAs required that the ingredients of the respective NAS be 
identical and four of the NRAs required that the indications, dose as well as the 




All of the NRAs accepted a closely similar product label to that submitted to the 
reference agency.  During the abridged review process, NRAs may choose to perform 
a detailed review of the reference agency assessment reports in lieu of performing an 
internal review of the CTD or review areas of the reference agency assessment report 
in the event that the reviewer identifies an issue.  Five of the participating NRAs 
indicated that a detailed review of the reference agency assessment report was 
performed during the abridged review.  The areas of the reference agency assessment 
report relating to quality/CMC, human pharmacology, clinical and non-clinical data 
were reviewed in detail by the NRAs as part of the abridged review. 
 
Clinical factors 
The majority of the participating NRAs indicated that clinical factors such as differences 
in medical practice, national disease patterns and unmet medical needs were taken 
into account during the clinical evaluation and the benefit-risk assessment that was 
conducted during the abridged review.  The majority of the NRAs indicated that ethnic 
factors were also, sometimes, considered during an abridged review.  
 
Enablers and barriers 
In Part V of the questionnaire the participating NRAs provided insight into the perceived 
enablers and barriers that impacted on the implementation of an abridged review 
(Table 8.3). 
 
Table 8.3. Enablers and barriers identified by national regulatory authorities 
(NRAs) in implementing an abridged review 
 
Enablers Barriers 
Availability of the un-redacted reference 
agency assessment reports 
Not receiving the un-redacted reference 
agency assessment reports from the 
applicant 
Availability of the list of questions from 
the reference agency to the applicant and 
post-approval commitments 
Resistance from applicants to apply for the 
abridged review process as requirements 
for supporting documents could not be met  
Approval of a NAS within two years from 
the reference agency 
Inadequate transparency with regard to 
reference agency decision making process  
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Applicants who are willing to answer 
questions throughout the course of the 
review rather than at the end of the 
review 
Benefit-risk assessment is not sufficiently 
detailed and presents challenges in 
application to the local NRA population 
Increased communication and interaction 
with other agencies 
Differences or diversity in regulatory 
requirements between the NRA and the 
reference agency 
Saves resources as the assessment 
report of the reference agency may be 
used for the review instead of contracting 
an external expert to conduct the review 
The reliance on work conducted by another 
agency requires a culture shift; unease that 
reliance will result in a loss of local 
expertise 
 
Abbreviations: NAS=New Active Substances; NRA=National Regulatory Authority 
 
Part - II:  Outcomes of focus group discussions 
The outcomes of the first focus group session that was held in South Africa in March 
2018 resulted in recommendations for consideration in the practical implementation of 
an abridged review process for NASs.  The participants concluded that the elements 
constituting an abridged review had to be identified.  It was recognised that the 
requirements for applications submitted for abridged review to the NRAs participating 
in the discussion, were similar.  The participants agreed that while information such as 
reference agency assessment reports were available in the public domain, these were 
often heavily redacted and ill equipped to support regulatory decisions made by NRAs 
during the abridged review process.  The participants endorsed the recommendation 
to perform a study to identify what NRAs evaluate when performing an abridged review. 
 
The outcomes of the second focus group session that was held in Singapore in March 
2019 resulted in recommendations for consideration in the review of the practicality of 
the draft WHO GRelPs guideline.  The participants agreed that reliance practices were 
largely based on the use of information or regulatory decisions of a trusted 
source/reference agency.  Through the discussion it was acknowledged that reliance 
practices were used in diverse applications and participants commented that shared 
inspection reports and CMC reports could be used to confirm the quality of an NAS 
without duplicating regulatory efforts.  Participants endorsed the application of a 
phased-approach in the implementation of GRelPs and commented positively 
regarding the requirement to provide a summary of the BR assessment and findings 
and/or recommendations prepared by the reference agency.  The participants 
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endorsed the outcomes of the study that identified which NRAs have implemented 
reliance pathways and what the requirements were for such pathways.  
 
Part III:  Evaluation of the abridged review process initiated in South Africa 
The SAHPRA initiated an abridged review process in 2019 in an effort to limit the 
evaluation time of medicines that had been registered by reference agencies 
recognised by SAHPRA.  All NASs including biological medicines, generic medicines, 
type II variations and MLEs would be eligible for an abridged review (SAHPRA, 2019a).  
Similar to the requirements of the participating NRAs in this study, SAHPRA required 
the submission of an application that was materially the same as that submitted to a 
reference agency recognised by SAHPRA.  The EMA was considered as the default 
reference agency by SAHPRA for reliance, however the USFDA, PMDA, Health 
Canada, Swissmedic, the TGA and MHRA were also listed as recognised agencies.  
Sponsors were required to submit the full CTD and were also requested to submit un-
redacted assessment reports from reference agencies.  Where these were not 
available, applicants were requested to submit a request to the reference agency to 
make the relevant un-redacted assessment reports available to SAHPRA.  SAHPRA 
also requested the submission of any correspondence between the applicant and the 
reference agency relating to safety and efficacy or queries regarding the risk 
management plan or BR decisions (SAHPRA, 2019a).  The clinical guideline published 
by SAHPRA in July 2019 described the requirements for the clinical evaluation of 
medicines using the abridged review (SAHPRA, 2019a).  The guideline indicated that 
only the overviews of the pre-clinical and clinical data described in CTD modules 2.4 
and 2.5 would be reviewed, however, reviewers were at liberty to perform a full review 
of CTD modules 4 and 5 if it was deemed necessary (SAHPRA, 2019a).   
 
The new SAHPRA Clinical Guideline indicated that the summary basis for registration 
(SBR) document, which was previously required by SAHPRA to support clinical 
evaluation of a medicine, was no longer required and would be replaced by the clinical 
overviews and summaries and the SCoRE document.  The SCoRE document was 
required to be submitted with all new applications for registration (SAHPRA, 2019b) 
and was required to be submitted as part of CTD module 3.2.R.8 (Other) in addition to 
the Quality Overall Summary.  Applicants were also required to submit the latest 
PSUR/PBRER and reference package insert approved by the reference agency.  The 
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SAHPRA also indicated that two additional reliance pathways had been developed for 
medicines that had been pre-qualified by the WHO and for medicines that had been 




Practical implementation of an abridged review process 
Strategies initiated by NRAs to leverage international collaboration in the form of 
reliance and referencing to enhance regulatory performance have been endorsed by 
the WHO (Azatyan, 2019).  The participants in the focus groups identified that there is 
a definite need for NRAs to use FRPs such as an abridged review to improve regulatory 
efficiencies.  The abridged review is based on the premise that the review time would 
be decreased as reliance on the assessment report of a reference agency and placing 
weight on the regulatory decision of a trusted NRA eliminated the need to do a full 
assessment of the quality, safety and efficacy data provided in the technical dossier.  
Typically, NRAs rely on the decision of one reference agency in support of an abridged 
review.  Applications submitted to NRAs for an abridged review should be identical to 
that submitted to the reference agency.  An abridged review of a NAS relies on the 
scientific, evidence-based assessment of the NAS by a reference agency.  
Subsequently, the NRA may review the reference agency’s assessment report and 
conduct an abridged review of certain parts of the technical dossier in support of local 
requirements.  Enablers supporting the implementation of an abridged review include 
the availability of un-redacted reference agency assessment reports, increased 
communication and interaction between NRAs and reference agencies and continued 
efforts to ensure that regulatory decisions are based on sound regulatory processes 
and standards. 
 
Practical implementation of good reliance practices 
“The recommendations from several WHO ICDRA meetings highlighted that the 
desired public health goals can only be achieved through collective efforts of regulators 
and other stakeholders” (Azatyan, 2019, p. 8).  The WHO conducted a survey on 
reliance practices amongst members of the International Pharmaceutical Regulators 
Programme (IPRP) in October 2018 (Cooke, 2019).  Responses to the survey were 
received from 8 member countries including Australia, Brazil, Canada, Japan, 
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Singapore, Switzerland, Taiwan and United States of America.  Additional responses 
were also received from Cuba, Europe, Mexico, New Zealand, Russia and Turkey. 
 
This survey set out to further understand the experience of the NRAs in implementing 
a reliance framework and what the perceived benefits, challenges and opportunities 
were (Cooke, 2019).  The results of the survey echoed the findings of the current study 
in that the rationale for choice of reference agencies was similar.  Perceived benefits 
of reliance included enhanced regulatory performance and shortened review times 
based on greater collaboration, the effective application of resources and opportunities 
for formalising reliance and work-sharing arrangements (Cooke, 2019). 
 
The responses from the survey unveiled similar concerns as those identified through 
the questionnaire used in this study.  Respondents identified the differences in 
regulatory systems and country-specific requirements as an area for improvement.  
National regulatory authorities (NRAs) relying on reference agencies were concerned 
about the lack of access to information from reference agencies.  Emphasis was placed 
on challenges experienced with highly redacted assessment reports and the lack of 
information available to document the rationale for the reference agency’s regulatory 
decisions.  The formal implementation of common review templates and assessor’s 
guides was recommended in order to optimise reliance frameworks. 
 
The respondents noted that the implementation of a reliance framework supported a 
number of opportunities in the post-approval phase.  These included proactive sharing 
of post-market safety data, work-sharing in terms of pharmacovigilance activities and 
enhanced efficiencies in monitoring activities and the standardisation of 
pharmacovigilance practices.  A reliance framework would support routine work-
sharing platforms and harmonisation in terms of templates for inspection and 
assessment and opportunities for emerging markets to gain experience in advanced 
regulatory practices (Cooke, 2019). 
 
The National Academies of Sciences, Engineering, and Medicine assembled an expert 
committee to examine the challenges and opportunities facing NRAs, particularly in 
the context of mutual recognition agreements and other forms of regulatory reliance 
(National Academies of Sciences, Engineering, and Medicine, 2019).  The findings of 
 
178 
the committee resonated with the outcomes of this study.  National regulatory 
authorities (NRAs) are faced with challenges in applying finite resources to effect 
regulatory mandates.  As such, NRAs have to explore opportunities to expand their 
capabilities and engage in collaborative initiatives. Information sharing and 
transparency amongst NRAs should be increased.  Formal and informal reliance 
frameworks should be considered and developed on a co-created results-framework 
that highlights measuring, monitoring and performance metrics in order to quantify the 
impact of these strategies (National Academies of Sciences, Engineering, and 
Medicine, 2019). 
 
The GRelPs have been drafted by the WHO to support the systematic and consistent 
implementation of a reliance framework within regulatory systems (Azatyan, 2019).  
Through the introduction of such GRelPs, NRAs are able to redirect limited resources 
to core regulatory functions that can only be performed by the NRA with an aim of 
accelerating patients’ access to medicines.  The implementation of GRelPs provides 
an opportunity for NRAs with limited expertise to rely on the technical assessment of 
reference agencies for complex medical products and consequently provide a solution 
for timely registration and access to advanced medicines by the local population 
(Azatyan, 2019).  National regulatory authorities (NRAs) that implement a reliance 
framework remain responsible for their regulatory decisions and the outcomes thereof 
(Ward, 2019; WHO, 2016). 
 
Current regulatory capacity, the needs of an efficient regulatory system and 
consideration of how the implementation of reliance models may contribute to 
enhancing the performance of an NRA should form the basis on which NRAs decide 
to adopt reliance models and implement GRelPs (PANDRH, 2018).  “Understanding 
the key principles through which reliance models operate (Figure 8.1) should guide 
and inform decision-making by NRAs contemplating the adoption and implementation 





Figure 8.1. Key operational principles of reliance models 
 
 
Adopted from PANDRH, 2018 
 
National regulatory authorities (NRAs) can tailor the application of these principles to 
meet the individual needs of national health and regulatory systems (PANDRH, 2018).  
The foundation for the implementation of a reliance model is dependent on the 
knowledge of or information gained from a trusted source that has based regulatory 
reviews and decision-making on sound scientific evidence, global standards and 
robust regulatory frameworks.  In this way, trust between NRAs becomes a critical 
component of reliance as confidence is built through trustworthy networks (PANDRH, 
2018).  Further initiatives to improve trust amongst NRAs have contributed to the 
reinforcement of reliance structures (PANDRH, 2018). These include the 
benchmarking of national regulatory systems of WHO Member States, using the 
standardised WHO GBT (WHO, 2020) and the evaluation of NRA inspection capacities 
by the PIC/S (PIC/S, 2019). 
 
The principles of GRelPs are illustrated in Figure 8.2.  The implementation of GRelPs 
should not undermine the authority of the NRA as underwritten by the relevant legal 
framework that supports the regulatory mandate (Bee, 2019).  Convergence of 
regulatory requirements among NRAs underpins the success of GRelPs which in turn 
SOVEREIGNTY
• Reliance should be a sovereign decision. 
• National authorities should decide if they want to use reliance, on whom 
they are going to rely and how.
TRANSPARENCY
• Reliance processes should be transparent regarding standards and 
processes. 
• In addition, the basis/rationale for relying on a specific entity should be 
disclosed and understood by all parties.
CONSISTENCY
• Reliance on a specific process/evaluation/decision should be established 
for specific and well-defined category of products/ practices and should 
as well be predictable. 
• Thus, it is expected that reliance shall be applied consistently for all 
products/practices in the same predetermined category.
LEGAL BASIS
• Reliance should be coherent with national legal frameworks and 
supported by clear mandates/regulations that aim at the efficient 
implementation. 
• Adoption of these legal frameworks should not detract from the 
efficiencies gained by reliance.
COMPETENCY
• Reliance requires that national authorities build the necessary 
competencies for critical decision making for proper implementation. 
• Authorities being relied on should have and maintain competencies.
• The competencies should be bench-marked by transparent processes 
that develop trust on the capacities of these reference authorities.
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facilitates enhanced decision-making (Bee, 2019).  The reliance models used for 
regulatory decision-making should be applied consistently and the decision-making 
process must remain evidence-based and in compliance with GRevPs (Bee, 2019).  
Reliance models used to support regulatory decision-making should be extended 
across the product life cycle to support the post-market robustness of the decision with 
respect to the local population (Bee, 2019). 
 
Figure 8.2. The principles of good reliance practices (GRelPs) 
 
 
Adopted from Bee, 2019 
 
Regulatory efficiency could be increased through the support of GRelPs which in turn 
contributes towards regulatory system strengthening (Bee, 2019).  However, NRAs 
should continue to develop their regulatory capabilities and develop reliance models 
based on a set of key principles (Table 8.4) (Azatyan, 2019).  Reliance models that 
may be used to facilitate the review of medicines include mutual recognition, 
referencing decisions using un-redacted assessment reports of reference agencies 
(e.g. use of assessment reports from reference agencies or WHO prequalification), 
work sharing (e.g. EU decentralised procedure and the Zazibona process in the SADC 
region; and joint assessment (e.g. WHO East African Community (EAC) joint 
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Table 8.4. Key principles in the development of reliance models 
 
Outcome orientation Efforts should lead to measurable public health gains. 
Operational flexibility One approach may not be appropriate for all situations. 
Pragmatism 
Employing a step wise approach that builds on 
successes and lessons learned. 
Utilising best 
international practices 
Importance of common requirements and approaches 
based on international best practices and standards, 
such as the Common Technical Document (CTD), in 
achieving optimal outcomes. 
Accountability 
The work needs to be planned and staffed 
appropriately and the outputs need to be implemented 
consistently, predictably, and transparently. 
Adopted from Azatyan, 2019 
 
The GRelPs must be integrated into the frameworks developed by NRAs to support 
the implementation of reliance models and a roadmap for the implementation of GRelP 
has been drafted (Figure 8.3) (Bee, 2019).  It is, therefore, important that reliance 
models are built on a legal and regulatory foundation that supports international 
cooperation and exchange of information with other NRAs (Bee, 2019).   
 
Figure 8.3 Roadmap for the implementation of good reliance practices (GRelPs) 
 
Abbreviations: GRelP=Good Reliance Practices; NRA=National Regulatory Authority 
Adopted from Bee, 2019 
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This might initially rely on NRAs leveraging existing international collaborative 
platforms to initiate and expedite the implementation of reliance models (Bee, 2019).  
National regulatory authorities (NRAs) should ensure that both internal and external 
stakeholders understand and accept the proposed reliance model (Bee, 2019).  Thus, 
providing clear guidance to sponsors and defining the relevant requirements for 
eligibility criteria, submission requirements, time lines and registration pathways is 
recommended to facilitate the process and ensure the intended outcomes (EFPIA, 
2017).  Furthermore, NRAs should ensure that the implementation of reliance models 
is underpinned by capacity building strategies and rolled out effectively to support the 
success of such initiative while continuing to enhance regulatory competencies to 
complement reliance models (Bee, 2019).  Reliance models may be used by NRAs to 
support the initial approval of a NAS as well as the management of post-approval 
variations.  While NRAs may rely on the decisions made by reference agencies, they 
should remain cognisant of the possibility that certain NASs may be developed in a 
manner that allowed for expedited approval, based on an abbreviated data-set, 
supported by well-defined post-approval commitments (EFPIA, 2017).  Transparent 
decision-making processes must be in place to ensure that the basis for the approval 
or rejection of a NAS is adequately documented. 
 
While NRAs strive to improve regulatory performance and work towards achieving 
accelerated approval times for NASs, many NRAs continue to face challenges due to 
resource constraints.  Increasing workloads, advancing technologies and limited 
expertise create the need for NRAs to leverage regulatory convergence initiatives, 
collaborative registration procedures and functional continental networks in order to 
fulfil their regulatory mandates (Azatyan, 2019). 
 
The SAHPRA has faced similar challenges and has taken steps towards embracing 
reliance models and employing an abridged review process for NASs.  Key 
recommendations to ensure the success of the proposed reliance model for an 
abridged review and the implementation of GRelPs by SAHPRA should include: 
 Formalising the implementation of GRelPs; 
 Continuing to place reliance on trusted reference agencies that have met the 
requirements of standardised regulatory benchmarking tools; 
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 The verification that the NAS applications submitted to SAHPRA are materially 
the same as that submitted to a reference agency recognised by SAHPRA; 
 Limiting the scope of the abridged review to a: 
o Detailed review of clinical data including consideration of clinical factors 
such as differences in medical practice, national disease patterns, unmet 
medical needs and ethnic factors; 
o Review of the quality data and non-clinical data only in the event of query; 
and 
o Selective review of human pharmacology data. 
 
The implementation of abridged reviews by SAHPRA based on these 
recommendations of GRelPs should have a major impact on regulatory review times 
which over the last four years (2015-2018) were in excess of five years.  Thus, this 
approach, if continued and endorsed by SAHPRA, will ensure the timely patients’ 






 This study aimed to identify the criteria and current practices for implementing 
an abridged review process as well as understanding the challenges, enablers 
and barriers in utilising reliance models and to offer recommendations for the 
implementation of an abridged review process in South Africa based on GRelPs 
 
 A questionnaire was completed by six NRAs to determine the criteria and 
current practices for implementing an abridged review process 
 
 Two focus group discussions were conducted to discuss the practical 
implementation of an abridged review process for new medicines based on 
GRelPs 
 
 The participating NRAs indicated that reliance would be placed on at least one 
reference agency 
 
 Applications submitted to NRAs for an abridged review had to be identical to 
that submitted to the reference agency 
 
 Un-redacted assessment reports from the reference agency would be required 
in order to facilitate the abridged review process 
 
 The results of the focus group discussions indicated that the elements 
constituting an abridged review had been identified and that these should be 
considered in line with the implementation of GRelPs 
 
 National regulatory authorities (NRAs) strive to improve regulatory performance 
and work towards achieving accelerated approval times for new active 
substances 
 
 Recommendations for the implementation of an abridged review process and a 
framework for GRelPs have been made with a view to optimising regulatory 





















The effective regulation of medicines, the strengthening of regulatory systems and the 
improvement of regulatory performance have become the focus for national regulatory 
authorities (NRAs) and governments worldwide.  National regulatory authorities 
(NRAs) are responsible for protecting and promoting public health, implementing 
rigorous regulatory standards and maintaining an assured supply of medicines which 
are safe, effective and of good quality (Rago & Santoso, 2008; Ndomondo-Sigonda et 
al., 2017; WHO, 2018a).  Global trends of mounting pressure on NRAs of all sizes and 
capacity have been noted due to the larger volumes of applications received, the 
complexity of the submissions and the increased categories of medicines (WHO, 
2015).  For many NRAs, particularly in emerging markets with resource-limited 
settings, achieving these types of results has not been a reality (WHO, 2014a).  Efforts 
to address the challenges faced by NRAs in low and middle-income countries have 
focused on strategies for identifying and performing core regulatory functions that have 
to be undertaken directly by NRAs to meet country or regional needs (Ward, 2014; 
WHO, 2014a).  National regulatory authorities (NRAs) have also been encouraged by 
the World Health Organization (WHO) to consider regulatory convergence and to 
collaborate with and recognise the work done by other NRAs in order to avoid the 
duplication of regulatory efforts and to ease the regulatory burden (Ward, 2014; WHO, 
2014a). 
 
The Medicines Control Council (MCC), the past NRA in South Africa, had historically 
faced similar difficulties.  The increasing volume of applications received by the MCC, 
coupled with resource constraints, resulted in the development of a significant backlog 
in medicine registration and unprecedented extension of their respective review 
timelines.  The approval timelines for new active substances (NASs) in South Africa 
were much longer than those achieved by NRAs in developed and comparable 
emerging markets.  The MCC regulatory review process was deemed to be inherently 
slow as a result of insufficient human and financial resources, outdated manual 
document management systems and legislative constraints that did not support the 
use of facilitated regulatory pathways (FRPs).  Undoubtedly, the delayed approval 




The need for a more effective regulatory framework in South Africa was prioritised and 
in June 2017 the Medicine and Related Substances Act, 1965 (Act 101 of 1965) was 
amended to allow for the transition of the MCC to the South African Health Products 
Regulatory Authority (SAHPRA).  With the legislative support for regulatory re-form, 
the South African NRA was provided with an opportunity to study the past practices of 
the MCC with a view to enhance the regulatory performance of SAHPRA and make 
substantive contributions within the advancing regulatory landscape. 
 
Research in this field has demonstrated that NRAs, of varying sizes and capacity, have 
been able to improve their regulatory performance and thus the objectives of this 
research were to identify the inefficiencies in the current regulatory framework of the 
MCC and the opportunities for improvement in the regulatory performance of the newly 
established SAHPRA.  The key recommendations stemming from this research have 
been prepared as a proposed improved model for consideration and implementation 
by SAHPRA to support the goals of shortened approval timelines, enhanced regulatory 
performance and accelerated patients’ access to new medicines. 
 
Six studies were conducted as part of this programme of research; these included a 
review of the regulatory environment and legislative developments in medicine 
regulation in South Africa (Study 1: Chapter 3), an evaluation of the MCC review 
process (Study 2: Chapter 4), an assessment of the resultant MCC performance 
metrics (Study 3: Chapter 5), a comparison of the MCC against other similar NRAs 
(Study 4: Chapter 6), a study on the use of a universal benefit-risk (BR) assessment 
template (Study 5: Chapter 7) and an appraisal of reliance models and an abridged 
review process to support a transparent, predictable and timely review of NASs (Study 
6: Chapter 8).  The data collected from each study were analysed and reviewed 
individually to facilitate a thorough evaluation of the regulatory environment in South 




RESEARCH OUTCOMES AND CONTRIBUTIONS 
Despite the interest of stakeholders to register NASs in South Africa and the increasing 
backlog in medicine registration, no studies have previously been undertaken to 
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evaluate the performance of the MCC in terms of the regulatory review process and 
the overall median approval timelines for the registration of NASs.  This programme of 
research has for the first time evaluated the regulatory review process of the MCC and 
has provided commentary and recommendations as the MCC transitioned to the newly 
established SAHPRA.  This research commenced with an in-depth review of the 
regulatory environment in South Africa in terms of the enabling legislation that resulted 
in the establishment of SAHPRA, the new NRA in South Africa and provided an 
assessment of the differences in the operational models of the MCC and the newly 
established SAHPRA as documented in Chapter 3.  The results of this study confirmed 
the challenges historically faced by the MCC and demonstrated the need for the 
formalisation of the SAHPRA quality management system, adoption of a risk-based 
approach to the evaluation of medicines and the implementation of routine and 
accurate metrics collection.  Key recommendations for a new regulatory environment 
were developed and were considered to be fundamental elements that may contribute 
to the success of SAHPRA. 
 
The evaluation of the status of the MCC, prior to the establishment of SAHPRA was 
the focus of Chapter 4, in terms of its organisational structure and the regulatory review 
process for NASs and included an assessment of the level of implementation of good 
regulatory practices (GRPs) and good review practices (GRevPs) by the MCC.  The 
results of this study documented the regulatory approval time for NASs in South Africa 
and the associated milestones within the review process for the first time.  This study 
provided an overview of the median approval timelines achieved by the MCC during 
2015-2017 and highlighted for the first time that the MCC in its current capacity was 
not able to achieve the target timelines for the regulatory review of NASs.  
Recommendations were made to support the implementation of a risk-based 
regulatory review process and the formalisation of reliance on the regulatory efforts of 
reference NRAs.  
 
A detailed account and evaluation of the NASs, including new chemical entities 
(NCEs), biologicals and major line extensions (MLEs), registered by the MCC during 
the period 2015-2017 as well as the NASs registered by SAHPRA during 2018 was 
provided in Chapter 5.  This was the first review of the key milestones and metrics in 
the regulatory review process applied by the MCC and those embedded within the 
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transitional process applied by SAHPRA during 2018.  The available data was 
collected and analysed in order to determine the overall median approval timelines for 
NASs.  The challenges and opportunities for expediting the overall review timelines 
were reviewed and recommendations for an enhanced regulatory performance in 
South Africa were made. 
 
The medicine review process applied by the MCC and its comparison with the medicine 
review processes applied by the NRAs in Australia, Canada, Singapore and 
Switzerland was described in Chapter 6.  The results of this study indicated that the 
timelines for the MCC medicine review process were considerably longer than those 
achieved by the comparative agencies.  Recommendations made as a result of this 
study echoed the need for the formalised implementation of GRevP, routine metrics 
collection and a template for BR assessment to support consistent, predictable, 
transparent and timely regulatory review. 
 
The assessment of a benefit-risk (BR) framework was further explored in Chapter 7.  
The public assessment reports (PARs) from the Australian Therapeutic Goods 
Administration (TGA), European Medicines Agency (EMA), Health Canada and United 
States Food and Drug Administration (USFDA) were compared to the validated 
Universal Methodology for Benefit-Risk Assessment (UMBRA) BR Summary Template 
to determine whether the BR decision had been documented in a systematic and 
structured manner.  A focus group was conducted to discuss the use of PARs as 
potential knowledge management tools for stakeholders in understanding the 
decisions made by reference agencies. The participants in the focus group agreed that 
a harmonised PAR template would support improved transparency in regulatory 
decision-making.  The approach initiated by SAHPRA to document and communicate 
the BR decisions was evaluated.  Key recommendations for SAHPRA for the 
implementation of an effective approach for communicating BR decisions were 
developed.  These included consideration of the UMBRA BR Summary Template as 
guidance for BR assessment as well as this approach as an outline for the preparation 
of a South African public assessment report (ZAPAR).  The publication of the ZAPAR 
would promote the transparency of SAHPRA’s decision-making.  It was also 
recommended that documented BR assessments, such as the PARs, may be relied 
on by other agencies in order to facilitate expedited review times.  The criteria and 
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current practices for implementing an abridged review process as well as 
understanding the challenges, enablers and barriers in utilising reliance models were 
identified and documented in Chapter 8.  Recommendations for the implementation of 
an abridged review process in South Africa based on good reliance practices (GRelPs) 
were developed through this study. 
 
This programme of research has culminated in the development of a set of 
recommendations for a proposed improved regulatory review model for SAHPRA. 
 
 
RECOMMENDATIONS FOR AN IMPROVED REGULATORY REVIEW MODEL FOR 
SAHPRA 
These recommendations have been based on an analysis of the results of the six 
studies conducted and are underpinned by GRPs, GRevPs and GRelPs.  This 
research has contributed towards the identification of the challenges and opportunities 
for regulatory reform and improved regulatory responsiveness and performance by 
SAHPRA.  A number of key recommendations have been developed throughout this 
programme of research and these recommendations have been identified as core 
elements required to support the proposed improved regulatory review model for 
SAHPRA.  The implementation of these recommendations is considered crucial in 
meeting the requirements of several of the sub-indicators within the World Health 
Organization (WHO) Global Benchmarking Tool (GBT) that contribute towards the 
regulatory performance of a sustainable and efficient regulatory system.  Furthermore; 
these recommendations are considered to be fundamental for SAHPRA in achieving a 
maturity level rating of either 3 or 4 and becoming a WHO-listed NRA.  These 
recommendations have been illustrated in Figure 9.1 and include the following; quality 
measures, measuring and monitoring, risk-based approach to the evaluation of 




Figure 9.1 Recommendations for the proposed improved regulatory review 
model for the South African Health Product Regulatory Authority (SAHPRA) 
 
Images adopted from: https://image.flaticon.com/sprites/new_packs/957317-corporate-business.png 
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Abbreviations: BR=Benefit-Risk; EDMS=Electronic Document Management System; FRP=Facilitated 
Regulatory Pathway; GBT= Global Benchmarking Tool; GRP=Good Regulatory Practice; GRevP=Good 
Review Practice; GRelP; Good Reliance Practice; MA=Marketing Authorisation; RS=Regulatory 
System; SAHPRA=South African Health Products Regulatory Authority; SOPs=Standard Operating 
Procedures; QMS=Quality Management System; UMBRA=Universal Methodologies for Benefit-Risk 
Assessment WHO=World Health Organization; ZAPAR=South African Public Assessment Report 
 
Quality measures 
A dedicated quality management unit should be established and a QMS be formally 
implemented and the quality policy, SOPs, guidelines and assessment templates 
should be codified and institutionalised into practice.  These recommendations are 
endorsed by the WHO GBT sub-indicator RS05.01 that states that top management is 
required to demonstrate commitment and leadership to develop and implement a 
QMS; sub-indicator RS05.02 that requires the quality policy, objectives, scope and 
action plans for the establishment of the QMS to be in place and to be communicated 
to all levels; and sub-indicator RS05.04 that requires the assignment of enough 
competent staff to develop, implement and maintain the QMS (WHO, 2018b).  It is 
recommended that SAHPRA consider following the WHO Guideline on the 
implementation of QMSs for NRAs (WHO, 2019) that was developed based on the 
principles of the ISO Standard 9001:2015 for QMSs.  GRPs, GRevPs and GRelPs 
should also be formally implemented and maintained in order to build quality into the 
review process.  This recommendation is supported by WHO GBT sub-indicator 
RS03.05 that requires the NRA to promote GRPs and to assure that the principles of 
GRP are applied to the regulation of medicines (WHO, 2018b) and the sub-indicator 
MA04.10 that requires the formal implementation of GRevPs (WHO, 2018c).   
The WHO GBT sub-indicator MA01.09 specifies that guidelines on the quality, 
nonclinical/safety and clinical aspects should be established and implemented and 
should specify the requirements for registration/granting market authorisation (WHO, 
2018c).  The WHO GBT sub-indicator MA04.01 states that documented 
procedures/tools should be implemented for the assessment of different parts of the 
application and for the assessment of specific requirements of specific classes of 
medical products (quality, safety & efficacy) (WHO, 2018c).  Both of these sub-
indicators endorse the recommendation to formalise the use of the UMBRA BR 
Summary Template as the guide for BR assessment and the outline for the preparation 
of the ZAPAR.  It is recommended that quality decision-making practices should be 
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employed to support transparent, consistent, predictable and defensible regulatory 
decisions as described in the requirements for sub-indicator MA04.10.  The objective 
of sub-indicator MA04.10 is to ensure that regulatory decisions are adequately 
documented and to ensure consistency throughout the review process in terms of 
requirements and criteria for registration (WHO, 2018c). 
 
Measuring and monitoring 
SAHPRA should identify the milestones in the regulatory review process and formalise 
target timelines for individual milestones as well as the entire review process.  The 
timelines for each of these milestones should be recorded and should be routinely and 
accurately measured.  The data collected should be monitored regularly (Quarterly) in 
order to ensure that target timelines for the review process are continuously met and 
improved.  The introduction of an electronic document management system (EDMS) 
should be prioritised to ensure the accurate tracking of applications through the 
milestones of the review process and to provide for the automated and assured 
collection of the timelines achieved throughout the review process.  These 
recommendations are endorsed by the sub-indicator MA04.06 that requires the 
establishment of timelines for the assessment of applications and an internal tracking 
system to follow the targeted timeframes (WHO, 2018c).  The target timelines for the 
review process should be embedded within the performance contracts and should be 
reflected as key performance indicators for personnel responsible for ensuring the 
timely review of medicines.  This recommendation is supported by the sub-indicator 
MA06 that requires the use of a mechanism to monitor regulatory performance and 
output (WHO, 2018c); sub-indicator MA06.02 that requires the establishment and 
implementation of performance indicators for registration and/or market authorisation 
activities (WHO, 2018c); and the sub-indicator RS10.01 that requires the monitoring, 
supervision and review of the performance of the NRA and affiliated institutions using 
key performance indicators (WHO, 2018b). 
 
Risk-based approach to the evaluation of medicines 
SAHPRA should apply a risk-based approach to the regulatory review of medicines 
whereby the allocation of resources is commensurate with product risk.  Facilitated 
regulatory pathways (FRPs) should be formalised in an effort to conserve limited 
resources, to avoid duplication of regulatory effort and shorten timelines for medicine 
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registration.  SAHPRA should consider alternatives to the full review process, such as 
the abridged and verification review and should rely on or recognise the PARs of 
reference agencies as well as the assessment reports of the regulatory decisions of 
reference agencies.  Initiatives for joint reviews or work-sharing should be further 
developed to support continued enhancement of regional such as Zazibona, 
continental and international collaborations.  These recommendations are endorsed 
by sub-indicator RS03.04 that supports the formalisation of reliance on the decision of 
other NRAs through documented policy, procedures and/or mechanisms and the sub-
indicator RS09.01 that encourages NRAs to participate in a regional and/or global 
networks in order to promote convergence and harmonisation efforts (WHO, 2018b). 
 
Transparency and communication 
SAHPRA should enhance stakeholder relationships through improved communication 
strategies and increased transparency.  The SAHPRA website should be 
supplemented with the publication of updated lists of SAHPRA licence holders and 
medicine registrations as well as information pertaining to vigilance activities such as 
medicine recalls and safety alerts.  SAHPRA should develop, implement and maintain 
enhanced ICT solutions to facilitate the online submission of applications supported by 
systems that allow the industry to track the progress of applications.  These 
recommendations are supported by the WHO GBT indicator MA05 that highlights the 
need for the NRA to ensure that mechanisms exist to promote transparency, 
accountability and communication.  These recommendations are further endorsed by 
the sub-indicator MA05.01 that requires the NRA to ensure the availability and of a 
website or other official publication that is regularly updated (WHO, 2018c); sub-
indicator MA05.02 that requires the publication of an updated list of all medicines 
granted market authorisation (WHO, 2018c); and the sub-indicator RS09.04 that 
requires the publication of information on marketed medical products, authorised 
companies and licensed facilities (WHO, 2018b).  SAHPRA should ensure consistent, 
defensible, predictable and transparent decision-making.  This can be achieved 
through the application of the UMBRA BR Summary Template for BR assessment and 
the publication of SAHPRA’s summary basis of decision in the form of the ZAPAR.  
This recommendation is endorsed by the sub-indicator MA05.03 that requires the 
publication of summary technical evaluation reports for approved applications of 
marketing authorisation in the public domain (WHO, 2018c) and the sub-indicator 
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RS09.03 that requires the publication of the NRA’s decisions related to regulatory 
activities in the public domain (WHO, 2018b).  The placement of the ZAPAR in the 
public domain will also support and strengthen the position of SAHPRA as an NRA 
whose regulatory decisions may be relied on or recognised by other NRAs in the 
emerging markets. 
 
Training and education 
Training programs should be formalised and priority should be placed on the 
professional development of internal and external assessors.  Ongoing skills 
development may be maintained through the initiation of mentorship programmes.  
These recommendations are endorsed by the requirements of the following sub-
indicators of the WHO GBT: MA03.01 states that enough competent staff (education 
training skills and experience) should be assigned to perform marketing authorisation; 
MA03.03 requires the development, implementation and annual updating of the 
training plan; MA03.04 describes the requirement of performing and maintaining 
records of staff training activities (WHO, 2018c); and RS05.14 requires the 
establishment of a mechanism to evaluate and demonstrate the effectiveness of 
training activities (WHO, 2018b).  Ensuring the development of additional capacity will 
contribute towards enhanced regulatory performance and shortened timelines for 





As with any research there are a number of limitations including the following:  
 This programme of research was limited to an evaluation of the regulatory 
review process in South Africa for new active substances (NASs) including new 
chemical entities (NCEs), biologicals and major line extensions (MLEs).  This 
study did not include a review of the overall approval timelines for applications 
for the registration of generic medicines, biosimilars or complementary 
medicines. 
 The performance metrics data collected for NASs for the period 2015-2018 was 
limited to the information that was documented and made available by the South 
African NRA.  While the dossier receipt date and date of allocation of the dossier 
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to a reviewer were recorded it was not possible to confirm the time taken to 
validate the document during the administrative and technical screening 
processes.  The data provided did not allow for the accurate calculation of the 
clock stop, so it was not possible to determine the amount of time each 
application spent with each of the various scientific committees nor the time it 
took for the applicant to provide the required response/s. 
 Chapter 5 documented the evaluation of the regulatory review times and 
products in South Africa for the period 2015-2018.  The data collected indicated 
the characteristics and number of the NASs approved (including NCEs, 
biologicals and MLEs) and the overall median approval timelines for these 
NASs.  Data collected for the period 2015-2017 represented the performance 
of the MCC and the results described for 2018 reflected the performance of 
SAHPRA during the initial stages of its establishment and transition.  The results 
for 2018 did not reflect the re-engineered, streamlined processes developed by 
SAHPRA that were still in the process of being piloted prior to final 
implementation. 
 Chapter 8 described the results following the distribution of a questionnaire to 
nine NRAs to gather information pertaining to the criteria and current practices 
for implementing an abridged review process.  Responses to the questionnaire 
were received from six out of the nine NRAs to whom the questionnaire was 
sent.  Nevertheless, the achieved 67% response rate in studies of such nature 




 This programme of research largely evaluated the regulatory performance of 
the MCC and has been valuable in providing a baseline against which the 
results of the recommended improvements to the reformed regulatory review 
process under SAHPRA may be quantitatively evaluated and presented.  
Following the implementation of the SAHPRA’s re-engineered processes it 
would be useful to: 
o Complete the questionnaire that was used in Study 2 (Chapter 4: Review 
of the Regulatory Review Process) to reflect on the organisational 




o Evaluate the performance metrics and overall median approval times for 
NASs (2019-2020) 
o Compare the new registration process and regulatory review model of 
SAHPRA against other similar-sized NRAs 
 Provided that the recommendation to identify and routinely measure and 
monitor the milestones in the regulatory review process is implemented, it would 
be useful to analyse the timelines achieved between these milestones in order 
to accurately determine the time taken by SAHPRA to review an application for 
the registration of NASs and the time taken by the applicant to provide the 
required response/s to SAHPRA. 
 Considering the intention of SAHPRA to implement FRPs it would be valuable 
to study the overall median approval timelines achieved for different review 
types (including full review, abridged review and verification) and the impact 
thereof on patients’ access to NASs 
 The drive for the implementation of collaborative initiatives to support the 
appropriate allocation of limited resources and to reduce the duplication of 
regulatory effort is evident.  SAHPRA has participated in such initiatives, most 
notably the regional Zazibona work sharing collaborative registration process.  
It would be valuable to study the regulatory performance and the opportunities 
for the enhancement of both regional and continental collaborative initiatives in 
Africa through: 
o The use of the questionnaire applied in Study 6 (Chapter 8) as well as 
interviewing regulatory agencies to determine the criteria and current 
practices for implementing an abridged review process by NRAs that 
have implemented these approaches in order to gain a better 
understanding of how FRPs may be used to strengthen regulatory 
performance of the Zazibona work sharing collaborative initiative or work-
sharing/joint reviews in the SADC region or within the African continent 
o To assess the impact of the use of a structured universal template for BR 
assessment on the quality of review supporting predictable, transparent 
and quality decision making and provide an effective approach for 







This programme of research has presented, in a seminal piece of work, an evaluation 
of the regulatory performance of the South African NRA.  The studies undertaken have 
for the first time made recommendations for an improved regulatory review model for 
the South African Health Products Regulatory Authority (SAHPRA).  
Recommendations have been made for the implementation of a universal framework 
for benefit-risk (BR) assessment and an abridged review process as well as formalised 
reliance mechanisms.  These recommendations may contribute towards enhancing 
global regulatory efficiencies and ensuring transparent, consistent and timey regulatory 
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REGULATORY REVIEW PROCESS IN EMERGING MARKETS 
Review of key milestones, target times and quality of decision-making in the  
assessment and registration process 
BACKGROUND 
This questionnaire represents an ongoing study of the CIRS Emerging Markets programme which is 
focusing on the regulation of new medicines in the Emerging Markets and looking at how regulatory 
agencies build quality into the review process.  
The first phase was initiated in January 2004 to assess the current regulatory environment in some 30 
countries, using comparative data, at the country and regional level, in order to identify the key issues 
for improving review practices and making new medicines available in an efficient and timely manner. 
Some of these, for example the timing and use of the Certificate of a Pharmaceutical Product (CPP) and 
the length of the review process were analysed in more detail in a smaller selection of countries. This 
study highlighted the need to understand more about the different steps in the review process and the 
way in which these affect the overall timeline. Regulatory authorities also showed an interest in having 
a greater understanding of how agencies are building quality into the review process.  
The second phase of the study was carried out in 2006-2008 among the regulatory agencies in twelve 
regulatory authorities: Argentina, Brazil, China, Egypt, India, Indonesia, Malaysia, Mexico, Saudi Arabia, 
South Africa, South Korea and Taiwan. 
Through this study, CIRS proposes to map the key milestones and associated activities, for each 
agency, for both marketing and clinical trial applications and to determine the quality measures 
employed by the agencies in their different procedures in Latin America.  
As many agencies in the second phase have evolved, so have their review processes and practices. 
Therefore, third phase of the study, CIRS focuses on updating the process maps for the regulatory 
agency as many on establishing a baseline to understand of the current practices and procedures being 
undertaken by agencies to support their GRevP initiatives. 
Through this study, CIRS proposes to map the key milestones and associated activities, for each 
agency, for marketing applications and to identify processes and procedures for GRevP. This would 
help provide a platform to enable information sharing including possibility of sharing assessment report 
in the future. 
 
OBJECTIVES 
The objectives are to: 
 To identify the organisation structure and capacity of each agency. 
 To identify the key milestones and target times for each authority and the main activities between 
milestones for registration 
 To identify the model(s) of the review which is being undertaken by each of the agencies. 
 To assess how agencies are building GRevP into the assessment and registration process. 
 To identify opportunities for the exchange of better practices amongst the regulatory authorities.  
OUTPUT 
Participating agencies will receive a report from which they can compare their regulatory procedures 
with those of peer agencies across the regions. This will include an analysis of where time is spent in 
the review process with the opportunity to identify where time is lost. 
The outcome will allow an analysis of the quality measures that are, or are not, in place for a certain 
type of review and provide a baseline for subsequent training in GRevP across agencies to establish a 







ABOUT THE QUESTIONNAIRE 
The attached questionnaire is divided into three sections: 
Part I: Organisation of the agency. The Introduction to the questionnaire asks the Authority to provide 
current information on its structure, organisation and resources. It also explores review model(s)for the 
scientific assessment of medicines in terms of the extent to which data is assessed in detail by the 
agency rather than relying on the results of assessments and reviews carried out elsewhere 
Part II: Key Milestones in the registration of medicines. This part of the questionnaire is based on 
the General Model giving a process map and milestones that has been developed from studying 
procedures followed in ‘established’ and ‘emerging’ regulatory agencies. It captures the main steps in 
the review and approval process and identifies key ‘milestone’ dates in the process for monitoring and 
analysing timelines 
Part III: Good Review Practice (GRevP): Building quality into the assessment and registration 
process looks at the activities that contribute to the quality of the decision-making process and those 
measures that have been adopted to improve consistency, transparency, timeliness and competency in 
the review processes 
 
The Introduction to the questionnaire asks the Authority to provide current information on its structure, 
organisation and resources. It also explores review model(s) for the scientific assessment in terms of 
the extent to which data is assessed in detail by the agency rather than relying on the results of 
assessments and reviews carried out elsewhere. The questionnaire is intended to be used as the basis 
for a face-to-face interview between Agency staff and CIRS. 
 
Focus of the Study 
The study is intended, primarily, to document procedures and practices that relate to medicines that are 
the subject of major applications, i.e., new active substances and major line extensions.  
New Active Substance  
A new chemical, biological or pharmaceutical active substance including: 
 a chemical, biological or radiopharmaceutical substance not previously authorised as a medicinal 
product; 
 an isomer, mixture of isomers, a complex or derivative or salt of a chemical substance not 
previously authorised as a medicinal product but differing in properties with regard to safety and 
efficacy from that chemical substance previously authorised; 
 a biological substance previously authorised as a medicinal product, but differing in molecular 
structure, nature of the source material or manufacturing process; 
 a radiopharmaceutical substance which is radio nucleotide, or a ligand not previously authorised as 
a medicinal product, or the coupling mechanism to link the molecule and the radio nucleotide has 
not been previously authorised 
Major line extension 
A major line extension is a change to an authorised Medicinal Product that is sufficiently great that it 
cannot be considered to be a simple variation to the original product, but requires a new product 
authorisation. Such changes include major new therapeutic indications or new disease states, extension 








PART I: ORGANISATIONAL STRUCTURE & TYPE OF REVIEW 
 
1. Information on the Regulatory Authority 
As background to the discussions about your agency, its practices and procedures it would be helpful 
to have the following basic information on its structure and the way it is established: 
Title of the Agency/Division responsible for the regulation of medicinal products for human use 
South African Health Products Regulatory Authority 
If this is part of a parent agency with a wider remit (e.g., Food and Drugs) please give the title: 
N/A 
Scope and remit 
1.1 Please indicate the scope of responsibility of the Agency: 
Medicinal products for human use  YES  NO 
Medicinal products for veterinary use  YES  NO 
Medical devices and in vitro diagnostics  YES  NO 
1.2 Indicate the main activities that are covered by the agency 
 Marketing authorisations/Product licences  Clinical trial authorisations 
 Post-marketing surveillance  Regulation of advertising 
 Laboratory analysis of samples  Price regulation 
 Other  Site inspections (site visits) 
 
Type of agency 
1.3 Indicate which of the following best describes this agency 
 Autonomous agency, independent from the Health Ministry administration 
 Operates within the administrative structure of the Health Ministry 
Date of establishment of the current agency   
 
Size of agency 
Please note that the following questions refer to the regulation of medicinal products for human use. 
1.4 Please provide information on staff numbers 
 Total staff in the agency   
   




1.5 Please indicate the professional background and numbers of the technical agency staff 
assigned to the review and assessment of medicinal products.   
External evaluators are appointed at the discretion of the Council and information pertaining to their 
professional background is not available. Internal evaluators are required to be suitably qualified as 
pharmacists or scientists. 
 Number Employed as assessors (Degree/Expertise) 
 Total: 
 
with PhD or 
PharmD:  




 Physicians     
 Statisticians     
 Pharmacists     
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 Other Scientists     
 Project Managers     
Fee structure 
1.6 Are fees charged to sponsors for the review and assessment 
of applications for medicinal products for human use? 
  
If YES, please provide the following information: 
Marketing Authorisation Application fee for Local currency  US$ (rounded) 
New Active substance 
  
   
    
Established ingredient - proprietary product 
 
   
    
Generic product 
 
   
    
Variations 
 
   
    
Major line extension 
 
   
    
Other (Please specify)    
Does the agency charge a fee for Scientific Advice 
YES  NO: If Yes please provide 
             
Budget  
Please indicate whether the following data    are in the public domain or 
  Should be treated as confidential 
1.7 Please provide the following information on the agency budget for the regulation of medicinal 
products for human use 
 Local currency  US$ 
Total annual budget    
    
 Year for which data are given    
If the budget is sub-divided according to different activities, please specify: N/A 
 % of total budget   
 Clinical trial authorisations         
    
 Marketing authorisations         
    
 Pharmacovigilance         
    
 Other post-marketing controls         
    
 Other activities (specify) 
 
        
   






1.8 Please provide the following information in relation to the way the agency is funded 
Funded entirely by the government  YES  NO 
Self-funded entirely from fees  YES  NO 
Partially funded from different sources (please give 
proportions of total budget) 
% Government % Fees 
% Other (specify) 
  
Additional documentation 
To assist CIRS to better understand your organisation please provide copies of any organisation 
charts that show the structure of the agency and its relationship to other regulatory bodies, e.g., 
medical device agency. It would also be very useful to have copies of any background papers that 





2. Type of data assessment 
Three basic types of scientific review have been identified as a result of discussions with regulatory 
agencies and presentations at the CMR International Institute Workshop on The Emerging Markets: 
Regulatory issues and the impact on patients’ access to medicines, Geneva, Switzerland, March 2006. 
Many agencies apply a different level of data assessment to different applications, according to the type 
of product and/or its regulatory status with other agencies. The data assessment models for scientific 
review are described in section 2.1 below and further questions are set out in 2.2 to analyse the types 
of scientific review in more detail. 
2.1 Please indicate by checking the boxes below, which descriptions fit the model(s) used by 
your agency in the assessment of major applications i.e., new active substances (NASs) and 
major line extensions as described on page 2. 
Data Assessment Type 1  
This model is used to reduce duplication of effort by agreeing that the importing country will allow certain 
products to be marketed locally once they have been authorised by one or more recognised reference 
agencies, elsewhere. The main responsibility of the agency in the importing country is to ‘verify’ that the 
product intended for local sale has been duly registered as declared in the application and that the 
product characteristics (formulation, composition) and the prescribing information (use, dosage, 
precautions) for local marketing conforms to that agreed in the reference authorisation(s)  
TYPE 1  Not used  Used for all major applications 
 Used for selected applications (please specify) 
 
 
Data Assessment Type 2  
This model also conserves resources by not re-assessing scientific supporting data that has been 
reviewed and accepted elsewhere but includes an ‘abridged’ independent review of the product in terms 
of its use under local conditions. This might include a review of the pharmaceutical (CMC) data in relation 
to climatic conditions and distribution infrastructure and a benefit-risk assessment in relation to use in 
the local ethnic population, medical practice/culture and patterns of disease and nutrition. 
Approval by a recognised agency elsewhere is a pre-requisite before the local authorisation can be 
granted but the initial application need not necessarily be delayed until formal documentation such as a 
Certificate of a Pharmaceutical Product (CPP) is available. 
TYPE 2  Not used  Used for all major applications 
 Used for selected applications (please specify) 
 
 
Data Assessment Type 3 
In this model the agency has suitable resources, including access to appropriate internal and external 
experts, to carry out a ‘full’ review and evaluation of the supporting scientific data (quality, pre-clinical, 
clinical) for a major application. A Type 3 assessment could be carried out on a new application that has 
not been approved elsewhere but, in practice, legal requirements may dictate that the product must be 
authorised by a reference agency before the local authorisation can be finalised.  
TYPE 3 Not used  Used for all major applications 
 Used under the following conditions (please specify) 
 
 Full review conducted but product must still be authorised by a reference agency prior to final 
authorisation 
 
If your agency has recognised ‘reference agencies’ (as in Types 1 and 2) please provide the list: 
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Type I Type II Type III Priority/fast track products 
Evidence of authorisation by other authorities 
Requirements for a CPP as part 
of the review 
 with application 
 before authorisation 
 not essential   
 with application 
 before authorisation 
 not essential   
 before local authorisation 
 not essential 
 if available at the time of 
submission 
 with application 
 before authorisation 
 not essential   
Other documentation from the 
authorising agencies accepted 
as evidence of registration 
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
Other evidence accepted       
 
      1.        
Verification of identity between the authorised product and the local application: THIS VERFICATION IS NOT PERFORMED 
The following are checked: Information must be: 
Identical Closely similar 
Information must be: 
Identical Closely similar 
Not applicable 
Information must be: 
Identical Closely similar 
Dosage form           
Strength           
Ingredients           
Indications and dose           
Warnings and precaution           
Product label           
Other (specify)                         
Scientific data required to support the application (Reference is made below to sections of the ICH Common Technical Document (CTD) as an example of the level of detail but 
does not imply that the CTD in necessarily accepted) 
Pharmaceutical quality/CMC  Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 






Type I Type II Type III Priority/fast track products 
 
Scientific data required to support the application (continued) 
Nonclinical data   Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
Clinical data  Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
Extent of Scientific Review 
Quality/CMC data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  
 Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  
 Only examined if there is a 
query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail (e.g. 
stability, specification) 
 Detailed assessment and 




                        
Non-clinical data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 Not at all 
 Only examined if there is a 
query 
 ‘Check list’ review for 
completeness of data 
  Detailed assessment and 









Type I Type II Type III Priority/fast track products 
 
 
Clinical data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 
evaluation report  
 Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 
evaluation report  
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 
evaluation report  
 Only examined if there is a 
query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail (e.g. 
bridging studies) 
 Detailed assessment and 




    
Clinical evaluation: factors included in the risk-benefit assessment 
The clinical opinion takes 
account of: Never sometimes always Never sometimes always Never sometimes always Never sometimes always 
Differences in medical 
culture/practice 
            
Ethnic factors             
National disease patterns             
Unmet medical need             
Additional information, not in the application: 
The agency tries to obtain Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Other agencies’ internal 
assessment reports 
            
Reports available on the 
Internet (e.g., EPARS) 
            





Type I Type II Type III Priority/fast track products 
Other data (specify:     ) 
 
         
 





PART II - KEY MILESTONES IN THE REGISTRATION OF MEDICINES 
Review Process Map and Milestones 
This part of the questionnaire is based on the General Model below giving a process map and milestones 
that has been developed from studying procedures followed in ‘established’ and ‘emerging’ regulatory 
agencies. It captures the main steps in the review and approval process and identifies key ‘milestone’ 




Receipt and validation may include 
administrative registration (reference number) 
and checks on legal requirements, status of 
company, local agent, manufacturer etc. as 
well as a ‘checklist’ validation of the application 
content (e.g., technical sections, CPP status).  
Queuing for review: Administrative time 1 is a 
measure of the ‘backlog’ time (if any) while 
valid applications wait for action to begin. 
Scientific Assessment extends from 
milestone C to milestone H and is a measure 
of ‘review time’. In some systems the ‘clock’ 
stops when questions are asked and Sponsor 
time(milestone D to milestone E) can be 
measured and deducted from the agency 
review time. 
Questions to sponsor may be batched and 
sent at one time or asked throughout the 
review process, in which case the Sponsor 
time is not easily measured.  
In some systems, questions may only be sent 
to the sponsor after the end of the ‘first cycle’ 
scientific assessment (at milestone H). 
Committee Procedure: Most review 
procedures for major applications include a 
step where the opinion of an expert advisory 
committee is sought. In this scheme, the 
Committee procedure is ‘nested’ within the 
Scientific Assessment but it may take place 
after the Agency’s scientific assessment is 
complete. 
Second cycle: If the application cannot be 
granted immediately, on technical grounds, it 
enters a second review cycle (new data point 
D: questions to sponsor) and a further scientific 
assessment is made of the additional data. The 
Committee Procedure may or may not need to 
be included in the second and subsequent 
review cycles. 
Approval procedure: The time interval after 
scientific review (Admin time 2) while the 
formal authorisation is issued may be extended 
by pricing negotiations and finalisation of 
analytical and GMP checks. 
Approval time is measured from milestone A 















































Queuing for review  
Reply from sponsor 
 
E 
Accepted for review 
 
B 





Questions to sponsor 
 
D 


























































Review stages and milestones 
This section of the questionnaire is based on the General Model shown on page 6. 
We recognise that not all systems conform to the general model and it would be very helpful if you could 
provide an outline of the model used by your authority. If this differs according to the Type of data 
assessment (see page 5) please provide information on the different models  
When information is given on target or actual times please indicate here whether these are counted in: 
 Calendar days  Working days 
When ‘milestone’ dates are recorded during the review process is the information entered into an 
electronic tracking/recording system? 
 YES, System in current use   NO, System in development (Target date: 2018) 
 NO, A manual system will be used for the foreseeable future 
3. Receipt and Validation 
 
Pre-submission requirements 
3.1. Are there any formal requirements before an 
application is submitted, for example, notification of 
intent to submit, assignment of registration code etc. 
X NO, milestone A is the formal start of the application 
procedure 
 YES  
Validation 
3.2 Is the date of receipt (milestone A) formally recorded?  YES  NO 
3.3 Are the following administrative items checked in the pre-review validation process? 
 Legal status of applicant/local agent   YES  NO 
 GMP status of manufacturer  YES  NO 
 Patent/IP status of active ingredient  YES  NO 
 Whether company has paid the correct fee  YES  NO 
Other:  
1. Sample of the product must be submitted 
2. CPP must be made available 
3.4 For those applications where prior authorisation elsewhere is essential (see Section 2) 
please answer the following questions about the Certificate of a Pharmaceutical Product(CPP) 
Is the inclusion of a CPP an absolute requirement before accepting the application as valid? 
 YES  NO  For some applications (please specify) 
If YES must the CPP be legalised by an Embassy or Consulate?  YES  NO 
If NO, please indicate which of the following apply 
 A CPP must be provided before the authorisation is issued  YES  NO 
 Other evidence of authorisation by other countries is accepted in 
place of the CPP (e.g., copy of authorisation, Internet reference) 
 YES  NO 
Comment 
      
 
  





















3.5 Is the application also checked for the following items? 
Acceptable format (e.g. ICH CTD or local requirements)  YES  NO 
Correct sections of scientific data (quality, safety, efficacy)  YES  NO 
Other technical items:  
The qualifications of the Responsible Pharmacist/Responsible Person as well as the relevant 
authorisation of the Responsible Pharmacist/Responsible Person must be submitted with the 
application. 
Acceptance for review/refusal to file 
3.6 Is the date of acceptance (milestone B) formally recorded?  YES  NO 
3.7 What happens if the application is incomplete? 
 Refusal to file: New application must be made 
 File pending: A request for the missing data is sent to the applicant 
 What is the time limit for the applicant to reply?  
Notes: 
In the event that there is no response from the applicant within 10 days the file will be refused. 
Target time for validation 
3.8 Is there a target validation time?  YES  
 NO 
4. Queuing/backlog 
 4.1 Which of the following applies to the queuing 
system for new applications? 
 Held in queue after validation (as in the General 
Model) after phase 1 validation 
 Held in queue before validation starts (milestone 
A) 
4.2 What is the current queue time (approximately)? 
 Less than 2 weeks  2-8 weeks 
 2-6 months               6 months-1 
year 
 More than 1 year  
4.3 Are priority products taken out of turn in the queuing 
system 
 YES, always 
 YES, sometimes 
 NO, all applications await their 
turn 
Comment: 
      
4.4 Does the Agency regard the backlog of applications 
as a problem 
 YES  NO 










Queuing for review  
Accepted for review 
 
B 





5. Scientific Assessment 
5.1 Initiation of scientific review 
 
5.1.1 Is the start of the 
Scientific Assessment 
formally recorded  
(milestone C)? 
 YES  NO 
5.1.2 Is the scientific data 
separated into three sections 
(quality, safety, and efficacy) 
for review? 
 YES  NO 
5.1.3 In what order are the different sections assessed: 
 In parallel  In sequence 
If in sequence, please give order 
      
 
5.1.4 Who carries out the primary scientific assessment? 
 Agency technical staff   Sent to outside experts 
 Different procedure for different sections 
Please describe the process: 
      
5.2 Use of outside experts 
If outside experts are used for the assessment of scientific data (5.1.4 above) please complete the 
following: 
5.2.1 Number of experts on the agency’s list or panel:   
 
5.2.2 Main responsibility:  To provide a detailed assessment report and recommendation 
  To provide a clinical opinion on the product 
  To provide advice to the agency staff on specific technical 
issues 
  Other (specify) 
 
5.2.3 Is there a contractual agreement on 
working within deadlines set by the agency? 
 YES  NO 
5.3 Interaction with the Sponsor 
 5.3.1 How are questions sent to the Sponsor 
 as they arise during the 
assessment 
 Collected into a 
single batch 
5.3.2 When are batched questions sent to the Sponsor 
 After the initial assessment but before reporting to 
the Scientific Committee (as in the General model) 
 Not until the Scientific Committee has given its 
advice 
 Before and after reference to the Scientific 
Committee 
5.3.3 Does the scientific review cease while questions are being 
processed by the Sponsor (‘clock stop’) 
 YES  NO 
Reply from sponsor 
 
E 
Questions to sponsor 
 
D 































Reply from sponsor 
 
E 





Questions to sponsor 
 
D 


















5.3 Interaction with the Sponsor (cont.) 
5.3.4 Can the sponsor time be calculated, i.e., are milestones D and E 
recorded? 
 YES  NO 
5.3.5 Is the sponsor given a time limit to reply  YES  NO 
  
If Yes, what time is allowed?   
Meetings 
5.3.6 Can the Sponsor hold meetings with the agency staff to discuss 
questions and queries that arise during the assessment 
 YES  NO 
If Yes, what conditions and restrictions (if any) are applied? 
1. Request formal meeting 
2. Require scientific argument to be provided beforehand 
3. Guideline is available to describe this procedure [IND Guideline] 
5.4 Review by Scientific Committee 
 
5.4.1 Is a Committee of 
Experts (internal and/or 




5.4.2 If Yes, at which stage in the review? 
 Responsible for the whole assessment of the 
dossier from the start of the review  
 Integrated into the agency’s own 
internal/external scientific review procedure 
 Consulted after the agency has reviewed and 
reported on the scientific data 
 Other (specify) 
5.4.3 Are the dates at the start and end of the Committee Review 
recorded (milestones F and G)? 
 YES  NO 
5.4.4 Is the agency mandated to follow the Committee 
recommendation? 
 YES  NO 
5.4.5 Is there a time limit for the Committee Procedure?  YES  NO 
If YES, please give the target 
If NO, what is the time range (e.g., 1-3 months)   
   
5.4.6 Is there an additional step in the scientific review process, after 
the Committee has given its opinion? 
 YES 
 NO 
If YES, please describe briefly the work carried out at this stage (e.g., final report and agency 
opinion) 
 
If NO, the milestone G will mark the end of the scientific review for the purpose of calculating the 
review time 
      
Target for scientific review 
5.4.7 Is a target time set for the scientific review (milestones C to H)  YES  NO 
If YES please give target   


































6. Decision on the Application 
 
At the end of the Scientific Review (see General Model, 
page 6) there is normally recommendation that either: 
 The product meets the scientific criteria for 
authorisation (proceed to approval procedure) or 
 Further data is required before the scientific criteria 
are met (application enters a second cycle at 
milestone D (questions to Sponsor) or 
 The application should be refused (not shown in the 
General Model) 
6.1 Responsibility for the authorisation decision 
6.1.1 Who makes the decision that a marketing authorisation can be granted? 
 The Scientific Committee  The Head of the Agency 
 The Minister of Health  
 Other  
 
6.2 Other Criteria to be met 
6.2.1 Is the issue of the authorisation dependent on a pricing 
agreement 
 YES  NO 
If YES, when are the pricing negotiations started?  
 At the start of the scientific review  After the end of the scientific review 
 After the start but before the end of the scientific review 
6.2.2 Is the issue of the authorisation dependent on sample analysis  YES  NO 
If YES, when is the analytical work started?  
 In parallel with the scientific review  At the end of the scientific review 
After the start but before the end of the scientific review 
6.2.3 Is there a separate negotiation of the product labelling/ product 
information after the scientific opinion is given but before the approval is 
issued? 
 YES  NO 
Comments: 
      
 
6.2.4 Please specify any other legal/administrative matters that must be finalised before the 
approval can be issued 
 
 
6.3 Approval procedure 
6.3.1 Is the Sponsor informed of a positive scientific opinion at 
milestone G, i.e., before the authorisation is issued? 
 YES  NO 
6.3.2 Approximately how long does it take from receiving a positive scientific opinion (at milestone 
H) to issuing an approval (milestone I) 
 Less than a month  1-3 months  3-6 months  Over 6 months 
Comment: 
      
 

















7. Metrics on the Approval Process for NAS 
It would be very helpful to have the following information on processing times for marketing 
authorisations that have been received and/or determined in the three years 2014, 2015, 2016. Data 
available does not provide a clear distinction between NAS and Major Line Extension. 
7.1 Applications received 
Type 
Number of applications received in each 
year 
Current backlog 2014 2015 2016 
New Active Substance & 
Major line extension 
    
 
7.2 Applications determined 
Type 
Number of applications determined in each year 
2014 2015 2016 
New Active Substances & Major line 
extension approved 
   
New Active Substances & Major line 
extension refused 
   
 
7.3 Average approval times 
Type 
Time from receipt of application to issue of approval 
2014 2015 2016 
New Active Substances & Major line 
extension 
   
 
7.4 Target for approval times 
Is a target time set for the overall approval process (milestones A to I)  YES  NO 
If YES please give target   






PART III-GOOD REVIEW PRACTICE (GREVP) 
BUILDING QUALITY INTO THE ASSESSMENT  
AND REGISTRATION PROCESS 
Quality in the assessment and registration process is important to regulatory authorities as it ensures 
consistency, transparency, timeliness and competency in the review processes. Regulatory authorities 
are continuously developing and implementing a variety of measures to improve and achieve higher 
quality standards and to meet the expectations of industry and the general public. 
The purpose of this section of the questionnaire is to obtain an insight into the strategies, measures and 
resources that agencies have in place to develop and maintain quality in their review processes.  
8. General Measures used to achieve quality 
Please indicate the quality measures currently in place and, where none, plans to introduce such 
measures in the foreseeable future. 
Good Review Practice (GRevP): A code about the process and the documentation of review 
procedures that aims to standardise and improve the overall documentation and ensure timeliness, 
predictability, consistency and high quality of reviews and review reports 
 
8.1 How does your agency define GRevP?: 
Is it different from the Glossary?     Yes  No 
 
If different, please define in here:  
Please Outline the key elements that make up GRevP in your agency: 
      
 
Has the Agency formally or informally implemented GRevP?  
 Yes (Informally) 
 NO  
.If YES please give the title and date of formal implementation:  
.      
 
 
How has this been implemented: (Please tick the appropriate Box(s)) 
 
Guidelines  Standard Operating Procedure   GRevP Training Program 
Other: Please specify:      
Are these documents open and available to the Public?       Yes No 
If Yes please describe: All relevant Guidelines are available on the MCC website (www.mccza.com) 
 
Was the establishment of your GRevP based on other agencies or 
International standards? 
YES NO  
If Yes: please state the name of the agency(ies)/ or Internationals standards  on which your GRevP 
has been based:  
Are you satisfied with your existing GRevP framework? 
Satisfied  Could be improved Unsatisfied 
If could be improved or Unsatisfied, please select reason(s) that best describes your situation. 
 System still evolving 
Requires additional training to understand and learn about Good Review Practice 
 Poor acceptance/utilization by staff 
 Benefits of implementing GRevP are not apparent so far 





If you do not have a formal GRevP system in place are there plans 
to establish this within the next two years? 
 Yes No 
Quality Policy: Overall intentions and direction of an organisation related to quality as formally 
expressed by top management. 
8.2 Does the Agency have an internal Quality Policy?  Yes No 
If NO are there plans to establish this within the next two years? Yes No  
SOPs (Standard Operating Procedures) are written documents that describe in detail the routine 
procedures to be followed for a specific operation. 
8.3 Are there SOPs for the guidance of scientific assessors Yes  No 
If NO are there plans to establish SOPs within the next two years? Yes No 
8.4 Are there SOPs for the advisory committee consulted 
during the review process  
Yes   No 
No committee 
If NO are there plans to establish SOPs within the next two years?  Yes No 
8.5 Are SOPs used for any other procedures in the regulatory 
review process (e.g., validation)? 
Yes No 
Please specify:       
 
Assessment Templates set out the content and format of written reports on scientific reviews. 
8.6 Are there Assessment Templates for reports on the 
scientific review of a NAS? 
 Yes  No 
If NO are there plans to establish this within the next two years?  Yes No 
If Yes are these based on another agencies assessment template Yes  No  
If Yes, which agency was the assessment template based? Please specify: 
      
Is there an SOP for completing an assessment template Yes  No 
Can you tick what elements from the list below are included in your agency assessment template?  
 Drug Substance 
Drug Product 
Comments on label 
Non clinical GLP Aspects 
Non clinical Pharmacokinetic 
Toxicology 
Regulatory background (worldwide status 
on regulatory agencies) 
Other (please specify):   
 
 GCP aspects 
Clinical Pharmacology (PK & PD) 
Clinical Efficacy 
Clinical Safety 
List of questions for sponsors 
Benefit Risk Reduction 
Ethnic factors (e.g. consideration of bridging  
studies 
Would the agency be open to sharing their assessment template 
or points to consider with CIRS? 
 
 YESNO  
Do you produce an assessment report (AR) following the review?  YESNO 
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If Yes : 
 
Is there an SOP for completing the AR: 
 
What language is the AR prepared in: 
 
 
Do you share your AR with other regulatory authorities 
 
 
Do you put your full AR on the website 
 
 
Do you put your abridged AR on the website 
 
YES   NO  






YES  NO 
SOMETIMES 
Do sponsors get a copy of the full assessment report? 
 
Do Sponsors have any involvement in the following in relation 
to AR: 
 
Preparation of assessment reports 
 
Comments on the assessment reports 
 
Translation of assessment reports 
 









Peer Review is an additional evaluation of an original assessment that is carried out by an 
independent person or committee. Peer review can occur either during assessment of a dossier or 
at the time of sign-off. 
8.7 Are external peer reviews carried out when a NAS is 
assessed? 
Yes No 
If NO are there plans to introduce these within the next two 
years? 
Yes No  
8.8 Are internal peer reviews carried out when a NAS is 
assessed? 
 Yes No 
 
If NO are there plans to introduce these within the next two 
years? 
Yes No 
Do you have target times for following activities and if so can 
you provide your target times? 
 
Overall approval times 
 




Company (clock stop), time 
 
Other: Please specify:       
 
 
If Target times given are they in working days? 
Yes       No 
 
 36 MONTHS 
 N/A 
 3 MONTHS 




8.9 Are there other general procedures in place to monitor the quality of the review process?  
What other tools does your agency use to build quality into the assessment process? 
(e.g. Internal procedure could include; Quality assurance and quality control meeting; Stakeholder 




9 Quality Management 
Reasons for introducing quality measures in the authority 
9.1 Please select, from the following list,  the three most important reasons for the introduction of  
quality measures 




 To increase transparency 
 
To achieve stakeholder satisfaction 
  
To improve communications in the 
authority 
  
To improve process predictability  
 
 To allocate the regulatory resources  
 
Other (please specify)  
      
 
Monitoring to improve quality 
9.2 Which of the following activities are undertaken by the authority to bring about continuous 
improvement in the assessment and registration process? 
 Reviewing assessors’ feedback and taking necessary action  Yes  NO 
 Reviewing stakeholders’ feedback (e.g. through complaints, 
meetings or workshops) and taking necessary action 
 Yes  NO 
 Using an internal tracking system to monitor (e.g. consistency, 
timeliness, efficiency and accuracy) 
 Yes  NO 
 Carrying out internal quality audits (e.g. self-assessments) and 
using findings to improve the system 
 Yes  NO 
 Having external quality audits by an accredited certification body to 
improve the system 
 Yes  NO  
 Having a ‘post approval’ discussion with the sponsor to provide 
feedback on the quality of the dossier and obtain the company’s 
comments  
 Yes  NO  
 
Management responsibility 
9.3 Does the authority have a dedicated department for assessing 
and/or ensuring quality in the assessment and registration process? 
 Yes  NO  
If YES, how many staff are involved?  
      
How often do you assess and/or ensure quality in assessment and registration process? 
 
Annually Semi-AnnuallyAdhocOther (please specify)      
 
To whom does this section report (e.g. the Chief Executive Officer of the authority)? 
      
If NO, is the Authority thinking of setting up such a department?  Yes NO  
To be more efficient 
To ensure consistency 




10. Quality in the Review and Assessment Process 
Improving the quality of applications 
10.1 Does the authority have official guidelines to assist industry in 
the registration of medicinal products?  Yes NO  
If YES, how are these guidelines made available? (Please indicate all that apply) 
   
 Through official publications  
   On request 
  
 Through Industry Associations 
 
Other, please specify:       
What language are the guidelines available in: 
Local language only    EnglishOther, please specify: 
Improving quality through interaction with applicants 
10.2 Does the authority provide pre-submission scientific advice to 
applicants 
 Yes  NO 
If YES how is the quality of that advice monitored?  
 
10.3 Is the applicant given details of technical staff that can be 
contacted to discuss an application during review?  
 Yes  NO 
10.4 Please indicate which of the following best describes the level of contact that companies 
have with agency staff or outside experts during development and during the agency’s assessment. 
 Development Assessment 
Extensive formal contact (including scheduled meetings)   
Extensive informal contact (frequent telephone or email 
contact) 
  
Some formal contact (possibility of meetings)   
Some informal contact (possibility of telephone or email contact)   
None, or minimal formal contact (rare occurrences of contact, 
via letter or fax) 
  
None, or minimal informal contact (rare telephone or email 
contact) 
  
Please comment on general policy for contact with applicants:  
The Authority endeavours to have an open-door policy through quarterly meetings with industry 
associations, workshops and one-on-one discussions with sponsors on the product reviews, 
general guidelines developed and new requirements as applicable. 
 
Committee Procedure 
10.5 If your review procedure includes obtaining the advice of a scientific committee of internal 
and/or external experts (as in Section 5.4) please complete the following:  
Name of the Committee :  
Number of Committee Members :       
How frequently does the Committee meet? 
Once a weekOnce a month   Other, please specify: Approximately every 8 weeks  
For NAS applications and major line extensions does the Committee review? 
 All applications Selected dossiers (specify)        
Through the authority's website  
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Does the Committee review? 
The complete dossier   Assessment reports from the reviewers 
 
 
Shared and Joint reviews with other Regulatory Agencies outside of your country 
A shared review is one where each participating authority takes responsibility for reviewing a separate 
part of the dossier. A joint review is one where the whole dossier is reviewed by each authority and the 
outcome is discussed before a decision is taken. 
Is your agency part of any regional alignment initiatives?  Yes      NO 
 
If Yes, please specify:  
      
Are bilateral-multilateral information sharing agreements in place with other jurisdictions? 
 Yes  NO  
 
If Yes, What is the general nature of those agreements?  
 
10.6 Does your authority conduct shared or joint reviews with other regulatory authorities? 





 YES Occasionally. Please state which 
authorities 
 
NO this has never been undertaken 
If YES do you have formal measures in place to ensure consistent 
quality during the review? 
If Yes, please specify 
      
 Yes  NO 
If NO, do you anticipate undertaking such reviews within the next two 
years? 
 Yes NO 
10.7 Have these joint reviews influenced the way in which your 
authority conducts reviews in general? If so, please comment 
 
 Yes  NO  
11. Training and continuing education as an element of quality 
The following questions relate to training and continuing education of assessors working within the 
authority, including those employed on a full-time basis and those contracted for specific assessments 
were necessary. 
11.1 Do you have a formal training programme for assessors?  Yes  NO 
11.2 Which of the following methods are used for training assessors? 
 Induction training 
 On job training 





 Placements and secondments in other 
regulatory authorities 
 External speakers invited to the authority 
 
 
 Participation in international workshops/ 
conferences 
In-house courses  
 Other, please specify:  
Does your authority seek direct assistance of more experienced 
agencies for development of SOPs and Guidelines? 
 
If Yes please give details:      
 
YES  NO 
 
Does your authority mainly develop SOP, Guidelines etc. based on 
information published by more experienced agencies: 
YES  NO 
11.3 Does your authority collaborate with other agencies in the 
training of assessors? 
Yes NO 
If Yes, please give details:  
 
11.4 Is training tested in examination situations once completed?  Yes  NO 
 Partly 
11.5 Is completion of training courses required for professional 
advancement? 










12. Transparency of the review procedure 
This section examines ‘transparency’ in terms of the ability and willingness of the agency to assign time 
and resources to providing information on its activities to both the informed public (which includes health 
professionals) and industry. 
12.1 What priority does your agency assign to being open and transparent in relationships with the 
public, professions and industry? 
 High priority Medium priority    Low priority 
 
Please comment:      
12.2 What are the main drivers for establishing transparency? Please indicate the top three 
incentives for assigning resources to activities that enhance the openness of the regulatory system 
 Political will   Public Pressure 
Press and media attention   Need to increase confidence in the system 
 
 Need to provide assurances on safety 
safeguards 
 
Better staff morale and performance 
  
Other, please specify: 
Transparency to the public 
The following questions explore the availability of information to the general public on the performance 
of regulatory authorities 
12.3 Please indicate which of the following information items about the assessment and 
registration of marketing applications is available to the public. 
 Approval of products  
Approval times 
Summary of the grounds on which the approval was granted  
 Advisory Committee meeting dates 
 Other, please specify 
 
12.4 How is this information made available 
 Official Journal/periodical publication 
 
 From an official Internet website 
 
On request Other, please specify:      
 
Transparency to companies on application progress 
12.5 Are companies able to follow the progress of their own applications?  Yes  NO 
If YES please indicate the mechanisms available to industry 
Electronic access to the status of 
applications 
 




E-mail contact Other, please specify      
12.6 Are companies given detailed reasons for rejecting an application for 
registration? 





Facilities for providing information 
12.7 Is there an electronic system for registering and tracking applications  Yes  NO 
If YES please indicate whether it has the following capabilities 
 Tracing applications that are under review and identifying the stage in 
the process 
 Yes  NO 
 Signalling that target review dates have been exceeded Yes  NO 
 Recording the terms of the authorisation once granted Yes  NO 
 Archiving information on applications in a way that can be searched Yes  NO 
If NO are there plans to introduce such a system?  Yes  NO 




PART IV – IDENTIFICATION OF ENABLERS AND BARRIERS 
The purpose of the following two questions is to try to identify the Agency’s own perception of its unique 
positive qualities and the major impediments it faces in carrying out the review of new medicines and 
making them available to meet patients’ needs.  
13.1 List three factors that make a major contribution to the effectiveness and efficiency of your 




13.2 List three factors that act as barriers to making new medicines available in a timely manner 





13.3 Any important documents related to GRevP that you would like to share with CIRS? 
YES  NO 
If yes please list and provide directly to CIRS 






































Thank you for completing this questionnaire 
 












Email address:  
 
248 





Additional data or additional analyses of existing data requested 




An expert committee that advises the regulatory authority of the 
safety, quality and efficacy of new medicines for human use 
Approval 
 
The approval of a drug product by a regulatory authority, signified by 
the granting of a marketing authorisation, or the issue of a technical 
approval letter. However the product may still not be marketable 
until negotiations for pricing and reimbursement are concluded. 
Clinical summary 
 
Summary of clinical study data that typically includes 
biopharmaceutic studies and associated analytical methods, clinical 
pharmacology studies, clinical efficacy, clinical safety, literature 
references, and synopses of individual studies. Refers to Module 2.7 
in CTD format. 
Common technical 
document (CTD) format 
 
Common technical document (CTD) as outlined in the ICH guideline 
M4 (Organisation of the common technical document for the 
registration of pharmaceuticals for human use; M4). 
CMC Chemistry, manufacturing and controls. All activities conducted to 
optimize, scale-up and validate the processes and technologies for 
transfer to manufacture and all QA, QC and CMC support activities 
(e.g. CMC project management including CMC contribution to project 
teams).  This includes all drug substance R&D i.e. process research 
and process development, all drug product R&D i.e. formulation 
development and process development, all analytical work for drug 
substance R&D and drug product R&D, clinical supplies and CMC’s 
involvement in the compilation of regulatory documentation. 
GCP Good Clinical Practice 
Good Review Practice 
(GRevP) 
 
A code about the process and the documentation of review 
procedures that aims to standardise and improve the overall 
documentation and ensure timeliness, predictability, consistency and 
high quality of reviews and review reports 




Internal reviewers  Internal reviewers are employees of the Authority 
Joint review The whole dossier is reviewed by each authority and the outcome is 
discussed before a decision is taken. 
Marketing Authorisation 
 





Authorisation application submitted to a regulatory authority to 





A milestone must involve some form of dated written document to 
which the regulatory authority can refer. In addition, a milestone 
must be considered by the regulatory authority to be the point at 
which one event stops and the next one begins so that the times for 
events are interdependent. 
Major Line Extension A major line extension is a modification to an authorised Medicinal 
Product that is sufficiently great that it cannot be considered to be a 
simple variation to the original product, but requires a new product 
authorisation. Such modifications include major new therapeutic 
indications or new disease states, extension to new patient 
populations (e.g., paediatrics), a new route of administration or a 
novel drug delivery system. 
NAS (New Active 
Substance) 
 
A new chemical, biological or pharmaceutical active substance 
includes: 
a chemical, biological or radiopharmaceutical substance not 
previously authorised as a medicinal product; 
an isomer, mixture of isomers, a complex or derivative or salt of a 
chemical substance not previously authorised as a medicinal product 
but differing in properties with regard to safety and efficacy from 
that chemical substance previously authorised; 
a biological substance previously authorised as a medicinal product, 
but differing in molecular structure, nature of the source material or 
manufacturing process; 
a radiopharmaceutical substance which is radio nucleotide, or a 
ligand not previously authorised as a medicinal product, or the 
coupling mechanism to link the molecule and the radio nucleotide 





Summary of non-clinical data including: pharmacology, 




Peer review means an additional evaluation of an original assessment 
carried out by an independent person or committee. Peer review can 
occur either during assessment of a dossier, or at sign-off. 
Quality control 
 
Quality control is operational techniques and activities that are used 
to fulfil requirements for quality. It involves techniques that monitor 
a process and eliminate causes of unsatisfactory performance at all 
stages of the quality cycle. 
Quality policy 
 
Overall intentions and direction of an organisation related to quality 
as formally expressed by top management. 
Questions to sponsor The process of asking the sponsor for additional data or additional 
analyses of existing data. The requests are made by the regulatory 
authority during the review process. 
Scientific assessment 
 








A company, person, organisation or institution that takes 




Detailed, written instructions to achieve uniformity of the 
performance of a specific function 
Validation of a dossier 
 
The process whereby the authority verifies that all parts of the 
submitted dossier are present and complete and suitable to be 






















Implementing an Abridged Review:  
What are the Criteria and current practice?  
Regulatory Agencies Pilot Study  
 
 
Review of inclusion criteria, documentation required, depth 





The Centre for Innovation in Regulatory Science 
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The Centre for Innovation  
in Regulatory Science (CIRS) 
The Centre for Innovation in Regulatory Science Limited - is a neutral, independently managed UK 
based subsidiary company, forming part of Clarivate Analytics (UK) Limited. CIRS’ mission is to 
maintain a leadership role in identifying and applying scientific principles for the purpose of advancing 
regulatory and HTA policies and processes. CIRS provides an international forum for industry, 
regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and 
reimbursement policy through the innovative application of regulatory science and to facilitate access 
to medical products through these activities. This is CIRS’ purpose. CIRS is operated solely for the 
promotion of its purpose. The organisation has its own dedicated management and advisory boards, 
and its funding is derived from membership dues, related activities, special projects and grants  
Confidentiality 
CIRS recognises that much of these data may be highly sensitive. CIRS has more than 25 years of 
experience in handling similar data provided by agencies regarding individual products in regulatory 
review. All information collected from individual agencies will be kept strictly confidential. No data 
that will identify an individual agency will be reported or made available to any third party.  












Implementing an Abridge Review:  
What are the Criteria and current practice?  
BACKGROUND 
Abridged review procedure: “This model relies on assessments of scientific supporting data that has been reviewed and 
accepted by SRA’s, but includes an ‘abridged’ independent review of a certain part of the registration dossier of the product  
(e.g. relevant to use under local condition). This might include a review of the pharmaceutical quality (CMC) data in relation 
to climatic conditions and distribution infrastructure and a benefit-risk assessment in relation to use in the local ethnic 
population, medical practice/culture and patterns of disease and nutrition.”  [Liberti, 2017].   
 
At the 2017 CIRS Workshop in Sao Paulo on this topic, it became clear that many agencies are 
interested in risk-based evaluations and would like to understand when and how they could and 
should practically implement a reliance model within their jurisdictions. It has been suggested that 
countries developing regulatory capabilities should consider a risk-based approach to the review of 
new medicines. Indeed, a number of agencies have recently adopted verification and abridged routes 
of regulatory review (Saudi Arabia, Brazil, Indonesia), which include consideration of reviews 
undertaken by reference agencies and which have accelerated timelines compared with standard 
reviews.  Accelerating the review process should not compromise the safety, quality and efficacy of 
medicines and irrespective of the reliance model, agencies still need to consider the local benefit-risk 
decisions as well as use of the medicine within their healthcare system. The disadvantages of such 
systems are the need to wait for a prior approval and appropriate documentation such as a 
Certificate of Pharmaceutical Product. However, the advantages are the ability to focus on locally 
critical issues and conserve regulatory resources and the opportunity to accelerate availability of 
medicines.  
 
However specifically for the abridged process many agencies evaluating this approach or having 
recently adopted such an approach are evaluating; what does this look like for us in reality; what are 
the areas the agency should evaluate specifically and in what depth; How do we enable the 
reviewers to see that such approaches does not diminish the review quality or level of scrutiny; How 
much should the agency rely on the reference agency and what detailed information do we need 
from the reference agency.  
At a CIRS workshop in March 2018 in South Africa, a roundtable discussion was held with both 
regulatory agencies and companies called “Practical Implementation of Reliance Models: What are 
the Barriers and Facilitators to the Successful Application of these Models for Innovative Medicines, 
Generics and Variations?” The Group addressed a number of issues including: 
• Experience of the group with abridged-based approaches: Examining the challenges, benefits and 
enablers 
• Elements that constitute an abridged application 
• Requirements for documentation from reference agencies 
• Which parts of the dossier should be focused on in an Abridged Review 





TABLE 1: BENEFITS CHALLENGES AND ENABLERS OF AN ABRIDGED REVIEW PROCESS 
 
 
The syndicate group discussed that it was important to clarify the elements that make up an abridged 
review in particular the need to understand what each agency may require in an abridged review and 
what is needed in terms of reference agencies assessment reports.  
Therefore, there is a need to identify what agencies currently evaluate when performing an abridged 
review. As many agencies are currently considering establishing a risk stratification approach for their 
review and placing some reliance on the decision and assessment of reference agencies. A pilot study 
is being proposed by CIRs and outlined below 
OBJECTIVES 
The objectives are to: 
 To identify criteria that agencies use to determine which products should be considered for an 
abridged review 
 To determine what elements of the submission are currently or intended to be reviewed and the 
detail that will be considered  
 To develop a framework based on current criteria and elements to enable agencies who wish to 
implement and abridged review process. 
 To recommend appropriate means to document the review 
PILOT STUDY  
To be conducted amongst the following agencies Indonesia, Brazil, Singapore, Israel and Saudi Arabia and to 
collect information directly from the agencies via a questionnaire 
OUTPUT 
Participating agencies will receive a report from which they can compare their regulatory procedures 
with those of other agencies conducting an abridged review. This information will also inform future 
discussions on the how agencies are approaching abridged reviews. 
ABOUT THE QUESTIONNAIRE 
The attached questionnaire is divided into three sections: 
Part I: Organisation of the agency. The Introduction to the questionnaire asks the Authority to provide 
current information on its structure, organisation and resources. It also explores review model(s) for 
the scientific assessment of medicines in terms of the extent to which data is assessed in detail by 
the agency rather than relying on the results of assessments and reviews carried out elsewhere 
Part II: Key Milestones in the registration of medicines.  This part of the questionnaire is based on 
the General Model giving a process map and milestones that has been developed from studying 
procedures followed in ‘established’ and ‘emerging’ regulatory agencies. It captures the main steps in 
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the review and approval process and identifies key ‘milestone’ dates in the process for monitoring and 
analysing timelines 
 
The Introduction to the questionnaire asks the Authority to provide current information on its abridged 
review process. It also explores the depth of the review model(s) for the scientific assessment in terms 
of the extent to which data is assessed in detail by the agency and what is used from the reference 
agency. The questionnaire is intended to be used as the basis for a face-to-face interview between 
Agency staff and CIRS. 
Focus of the Study 
The study is intended, primarily, to document procedures and practices that relate to medicines that are 
the subject of abridged reviews of major applications, i.e., new active substances and major line 
extensions.  
New Active Substance   
A new chemical, biological or pharmaceutical active substance including: 
 a chemical, biological or radiopharmaceutical substance not previously authorised as a medicinal 
product; 
 an isomer, mixture of isomers, a complex or derivative or salt of a chemical substance not 
previously authorised as a medicinal product but differing in properties with regard to safety and 
efficacy from that chemical substance previously authorised; 
 a biological substance previously authorised as a medicinal product, but differing in molecular 
structure, nature of the source material or manufacturing process; 
 a radiopharmaceutical substance which is radio nucleotide, or a ligand not previously authorised as 
a medicinal product, or the coupling mechanism to link the molecule and the radio nucleotide has 
not been previously authorised 
Major line extension 
A major line extension is a change to an authorised Medicinal Product that is sufficiently great that it 
cannot be considered to be a simple variation to the original product, but requires a new product 
authorisation. Such changes include major new therapeutic indications or new disease states, extension 








PART I: ORGANISATIONA STRUCTURE & TYPE OF REVIEW 
 
1. Information on the Regulatory Authority 
As background to the discussions about your agency, its practices and procedures it would be helpful 
to have the following basic information on its structure and the way it is established: 
Title of the Agency/Division responsible for the regulation of medicinal products for human use 
      
If this is part of a parent agency with a wider remit (e.g., Food and Drugs) please give the title: 
      
Scope and remit 
1.1 Please indicate the scope of responsibility of the Agency: 
Medicinal products for human use  YES  NO 
Medicinal products for veterinary use  YES  NO 
Medical devices and in vitro diagnostics  YES  NO 
1.2 Indicate the main activities that are covered by the agency 
 Marketing authorisations/Product licences  Clinical trial authorisations 
 Post-marketing surveillance  Regulation of advertising 
 Laboratory analysis of samples  Price regulation 
 Other                                                                    Site inspections (site visits) 
 
Type of agency 
1.3 Indicate which of the following best describes this agency 
 Autonomous agency, independent from the Health Ministry administration 
 Operates within the administrative structure of the Health Ministry 
Date of establishment of the current agency        
 
Size of agency 
Please note that the following questions refer to the regulation of medicinal products for human use. 
1.4 Please provide information on staff numbers 
 Total staff in the agency        
   
 Number of reviewers for applications for marketing 
authorisations/ product licences 
        
 
1.5 Please indicate the professional background and numbers of the technical agency staff 
assigned to the review and assessment of medicinal products 
 Number Employed as assessors (Degree/Expertise) 
 Total: 
 
with PhD or 
PharmD:  




 Physicians                         
 Statisticians                           
 Pharmacists                          
 Other Scientists                          






Sources of funding 
1.7 Please provide the following information in relation to the way the agency is funded 
Funded entirely by the government   YES   NO 
Self-funded entirely from fees   YES   NO 
Partially funded from different sources (please give 
proportions of total budget) 
       % Government         % Fees 
       % Other (specify) 
  
Additional documentation 
To assist CIRS to better understand your organisation please provide copies of any organisation 
charts that show the structure of the agency and its relationship to other regulatory bodies, e.g., 
medical device agency. It would also be very useful to have copies of any background papers that 
describe the functions, remit and mission of the agency. 
 
  
1.6 Are fees charged to sponsors for the review and assessment 
of applications for medicinal products for human use? 
                 
If YES, please provide the following information: 
Marketing Authorisation Application fee for  Local currency  US$ (rounded) 
  New Active substance (Full Review) 
   
             
 New Active substance (Abridged Review)    
              
    
 Major line extension (Full)              
    
 Major line extension (Abridged Review)              






2. Abridged Review - Inclusion Criteria and Reference agency 
Data Assessment: Abridged Review  
This model also conserves resources by not re-assessing scientific supporting data that has been 
reviewed and accepted elsewhere but includes an ‘abridged’ independent review of the product in terms 
of its use under local conditions. This might include a review of the pharmaceutical (CMC) data in relation 
to climatic conditions and distribution infrastructure and a benefit-risk assessment in relation to use in 
the local ethnic population, medical practice/culture and patterns of disease and nutrition. 
Approval by a recognised agency elsewhere is a pre-requisite before the local authorisation can be 
granted but the initial application need not necessarily be delayed until formal documentation such as a 
Certificate of a Pharmaceutical Product (CPP) is available. 
 Used for all NAS and Major Line Extensions applications  
 Used for selected applications meeting specific criteria on request by sponsoring companies  
 Used for selected applications meeting specific criteria but agency designated 
 
Inclusion Criteria used by your agency  
Does your agency have specific inclusion criteria, please tick all that apply 
 Identical to that approved by, or submitted to, reference agency (i.e. dosage form, strength, 
formulation and manufacture)  
 The proposed indication for the medicine would need to be based on broadly similar population 
demographics, disease profiles, and expectations regarding public health outcomes between your 
jurisdiction and Reference agency  
   Criteria for timeframe between Reference agencies and submission to agency (if yes please 
specify: ____________________________________ 
 
 Other - Please Specify:  
Reference Agencies 
If your agency has recognised ‘reference agencies’ please tick which ones accepted: 
 US FDA  
 European Medicines Agency (EMA)  
 PMDA Japan 
 WHO listed agencies?  
 Health Canada 
 Swissmedic  
 UK MHRA  
 Australian TGA  
 Other Please Specify:   
 
How Many Reference agencies are required for an application:  __________________ 
 
In selection reference agencies – what are your key considerations? 
 
 Risk tolerance,  
 Objectives and goals,  
 Standards and technical guidelines,  
 Predictability in review process,  
 Integrity of decision making and  
 Transparent communication of processes and decision making. 
You have an MOU with the reference agency(ies) 
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Reference agency conduct their business and release reports in English 
 Other – Please specify  
 
 
What information is required from the reference agency (tick all that apply) 
 Assessment report 
 Un Redacted 
   Redacted can be submitted 
  Public Assessment reports 
 
Please state level of detailed required. E.g. include correspondence related to the application 
(e.g. questions asked of, and deliberations by, advisory bodies). 
 
What other types of documents need to be submitted from a reference agency: 
 
 Certificate of Pharmaceutical Product 
 Approval letter 
 Other: Please specify 
 
  




Abridged Review Full review 
Evidence of authorisation by other authorities  
Requirements for assessment 
report and other documentation 
eg CPP as part of the review 
 with application 
 before authorisation 
 not essential   
 before local authorisation 
 not essential 
 if available at the time of 
submission   
Other evidence 
required/accepted 
      
 
      
Verification of identity between the authorised product and 
the local application 
 
The following are checked: Information must be: 
Identical Closely similar 
Not applicable 
Dosage form     
Strength     
Ingredients     
Indications and dose     
Warnings and precaution     
Product label     
Other (specify)             
Scientific data required to support the application (Reference is 






Abridged Review Full review 
as an example of the level of detail but does not imply that the CTD in 
necessarily accepted) 
Pharmaceutical quality/CMC  Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
Scientific data required to support the application (continued)  
Nonclinical data   Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
Clinical data  Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
Extent of Scientific Review  
Quality/CMC data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  






            
Non-clinical data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 Not at all 








            
Clinical data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 





Abridged Review Full review 
 Detailed assessment and 
evaluation report  







Clinical evaluation: factors included in the risk-benefit 
assessment 
 
The clinical opinion takes 
account of: Never sometimes always Never sometimes always 
Differences in medical 
culture/practice 
      
Ethnic factors       
National disease patterns       
Unmet medical need       
Additional information, not in the application:   
The agency tries to obtain Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Other agencies’ internal 
assessment reports 
      
Reports available on the 
Internet (e.g., EPARS) 
      
General Internet search       
Other data (specify:      ) 
 






Thank you for completing this questionnaire 
 



























APPENDIX 3:  
Poster presented at the School of Life and Medical 
Sciences (LMS) Research Conference 2019, 
16 April 2019, 










Poster presented at the Drug Information Association (DIA) 
Global Annual Meeting 2019, 
23-27 June 2019, 
San Diego, United States of America 
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